{
"instance": {
"cldx-20220630x10q.htm": {
"axisCustom": 0,
"axisStandard": 14,
"contextCount": 111,
"dts": {
"calculationLink": {
"local": [
"cldx-20220630_cal.xml"
]
},
"definitionLink": {
"local": [
"cldx-20220630_def.xml"
]
},
"inline": {
"local": [
"cldx-20220630x10q.htm"
]
},
"labelLink": {
"local": [
"cldx-20220630_lab.xml"
]
},
"presentationLink": {
"local": [
"cldx-20220630_pre.xml"
]
},
"schema": {
"local": [
"cldx-20220630.xsd"
],
"remote": [
"http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
"http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
"http://www.xbrl.org/2003/xl-2003-12-31.xsd",
"http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
"http://www.xbrl.org/2005/xbrldt-2005.xsd",
"http://www.xbrl.org/2006/ref-2006-02-27.xsd",
"http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd",
"http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
"http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
"https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
"https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
"https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd",
"https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd",
"https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd",
"https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd",
"https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd",
"https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd",
"https://xbrl.sec.gov/country/2022/country-2022.xsd",
"https://xbrl.sec.gov/dei/2022/dei-2022.xsd"
]
}
},
"elementCount": 314,
"entityCount": 1,
"hidden": {
"http://fasb.org/us-gaap/2022": 19,
"http://xbrl.sec.gov/dei/2022": 5,
"total": 24
},
"keyCustom": 14,
"keyStandard": 185,
"memberCustom": 5,
"memberStandard": 19,
"nsprefix": "cldx",
"nsuri": "http://www.celldextherapeutics.com/20220630",
"report": {
"R1": {
"firstAnchor": {
"ancestors": [
"p",
"div",
"div",
"body",
"html"
],
"baseRef": "cldx-20220630x10q.htm",
"contextRef": "Duration_1_1_2022_To_6_30_2022_KHKWq_OTTUqEPCrEoEzJ4w",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "dei:DocumentType",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
},
"groupType": "document",
"isDefault": "true",
"longName": "00090 - Document - Document and Entity Information",
"role": "http://www.celldextherapeutics.com/role/DocumentDocumentAndEntityInformation",
"shortName": "Document and Entity Information",
"subGroupType": "",
"uniqueAnchor": {
"ancestors": [
"p",
"div",
"div",
"body",
"html"
],
"baseRef": "cldx-20220630x10q.htm",
"contextRef": "Duration_1_1_2022_To_6_30_2022_KHKWq_OTTUqEPCrEoEzJ4w",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "dei:DocumentType",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
}
},
"R10": {
"firstAnchor": {
"ancestors": [
"div",
"div",
"body",
"html"
],
"baseRef": "cldx-20220630x10q.htm",
"contextRef": "Duration_1_1_2022_To_6_30_2022_KHKWq_OTTUqEPCrEoEzJ4w",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "10501 - Disclosure - Intangible Assets",
"role": "http://www.celldextherapeutics.com/role/DisclosureIntangibleAssets",
"shortName": "Intangible Assets",
"subGroupType": "",
"uniqueAnchor": {
"ancestors": [
"div",
"div",
"body",
"html"
],
"baseRef": "cldx-20220630x10q.htm",
"contextRef": "Duration_1_1_2022_To_6_30_2022_KHKWq_OTTUqEPCrEoEzJ4w",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
}
},
"R11": {
"firstAnchor": {
"ancestors": [
"div",
"div",
"body",
"html"
],
"baseRef": "cldx-20220630x10q.htm",
"contextRef": "Duration_1_1_2022_To_6_30_2022_KHKWq_OTTUqEPCrEoEzJ4w",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:OtherLiabilitiesDisclosureTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "10601 - Disclosure - Other Long-Term Liabilities",
"role": "http://www.celldextherapeutics.com/role/DisclosureOtherLongTermLiabilities",
"shortName": "Other Long-Term Liabilities",
"subGroupType": "",
"uniqueAnchor": {
"ancestors": [
"div",
"div",
"body",
"html"
],
"baseRef": "cldx-20220630x10q.htm",
"contextRef": "Duration_1_1_2022_To_6_30_2022_KHKWq_OTTUqEPCrEoEzJ4w",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:OtherLiabilitiesDisclosureTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
}
},
"R12": {
"firstAnchor": {
"ancestors": [
"div",
"div",
"body",
"html"
],
"baseRef": "cldx-20220630x10q.htm",
"contextRef": "Duration_1_1_2022_To_6_30_2022_KHKWq_OTTUqEPCrEoEzJ4w",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "10701 - Disclosure - Stockholders' Equity",
"role": "http://www.celldextherapeutics.com/role/DisclosureStockholdersEquity",
"shortName": "Stockholders' Equity",
"subGroupType": "",
"uniqueAnchor": {
"ancestors": [
"div",
"div",
"body",
"html"
],
"baseRef": "cldx-20220630x10q.htm",
"contextRef": "Duration_1_1_2022_To_6_30_2022_KHKWq_OTTUqEPCrEoEzJ4w",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
}
},
"R13": {
"firstAnchor": {
"ancestors": [
"div",
"div",
"body",
"html"
],
"baseRef": "cldx-20220630x10q.htm",
"contextRef": "Duration_1_1_2022_To_6_30_2022_KHKWq_OTTUqEPCrEoEzJ4w",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "10801 - Disclosure - Stock-Based Compensation",
"role": "http://www.celldextherapeutics.com/role/DisclosureStockBasedCompensation",
"shortName": "Stock-Based Compensation",
"subGroupType": "",
"uniqueAnchor": {
"ancestors": [
"div",
"div",
"body",
"html"
],
"baseRef": "cldx-20220630x10q.htm",
"contextRef": "Duration_1_1_2022_To_6_30_2022_KHKWq_OTTUqEPCrEoEzJ4w",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
}
},
"R14": {
"firstAnchor": {
"ancestors": [
"div",
"div",
"body",
"html"
],
"baseRef": "cldx-20220630x10q.htm",
"contextRef": "Duration_1_1_2022_To_6_30_2022_KHKWq_OTTUqEPCrEoEzJ4w",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:ComprehensiveIncomeNoteTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "10901 - Disclosure - Accumulated Other Comprehensive Income",
"role": "http://www.celldextherapeutics.com/role/DisclosureAccumulatedOtherComprehensiveIncome",
"shortName": "Accumulated Other Comprehensive Income",
"subGroupType": "",
"uniqueAnchor": {
"ancestors": [
"div",
"div",
"body",
"html"
],
"baseRef": "cldx-20220630x10q.htm",
"contextRef": "Duration_1_1_2022_To_6_30_2022_KHKWq_OTTUqEPCrEoEzJ4w",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:ComprehensiveIncomeNoteTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
}
},
"R15": {
"firstAnchor": {
"ancestors": [
"div",
"div",
"body",
"html"
],
"baseRef": "cldx-20220630x10q.htm",
"contextRef": "Duration_1_1_2022_To_6_30_2022_KHKWq_OTTUqEPCrEoEzJ4w",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "11001 - Disclosure - Revenue",
"role": "http://www.celldextherapeutics.com/role/DisclosureRevenue",
"shortName": "Revenue",
"subGroupType": "",
"uniqueAnchor": {
"ancestors": [
"div",
"div",
"body",
"html"
],
"baseRef": "cldx-20220630x10q.htm",
"contextRef": "Duration_1_1_2022_To_6_30_2022_KHKWq_OTTUqEPCrEoEzJ4w",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
}
},
"R16": {
"firstAnchor": {
"ancestors": [
"div",
"div",
"body",
"html"
],
"baseRef": "cldx-20220630x10q.htm",
"contextRef": "Duration_1_1_2022_To_6_30_2022_KHKWq_OTTUqEPCrEoEzJ4w",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:IncomeTaxDisclosureTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "11101 - Disclosure - Income Taxes",
"role": "http://www.celldextherapeutics.com/role/DisclosureIncomeTaxes",
"shortName": "Income Taxes",
"subGroupType": "",
"uniqueAnchor": {
"ancestors": [
"div",
"div",
"body",
"html"
],
"baseRef": "cldx-20220630x10q.htm",
"contextRef": "Duration_1_1_2022_To_6_30_2022_KHKWq_OTTUqEPCrEoEzJ4w",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:IncomeTaxDisclosureTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
}
},
"R17": {
"firstAnchor": {
"ancestors": [
"div",
"div",
"body",
"html"
],
"baseRef": "cldx-20220630x10q.htm",
"contextRef": "Duration_1_1_2022_To_6_30_2022_KHKWq_OTTUqEPCrEoEzJ4w",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:EarningsPerShareTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "11201 - Disclosure - Net Loss Per Share",
"role": "http://www.celldextherapeutics.com/role/DisclosureNetLossPerShare",
"shortName": "Net Loss Per Share",
"subGroupType": "",
"uniqueAnchor": {
"ancestors": [
"div",
"div",
"body",
"html"
],
"baseRef": "cldx-20220630x10q.htm",
"contextRef": "Duration_1_1_2022_To_6_30_2022_KHKWq_OTTUqEPCrEoEzJ4w",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:EarningsPerShareTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
}
},
"R18": {
"firstAnchor": {
"ancestors": [
"div",
"div",
"body",
"html"
],
"baseRef": "cldx-20220630x10q.htm",
"contextRef": "Duration_1_1_2022_To_6_30_2022_KHKWq_OTTUqEPCrEoEzJ4w",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:BusinessCombinationDisclosureTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "11301 - Disclosure - Kolltan Acquisition",
"role": "http://www.celldextherapeutics.com/role/DisclosureKolltanAcquisition",
"shortName": "Kolltan Acquisition",
"subGroupType": "",
"uniqueAnchor": {
"ancestors": [
"div",
"div",
"body",
"html"
],
"baseRef": "cldx-20220630x10q.htm",
"contextRef": "Duration_1_1_2022_To_6_30_2022_KHKWq_OTTUqEPCrEoEzJ4w",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:BusinessCombinationDisclosureTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
}
},
"R19": {
"firstAnchor": {
"ancestors": [
"us-gaap:SignificantAccountingPoliciesTextBlock",
"div",
"div",
"body",
"html"
],
"baseRef": "cldx-20220630x10q.htm",
"contextRef": "Duration_1_1_2022_To_6_30_2022_KHKWq_OTTUqEPCrEoEzJ4w",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "20202 - Disclosure - Significant Accounting Policies (Policies)",
"role": "http://www.celldextherapeutics.com/role/DisclosureSignificantAccountingPoliciesPolicies",
"shortName": "Significant Accounting Policies (Policies)",
"subGroupType": "policies",
"uniqueAnchor": {
"ancestors": [
"us-gaap:SignificantAccountingPoliciesTextBlock",
"div",
"div",
"body",
"html"
],
"baseRef": "cldx-20220630x10q.htm",
"contextRef": "Duration_1_1_2022_To_6_30_2022_KHKWq_OTTUqEPCrEoEzJ4w",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
}
},
"R2": {
"firstAnchor": {
"ancestors": [
"p",
"td",
"tr",
"table",
"div",
"div",
"body",
"html"
],
"baseRef": "cldx-20220630x10q.htm",
"contextRef": "As_Of_6_30_2022_cyrbP5SM8kCkqqyuoByXEQ",
"decimals": "-3",
"first": true,
"lang": null,
"name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
"reportCount": 1,
"unique": true,
"unitRef": "Unit_Standard_USD_9yqCLo5SPkuNdCi4sBRpIw",
"xsiNil": "false"
},
"groupType": "statement",
"isDefault": "false",
"longName": "00100 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS",
"role": "http://www.celldextherapeutics.com/role/StatementCondensedConsolidatedBalanceSheets",
"shortName": "CONDENSED CONSOLIDATED BALANCE SHEETS",
"subGroupType": "",
"uniqueAnchor": {
"ancestors": [
"p",
"td",
"tr",
"table",
"div",
"div",
"body",
"html"
],
"baseRef": "cldx-20220630x10q.htm",
"contextRef": "As_Of_6_30_2022_cyrbP5SM8kCkqqyuoByXEQ",
"decimals": "-3",
"first": true,
"lang": null,
"name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
"reportCount": 1,
"unique": true,
"unitRef": "Unit_Standard_USD_9yqCLo5SPkuNdCi4sBRpIw",
"xsiNil": "false"
}
},
"R20": {
"firstAnchor": {
"ancestors": [
"us-gaap:FairValueDisclosuresTextBlock",
"div",
"div",
"body",
"html"
],
"baseRef": "cldx-20220630x10q.htm",
"contextRef": "Duration_1_1_2022_To_6_30_2022_KHKWq_OTTUqEPCrEoEzJ4w",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "30303 - Disclosure - Fair Value Measurements (Tables)",
"role": "http://www.celldextherapeutics.com/role/DisclosureFairValueMeasurementsTables",
"shortName": "Fair Value Measurements (Tables)",
"subGroupType": "tables",
"uniqueAnchor": {
"ancestors": [
"us-gaap:FairValueDisclosuresTextBlock",
"div",
"div",
"body",
"html"
],
"baseRef": "cldx-20220630x10q.htm",
"contextRef": "Duration_1_1_2022_To_6_30_2022_KHKWq_OTTUqEPCrEoEzJ4w",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
}
},
"R21": {
"firstAnchor": {
"ancestors": [
"us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
"div",
"div",
"body",
"html"
],
"baseRef": "cldx-20220630x10q.htm",
"contextRef": "Duration_1_1_2022_To_6_30_2022_KHKWq_OTTUqEPCrEoEzJ4w",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "30403 - Disclosure - Marketable Securities (Tables)",
"role": "http://www.celldextherapeutics.com/role/DisclosureMarketableSecuritiesTables",
"shortName": "Marketable Securities (Tables)",
"subGroupType": "tables",
"uniqueAnchor": {
"ancestors": [
"us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
"div",
"div",
"body",
"html"
],
"baseRef": "cldx-20220630x10q.htm",
"contextRef": "Duration_1_1_2022_To_6_30_2022_KHKWq_OTTUqEPCrEoEzJ4w",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
}
},
"R22": {
"firstAnchor": {
"ancestors": [
"us-gaap:OtherLiabilitiesDisclosureTextBlock",
"div",
"div",
"body",
"html"
],
"baseRef": "cldx-20220630x10q.htm",
"contextRef": "Duration_1_1_2022_To_6_30_2022_KHKWq_OTTUqEPCrEoEzJ4w",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:OtherNoncurrentLiabilitiesTableTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "30603 - Disclosure - Other Long-Term Liabilities (Tables)",
"role": "http://www.celldextherapeutics.com/role/DisclosureOtherLongTermLiabilitiesTables",
"shortName": "Other Long-Term Liabilities (Tables)",
"subGroupType": "tables",
"uniqueAnchor": {
"ancestors": [
"us-gaap:OtherLiabilitiesDisclosureTextBlock",
"div",
"div",
"body",
"html"
],
"baseRef": "cldx-20220630x10q.htm",
"contextRef": "Duration_1_1_2022_To_6_30_2022_KHKWq_OTTUqEPCrEoEzJ4w",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:OtherNoncurrentLiabilitiesTableTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
}
},
"R23": {
"firstAnchor": {
"ancestors": [
"ix:continuation",
"div",
"div",
"body",
"html"
],
"baseRef": "cldx-20220630x10q.htm",
"contextRef": "Duration_1_1_2022_To_6_30_2022_KHKWq_OTTUqEPCrEoEzJ4w",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:ScheduleOfStockholdersEquityTableTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "30703 - Disclosure - Stockholders' Equity (Tables)",
"role": "http://www.celldextherapeutics.com/role/DisclosureStockholdersEquityTables",
"shortName": "Stockholders' Equity (Tables)",
"subGroupType": "tables",
"uniqueAnchor": {
"ancestors": [
"ix:continuation",
"div",
"div",
"body",
"html"
],
"baseRef": "cldx-20220630x10q.htm",
"contextRef": "Duration_1_1_2022_To_6_30_2022_KHKWq_OTTUqEPCrEoEzJ4w",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:ScheduleOfStockholdersEquityTableTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
}
},
"R24": {
"firstAnchor": {
"ancestors": [
"us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
"div",
"div",
"body",
"html"
],
"baseRef": "cldx-20220630x10q.htm",
"contextRef": "Duration_1_1_2022_To_6_30_2022_KHKWq_OTTUqEPCrEoEzJ4w",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "30803 - Disclosure - Stock-Based Compensation (Tables)",
"role": "http://www.celldextherapeutics.com/role/DisclosureStockBasedCompensationTables",
"shortName": "Stock-Based Compensation (Tables)",
"subGroupType": "tables",
"uniqueAnchor": {
"ancestors": [
"us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
"div",
"div",
"body",
"html"
],
"baseRef": "cldx-20220630x10q.htm",
"contextRef": "Duration_1_1_2022_To_6_30_2022_KHKWq_OTTUqEPCrEoEzJ4w",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
}
},
"R25": {
"firstAnchor": {
"ancestors": [
"us-gaap:ComprehensiveIncomeNoteTextBlock",
"div",
"div",
"body",
"html"
],
"baseRef": "cldx-20220630x10q.htm",
"contextRef": "Duration_1_1_2022_To_6_30_2022_KHKWq_OTTUqEPCrEoEzJ4w",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "30903 - Disclosure - Accumulated Other Comprehensive Income (Tables)",
"role": "http://www.celldextherapeutics.com/role/DisclosureAccumulatedOtherComprehensiveIncomeTables",
"shortName": "Accumulated Other Comprehensive Income (Tables)",
"subGroupType": "tables",
"uniqueAnchor": {
"ancestors": [
"us-gaap:ComprehensiveIncomeNoteTextBlock",
"div",
"div",
"body",
"html"
],
"baseRef": "cldx-20220630x10q.htm",
"contextRef": "Duration_1_1_2022_To_6_30_2022_KHKWq_OTTUqEPCrEoEzJ4w",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
}
},
"R26": {
"firstAnchor": {
"ancestors": [
"us-gaap:EarningsPerShareTextBlock",
"div",
"div",
"body",
"html"
],
"baseRef": "cldx-20220630x10q.htm",
"contextRef": "Duration_1_1_2022_To_6_30_2022_KHKWq_OTTUqEPCrEoEzJ4w",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "31203 - Disclosure - Net Loss Per Share (Tables)",
"role": "http://www.celldextherapeutics.com/role/DisclosureNetLossPerShareTables",
"shortName": "Net Loss Per Share (Tables)",
"subGroupType": "tables",
"uniqueAnchor": {
"ancestors": [
"us-gaap:EarningsPerShareTextBlock",
"div",
"div",
"body",
"html"
],
"baseRef": "cldx-20220630x10q.htm",
"contextRef": "Duration_1_1_2022_To_6_30_2022_KHKWq_OTTUqEPCrEoEzJ4w",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
}
},
"R27": {
"firstAnchor": {
"ancestors": [
"p",
"us-gaap:BasisOfAccounting",
"div",
"div",
"body",
"html"
],
"baseRef": "cldx-20220630x10q.htm",
"contextRef": "As_Of_6_30_2022_cyrbP5SM8kCkqqyuoByXEQ",
"decimals": "-5",
"first": true,
"lang": null,
"name": "us-gaap:InvestmentsAndCash",
"reportCount": 1,
"unitRef": "Unit_Standard_USD_9yqCLo5SPkuNdCi4sBRpIw",
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "40101 - Disclosure - Basis of Presentation (Details)",
"role": "http://www.celldextherapeutics.com/role/DisclosureBasisOfPresentationDetails",
"shortName": "Basis of Presentation (Details)",
"subGroupType": "details",
"uniqueAnchor": null
},
"R28": {
"firstAnchor": {
"ancestors": [
"p",
"td",
"tr",
"table",
"us-gaap:OtherNoncurrentLiabilitiesTableTextBlock",
"us-gaap:OtherLiabilitiesDisclosureTextBlock",
"div",
"div",
"body",
"html"
],
"baseRef": "cldx-20220630x10q.htm",
"contextRef": "As_Of_12_31_2021_H0XNo4GTBEKjprQCelTZGQ",
"decimals": "-3",
"first": true,
"lang": null,
"name": "us-gaap:BusinessCombinationContingentConsiderationLiability",
"reportCount": 1,
"unitRef": "Unit_Standard_USD_9yqCLo5SPkuNdCi4sBRpIw",
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "40301 - Disclosure - Fair Value Measurements (Details)",
"role": "http://www.celldextherapeutics.com/role/DisclosureFairValueMeasurementsDetails",
"shortName": "Fair Value Measurements (Details)",
"subGroupType": "details",
"uniqueAnchor": {
"ancestors": [
"p",
"td",
"tr",
"table",
"us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
"us-gaap:FairValueDisclosuresTextBlock",
"div",
"div",
"body",
"html"
],
"baseRef": "cldx-20220630x10q.htm",
"contextRef": "As_Of_6_30_2022_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_V1PK-bDL0EeHn8zTsrN4AA",
"decimals": "-3",
"lang": null,
"name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure",
"reportCount": 1,
"unique": true,
"unitRef": "Unit_Standard_USD_9yqCLo5SPkuNdCi4sBRpIw",
"xsiNil": "false"
}
},
"R29": {
"firstAnchor": {
"ancestors": [
"p",
"td",
"tr",
"table",
"us-gaap:OtherNoncurrentLiabilitiesTableTextBlock",
"us-gaap:OtherLiabilitiesDisclosureTextBlock",
"div",
"div",
"body",
"html"
],
"baseRef": "cldx-20220630x10q.htm",
"contextRef": "As_Of_12_31_2021_H0XNo4GTBEKjprQCelTZGQ",
"decimals": "-3",
"first": true,
"lang": null,
"name": "us-gaap:BusinessCombinationContingentConsiderationLiability",
"reportCount": 1,
"unitRef": "Unit_Standard_USD_9yqCLo5SPkuNdCi4sBRpIw",
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "40302 - Disclosure - Fair Value Measurements - Contingent Consideration Liabilities (Details)",
"role": "http://www.celldextherapeutics.com/role/DisclosureFairValueMeasurementsContingentConsiderationLiabilitiesDetails",
"shortName": "Fair Value Measurements - Contingent Consideration Liabilities (Details)",
"subGroupType": "details",
"uniqueAnchor": {
"ancestors": [
"p",
"td",
"tr",
"table",
"us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
"us-gaap:FairValueDisclosuresTextBlock",
"div",
"div",
"body",
"html"
],
"baseRef": "cldx-20220630x10q.htm",
"contextRef": "Duration_1_1_2022_To_6_30_2022_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_9E5k5SwMLkqwKkpSWNmwfg",
"decimals": "-3",
"lang": null,
"name": "us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1",
"reportCount": 1,
"unique": true,
"unitRef": "Unit_Standard_USD_9yqCLo5SPkuNdCi4sBRpIw",
"xsiNil": "false"
}
},
"R3": {
"firstAnchor": {
"ancestors": [
"p",
"td",
"tr",
"table",
"div",
"div",
"body",
"html"
],
"baseRef": "cldx-20220630x10q.htm",
"contextRef": "As_Of_6_30_2022_cyrbP5SM8kCkqqyuoByXEQ",
"decimals": "INF",
"first": true,
"lang": null,
"name": "us-gaap:PreferredStockParOrStatedValuePerShare",
"reportCount": 1,
"unique": true,
"unitRef": "Unit_Divide_USD_shares_dXAUZSzNJUCJY8yix0XzKw",
"xsiNil": "false"
},
"groupType": "statement",
"isDefault": "false",
"longName": "00105 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)",
"role": "http://www.celldextherapeutics.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical",
"shortName": "CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)",
"subGroupType": "parenthetical",
"uniqueAnchor": {
"ancestors": [
"p",
"td",
"tr",
"table",
"div",
"div",
"body",
"html"
],
"baseRef": "cldx-20220630x10q.htm",
"contextRef": "As_Of_6_30_2022_cyrbP5SM8kCkqqyuoByXEQ",
"decimals": "INF",
"first": true,
"lang": null,
"name": "us-gaap:PreferredStockParOrStatedValuePerShare",
"reportCount": 1,
"unique": true,
"unitRef": "Unit_Divide_USD_shares_dXAUZSzNJUCJY8yix0XzKw",
"xsiNil": "false"
}
},
"R30": {
"firstAnchor": {
"ancestors": [
"p",
"td",
"tr",
"table",
"div",
"div",
"body",
"html"
],
"baseRef": "cldx-20220630x10q.htm",
"contextRef": "Duration_4_1_2022_To_6_30_2022_FIKPNAs7BkWCFQIDDZOnOQ",
"decimals": "-3",
"first": true,
"lang": null,
"name": "us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1",
"reportCount": 1,
"unitRef": "Unit_Standard_USD_9yqCLo5SPkuNdCi4sBRpIw",
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "40303 - Disclosure - Fair Value Measurements - Additional information (Details)",
"role": "http://www.celldextherapeutics.com/role/DisclosureFairValueMeasurementsAdditionalInformationDetails",
"shortName": "Fair Value Measurements - Additional information (Details)",
"subGroupType": "details",
"uniqueAnchor": null
},
"R31": {
"firstAnchor": {
"ancestors": [
"p",
"td",
"tr",
"table",
"us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
"us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
"div",
"div",
"body",
"html"
],
"baseRef": "cldx-20220630x10q.htm",
"contextRef": "As_Of_6_30_2022_cyrbP5SM8kCkqqyuoByXEQ",
"decimals": "-3",
"first": true,
"lang": null,
"name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
"reportCount": 1,
"unique": true,
"unitRef": "Unit_Standard_USD_9yqCLo5SPkuNdCi4sBRpIw",
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "40401 - Disclosure - Marketable Securities (Details)",
"role": "http://www.celldextherapeutics.com/role/DisclosureMarketableSecuritiesDetails",
"shortName": "Marketable Securities (Details)",
"subGroupType": "details",
"uniqueAnchor": {
"ancestors": [
"p",
"td",
"tr",
"table",
"us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
"us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
"div",
"div",
"body",
"html"
],
"baseRef": "cldx-20220630x10q.htm",
"contextRef": "As_Of_6_30_2022_cyrbP5SM8kCkqqyuoByXEQ",
"decimals": "-3",
"first": true,
"lang": null,
"name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
"reportCount": 1,
"unique": true,
"unitRef": "Unit_Standard_USD_9yqCLo5SPkuNdCi4sBRpIw",
"xsiNil": "false"
}
},
"R32": {
"firstAnchor": {
"ancestors": [
"p",
"us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
"div",
"div",
"body",
"html"
],
"baseRef": "cldx-20220630x10q.htm",
"contextRef": "As_Of_6_30_2022_cyrbP5SM8kCkqqyuoByXEQ",
"decimals": "-3",
"first": true,
"lang": null,
"name": "us-gaap:OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCreditLossesOnDebtSecuritiesHeld",
"reportCount": 1,
"unique": true,
"unitRef": "Unit_Standard_USD_9yqCLo5SPkuNdCi4sBRpIw",
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "40402 - Disclosure - Marketable Securities - Additional Information (Details)",
"role": "http://www.celldextherapeutics.com/role/DisclosureMarketableSecuritiesAdditionalInformationDetails",
"shortName": "Marketable Securities - Additional Information (Details)",
"subGroupType": "details",
"uniqueAnchor": {
"ancestors": [
"p",
"us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
"div",
"div",
"body",
"html"
],
"baseRef": "cldx-20220630x10q.htm",
"contextRef": "As_Of_6_30_2022_cyrbP5SM8kCkqqyuoByXEQ",
"decimals": "-3",
"first": true,
"lang": null,
"name": "us-gaap:OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCreditLossesOnDebtSecuritiesHeld",
"reportCount": 1,
"unique": true,
"unitRef": "Unit_Standard_USD_9yqCLo5SPkuNdCi4sBRpIw",
"xsiNil": "false"
}
},
"R33": {
"firstAnchor": {
"ancestors": [
"p",
"ix:continuation",
"div",
"div",
"body",
"html"
],
"baseRef": "cldx-20220630x10q.htm",
"contextRef": "As_Of_6_30_2022_cyrbP5SM8kCkqqyuoByXEQ",
"decimals": "-5",
"first": true,
"lang": null,
"name": "us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill",
"reportCount": 1,
"unitRef": "Unit_Standard_USD_9yqCLo5SPkuNdCi4sBRpIw",
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "40501 - Disclosure - Intangible Assets (Details)",
"role": "http://www.celldextherapeutics.com/role/DisclosureIntangibleAssetsDetails",
"shortName": "Intangible Assets (Details)",
"subGroupType": "details",
"uniqueAnchor": null
},
"R34": {
"firstAnchor": {
"ancestors": [
"p",
"td",
"tr",
"table",
"us-gaap:OtherNoncurrentLiabilitiesTableTextBlock",
"us-gaap:OtherLiabilitiesDisclosureTextBlock",
"div",
"div",
"body",
"html"
],
"baseRef": "cldx-20220630x10q.htm",
"contextRef": "As_Of_6_30_2022_cyrbP5SM8kCkqqyuoByXEQ",
"decimals": "-3",
"first": true,
"lang": null,
"name": "us-gaap:DeferredTaxLiabilities",
"reportCount": 1,
"unitRef": "Unit_Standard_USD_9yqCLo5SPkuNdCi4sBRpIw",
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "40601 - Disclosure - Other Long-Term Liabilities (Details)",
"role": "http://www.celldextherapeutics.com/role/DisclosureOtherLongTermLiabilitiesDetails",
"shortName": "Other Long-Term Liabilities (Details)",
"subGroupType": "details",
"uniqueAnchor": {
"ancestors": [
"p",
"td",
"tr",
"table",
"us-gaap:OtherNoncurrentLiabilitiesTableTextBlock",
"us-gaap:OtherLiabilitiesDisclosureTextBlock",
"div",
"div",
"body",
"html"
],
"baseRef": "cldx-20220630x10q.htm",
"contextRef": "As_Of_6_30_2022_cyrbP5SM8kCkqqyuoByXEQ",
"decimals": "-3",
"lang": null,
"name": "cldx:DeferredIncomeFromSaleOfTaxBenefits",
"reportCount": 1,
"unique": true,
"unitRef": "Unit_Standard_USD_9yqCLo5SPkuNdCi4sBRpIw",
"xsiNil": "false"
}
},
"R35": {
"firstAnchor": {
"ancestors": [
"p",
"td",
"tr",
"table",
"div",
"div",
"body",
"html"
],
"baseRef": "cldx-20220630x10q.htm",
"contextRef": "Duration_4_1_2022_To_6_30_2022_FIKPNAs7BkWCFQIDDZOnOQ",
"decimals": "-3",
"first": true,
"lang": null,
"name": "us-gaap:InterestAndOtherIncome",
"reportCount": 1,
"unitRef": "Unit_Standard_USD_9yqCLo5SPkuNdCi4sBRpIw",
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "40602 - Disclosure - Other Long-Term Liabilities- New Jersey tax benefits (Details)",
"role": "http://www.celldextherapeutics.com/role/DisclosureOtherLongTermLiabilitiesNewJerseyTaxBenefitsDetails",
"shortName": "Other Long-Term Liabilities- New Jersey tax benefits (Details)",
"subGroupType": "details",
"uniqueAnchor": {
"ancestors": [
"p",
"us-gaap:OtherLiabilitiesDisclosureTextBlock",
"div",
"div",
"body",
"html"
],
"baseRef": "cldx-20220630x10q.htm",
"contextRef": "Duration_3_1_2022_To_3_31_2022_us-gaap_IncomeTaxAuthorityNameAxis_us-gaap_NewJerseyDivisionOfTaxationMember_PbOlpnnnAEi_7GqgyKhrsg",
"decimals": "-5",
"lang": null,
"name": "us-gaap:CurrentStateAndLocalTaxExpenseBenefit",
"reportCount": 1,
"unique": true,
"unitRef": "Unit_Standard_USD_9yqCLo5SPkuNdCi4sBRpIw",
"xsiNil": "false"
}
},
"R36": {
"firstAnchor": {
"ancestors": [
"p",
"td",
"tr",
"table",
"us-gaap:ScheduleOfStockholdersEquityTableTextBlock",
"ix:continuation",
"div",
"div",
"body",
"html"
],
"baseRef": "cldx-20220630x10q.htm",
"contextRef": "As_Of_3_31_2022_MaBdvDMKfkO7Im0RaiBqUQ",
"decimals": "-3",
"first": true,
"lang": null,
"name": "us-gaap:StockholdersEquity",
"reportCount": 1,
"unitRef": "Unit_Standard_USD_9yqCLo5SPkuNdCi4sBRpIw",
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "40701 - Disclosure - Stockholders' Equity (Details)",
"role": "http://www.celldextherapeutics.com/role/DisclosureStockholdersEquityDetails",
"shortName": "Stockholders' Equity (Details)",
"subGroupType": "details",
"uniqueAnchor": {
"ancestors": [
"p",
"td",
"tr",
"table",
"us-gaap:ScheduleOfStockholdersEquityTableTextBlock",
"ix:continuation",
"div",
"div",
"body",
"html"
],
"baseRef": "cldx-20220630x10q.htm",
"contextRef": "Duration_4_1_2022_To_6_30_2022_FIKPNAs7BkWCFQIDDZOnOQ",
"decimals": "-3",
"lang": null,
"name": "us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan",
"reportCount": 1,
"unique": true,
"unitRef": "Unit_Standard_USD_9yqCLo5SPkuNdCi4sBRpIw",
"xsiNil": "false"
}
},
"R37": {
"firstAnchor": {
"ancestors": [
"p",
"td",
"tr",
"table",
"us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
"us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
"div",
"div",
"body",
"html"
],
"baseRef": "cldx-20220630x10q.htm",
"contextRef": "As_Of_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_fVZ1w9vhME2ekjKDI5K6fA",
"decimals": "INF",
"first": true,
"lang": null,
"name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
"reportCount": 1,
"unitRef": "Unit_Standard_shares_Ca7E_suvwkOQUnA-PI9_yA",
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "40801 - Disclosure - Stock-Based Compensation - Stock Option Activity (Details)",
"role": "http://www.celldextherapeutics.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails",
"shortName": "Stock-Based Compensation - Stock Option Activity (Details)",
"subGroupType": "details",
"uniqueAnchor": {
"ancestors": [
"p",
"td",
"tr",
"table",
"us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
"us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
"div",
"div",
"body",
"html"
],
"baseRef": "cldx-20220630x10q.htm",
"contextRef": "Duration_1_1_2022_To_6_30_2022_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_x6WjrftjAEOqiMavLc6bJg",
"decimals": "INF",
"lang": null,
"name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
"reportCount": 1,
"unique": true,
"unitRef": "Unit_Standard_shares_Ca7E_suvwkOQUnA-PI9_yA",
"xsiNil": "false"
}
},
"R38": {
"firstAnchor": {
"ancestors": [
"p",
"ix:continuation",
"div",
"div",
"body",
"html"
],
"baseRef": "cldx-20220630x10q.htm",
"contextRef": "Duration_4_1_2022_To_6_30_2022_FIKPNAs7BkWCFQIDDZOnOQ",
"decimals": "2",
"first": true,
"lang": null,
"name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
"reportCount": 1,
"unique": true,
"unitRef": "Unit_Divide_USD_shares_dXAUZSzNJUCJY8yix0XzKw",
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "40802 - Disclosure - Stock-Based Compensation - Employee Stock Option and Incentive Plan Activity Additional Information (Details)",
"role": "http://www.celldextherapeutics.com/role/DisclosureStockBasedCompensationEmployeeStockOptionAndIncentivePlanActivityAdditionalInformationDetails",
"shortName": "Stock-Based Compensation - Employee Stock Option and Incentive Plan Activity Additional Information (Details)",
"subGroupType": "details",
"uniqueAnchor": {
"ancestors": [
"p",
"ix:continuation",
"div",
"div",
"body",
"html"
],
"baseRef": "cldx-20220630x10q.htm",
"contextRef": "Duration_4_1_2022_To_6_30_2022_FIKPNAs7BkWCFQIDDZOnOQ",
"decimals": "2",
"first": true,
"lang": null,
"name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
"reportCount": 1,
"unique": true,
"unitRef": "Unit_Divide_USD_shares_dXAUZSzNJUCJY8yix0XzKw",
"xsiNil": "false"
}
},
"R39": {
"firstAnchor": {
"ancestors": [
"p",
"td",
"tr",
"table",
"us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
"ix:continuation",
"div",
"div",
"body",
"html"
],
"baseRef": "cldx-20220630x10q.htm",
"contextRef": "Duration_4_1_2022_To_6_30_2022_FIKPNAs7BkWCFQIDDZOnOQ",
"decimals": "-3",
"first": true,
"lang": null,
"name": "us-gaap:AllocatedShareBasedCompensationExpense",
"reportCount": 1,
"unique": true,
"unitRef": "Unit_Standard_USD_9yqCLo5SPkuNdCi4sBRpIw",
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "40803 - Disclosure - Stock-Based Compensation - Expenses (Details)",
"role": "http://www.celldextherapeutics.com/role/DisclosureStockBasedCompensationExpensesDetails",
"shortName": "Stock-Based Compensation - Expenses (Details)",
"subGroupType": "details",
"uniqueAnchor": {
"ancestors": [
"p",
"td",
"tr",
"table",
"us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
"ix:continuation",
"div",
"div",
"body",
"html"
],
"baseRef": "cldx-20220630x10q.htm",
"contextRef": "Duration_4_1_2022_To_6_30_2022_FIKPNAs7BkWCFQIDDZOnOQ",
"decimals": "-3",
"first": true,
"lang": null,
"name": "us-gaap:AllocatedShareBasedCompensationExpense",
"reportCount": 1,
"unique": true,
"unitRef": "Unit_Standard_USD_9yqCLo5SPkuNdCi4sBRpIw",
"xsiNil": "false"
}
},
"R4": {
"firstAnchor": {
"ancestors": [
"p",
"td",
"tr",
"table",
"div",
"div",
"body",
"html"
],
"baseRef": "cldx-20220630x10q.htm",
"contextRef": "Duration_4_1_2022_To_6_30_2022_FIKPNAs7BkWCFQIDDZOnOQ",
"decimals": "-3",
"first": true,
"lang": null,
"name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
"reportCount": 1,
"unitRef": "Unit_Standard_USD_9yqCLo5SPkuNdCi4sBRpIw",
"xsiNil": "false"
},
"groupType": "statement",
"isDefault": "false",
"longName": "00200 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS",
"role": "http://www.celldextherapeutics.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss",
"shortName": "CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS",
"subGroupType": "",
"uniqueAnchor": {
"ancestors": [
"p",
"td",
"tr",
"table",
"div",
"div",
"body",
"html"
],
"baseRef": "cldx-20220630x10q.htm",
"contextRef": "Duration_4_1_2022_To_6_30_2022_FIKPNAs7BkWCFQIDDZOnOQ",
"decimals": "-3",
"lang": null,
"name": "us-gaap:ResearchAndDevelopmentExpense",
"reportCount": 1,
"unique": true,
"unitRef": "Unit_Standard_USD_9yqCLo5SPkuNdCi4sBRpIw",
"xsiNil": "false"
}
},
"R40": {
"firstAnchor": {
"ancestors": [
"p",
"td",
"tr",
"table",
"us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
"ix:continuation",
"div",
"div",
"body",
"html"
],
"baseRef": "cldx-20220630x10q.htm",
"contextRef": "Duration_4_1_2022_To_6_30_2022_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_U9EGBeyrFE22cQlezWEvFA",
"decimals": "2",
"first": true,
"lang": null,
"name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum",
"reportCount": 1,
"unique": true,
"unitRef": "Unit_Standard_pure_nvRhidLZ-E2hiZygC8cpeQ",
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "40804 - Disclosure - Stock-Based Compensation - Valuation (Details)",
"role": "http://www.celldextherapeutics.com/role/DisclosureStockBasedCompensationValuationDetails",
"shortName": "Stock-Based Compensation - Valuation (Details)",
"subGroupType": "details",
"uniqueAnchor": {
"ancestors": [
"p",
"td",
"tr",
"table",
"us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
"ix:continuation",
"div",
"div",
"body",
"html"
],
"baseRef": "cldx-20220630x10q.htm",
"contextRef": "Duration_4_1_2022_To_6_30_2022_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_U9EGBeyrFE22cQlezWEvFA",
"decimals": "2",
"first": true,
"lang": null,
"name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum",
"reportCount": 1,
"unique": true,
"unitRef": "Unit_Standard_pure_nvRhidLZ-E2hiZygC8cpeQ",
"xsiNil": "false"
}
},
"R41": {
"firstAnchor": {
"ancestors": [
"p",
"td",
"tr",
"table",
"div",
"div",
"body",
"html"
],
"baseRef": "cldx-20220630x10q.htm",
"contextRef": "As_Of_12_31_2021_H0XNo4GTBEKjprQCelTZGQ",
"decimals": "-3",
"first": true,
"lang": null,
"name": "us-gaap:StockholdersEquity",
"reportCount": 1,
"unitRef": "Unit_Standard_USD_9yqCLo5SPkuNdCi4sBRpIw",
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "40901 - Disclosure - Accumulated Other Comprehensive Income (Details)",
"role": "http://www.celldextherapeutics.com/role/DisclosureAccumulatedOtherComprehensiveIncomeDetails",
"shortName": "Accumulated Other Comprehensive Income (Details)",
"subGroupType": "details",
"uniqueAnchor": {
"ancestors": [
"p",
"us-gaap:ComprehensiveIncomeNoteTextBlock",
"div",
"div",
"body",
"html"
],
"baseRef": "cldx-20220630x10q.htm",
"contextRef": "Duration_1_1_2022_To_6_30_2022_KHKWq_OTTUqEPCrEoEzJ4w",
"decimals": "-3",
"lang": null,
"name": "us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax",
"reportCount": 1,
"unique": true,
"unitRef": "Unit_Standard_USD_9yqCLo5SPkuNdCi4sBRpIw",
"xsiNil": "false"
}
},
"R42": {
"firstAnchor": {
"ancestors": [
"p",
"ix:continuation",
"div",
"div",
"body",
"html"
],
"baseRef": "cldx-20220630x10q.htm",
"contextRef": "Duration_4_1_2022_To_6_30_2022_FIKPNAs7BkWCFQIDDZOnOQ",
"decimals": "-5",
"first": true,
"lang": null,
"name": "us-gaap:ContractWithCustomerLiabilityRevenueRecognized",
"reportCount": 1,
"unique": true,
"unitRef": "Unit_Standard_USD_9yqCLo5SPkuNdCi4sBRpIw",
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "41001 - Disclosure - Revenue (Details)",
"role": "http://www.celldextherapeutics.com/role/DisclosureRevenueDetails",
"shortName": "Revenue (Details)",
"subGroupType": "details",
"uniqueAnchor": {
"ancestors": [
"p",
"ix:continuation",
"div",
"div",
"body",
"html"
],
"baseRef": "cldx-20220630x10q.htm",
"contextRef": "Duration_4_1_2022_To_6_30_2022_FIKPNAs7BkWCFQIDDZOnOQ",
"decimals": "-5",
"first": true,
"lang": null,
"name": "us-gaap:ContractWithCustomerLiabilityRevenueRecognized",
"reportCount": 1,
"unique": true,
"unitRef": "Unit_Standard_USD_9yqCLo5SPkuNdCi4sBRpIw",
"xsiNil": "false"
}
},
"R43": {
"firstAnchor": {
"ancestors": [
"p",
"td",
"tr",
"table",
"us-gaap:OtherNoncurrentLiabilitiesTableTextBlock",
"us-gaap:OtherLiabilitiesDisclosureTextBlock",
"div",
"div",
"body",
"html"
],
"baseRef": "cldx-20220630x10q.htm",
"contextRef": "As_Of_6_30_2022_cyrbP5SM8kCkqqyuoByXEQ",
"decimals": "-3",
"first": true,
"lang": null,
"name": "us-gaap:DeferredTaxLiabilities",
"reportCount": 1,
"unitRef": "Unit_Standard_USD_9yqCLo5SPkuNdCi4sBRpIw",
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "41101 - Disclosure - Income Taxes (Details)",
"role": "http://www.celldextherapeutics.com/role/DisclosureIncomeTaxesDetails",
"shortName": "Income Taxes (Details)",
"subGroupType": "details",
"uniqueAnchor": null
},
"R44": {
"firstAnchor": {
"ancestors": [
"p",
"td",
"tr",
"table",
"us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
"us-gaap:EarningsPerShareTextBlock",
"div",
"div",
"body",
"html"
],
"baseRef": "cldx-20220630x10q.htm",
"contextRef": "Duration_1_1_2022_To_6_30_2022_KHKWq_OTTUqEPCrEoEzJ4w",
"decimals": "0",
"first": true,
"lang": null,
"name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
"reportCount": 1,
"unique": true,
"unitRef": "Unit_Standard_shares_Ca7E_suvwkOQUnA-PI9_yA",
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "41201 - Disclosure - Net Loss Per Share (Details)",
"role": "http://www.celldextherapeutics.com/role/DisclosureNetLossPerShareDetails",
"shortName": "Net Loss Per Share (Details)",
"subGroupType": "details",
"uniqueAnchor": {
"ancestors": [
"p",
"td",
"tr",
"table",
"us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
"us-gaap:EarningsPerShareTextBlock",
"div",
"div",
"body",
"html"
],
"baseRef": "cldx-20220630x10q.htm",
"contextRef": "Duration_1_1_2022_To_6_30_2022_KHKWq_OTTUqEPCrEoEzJ4w",
"decimals": "0",
"first": true,
"lang": null,
"name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
"reportCount": 1,
"unique": true,
"unitRef": "Unit_Standard_shares_Ca7E_suvwkOQUnA-PI9_yA",
"xsiNil": "false"
}
},
"R45": {
"firstAnchor": {
"ancestors": [
"span",
"td",
"tr",
"table",
"ix:continuation",
"div",
"div",
"body",
"html"
],
"baseRef": "cldx-20220630x10q.htm",
"contextRef": "Duration_6_20_2022_To_6_20_2022_wkuvlmWXhU2gC4crDwi8-Q",
"decimals": "0",
"first": true,
"lang": null,
"name": "cldx:BusinessCombinationContingentConsiderationSettlementAgreementAmountPaid",
"reportCount": 1,
"unique": true,
"unitRef": "Unit_Standard_USD_9yqCLo5SPkuNdCi4sBRpIw",
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "41301 - Disclosure - Kolltan Acquisition (Details)",
"role": "http://www.celldextherapeutics.com/role/DisclosureKolltanAcquisitionDetails",
"shortName": "Kolltan Acquisition (Details)",
"subGroupType": "details",
"uniqueAnchor": {
"ancestors": [
"span",
"td",
"tr",
"table",
"ix:continuation",
"div",
"div",
"body",
"html"
],
"baseRef": "cldx-20220630x10q.htm",
"contextRef": "Duration_6_20_2022_To_6_20_2022_wkuvlmWXhU2gC4crDwi8-Q",
"decimals": "0",
"first": true,
"lang": null,
"name": "cldx:BusinessCombinationContingentConsiderationSettlementAgreementAmountPaid",
"reportCount": 1,
"unique": true,
"unitRef": "Unit_Standard_USD_9yqCLo5SPkuNdCi4sBRpIw",
"xsiNil": "false"
}
},
"R5": {
"firstAnchor": {
"ancestors": [
"p",
"td",
"tr",
"table",
"div",
"div",
"body",
"html"
],
"baseRef": "cldx-20220630x10q.htm",
"contextRef": "Duration_1_1_2022_To_6_30_2022_KHKWq_OTTUqEPCrEoEzJ4w",
"decimals": "-3",
"first": true,
"lang": null,
"name": "us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic",
"reportCount": 1,
"unitRef": "Unit_Standard_USD_9yqCLo5SPkuNdCi4sBRpIw",
"xsiNil": "false"
},
"groupType": "statement",
"isDefault": "false",
"longName": "00300 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOW",
"role": "http://www.celldextherapeutics.com/role/StatementCondensedConsolidatedStatementsOfCashFlow",
"shortName": "CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOW",
"subGroupType": "",
"uniqueAnchor": {
"ancestors": [
"p",
"td",
"tr",
"table",
"div",
"div",
"body",
"html"
],
"baseRef": "cldx-20220630x10q.htm",
"contextRef": "Duration_1_1_2022_To_6_30_2022_KHKWq_OTTUqEPCrEoEzJ4w",
"decimals": "-3",
"lang": null,
"name": "us-gaap:DepreciationDepletionAndAmortization",
"reportCount": 1,
"unique": true,
"unitRef": "Unit_Standard_USD_9yqCLo5SPkuNdCi4sBRpIw",
"xsiNil": "false"
}
},
"R6": {
"firstAnchor": {
"ancestors": [
"div",
"div",
"body",
"html"
],
"baseRef": "cldx-20220630x10q.htm",
"contextRef": "Duration_1_1_2022_To_6_30_2022_KHKWq_OTTUqEPCrEoEzJ4w",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:BasisOfAccounting",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "10101 - Disclosure - Basis of Presentation",
"role": "http://www.celldextherapeutics.com/role/DisclosureBasisOfPresentation",
"shortName": "Basis of Presentation",
"subGroupType": "",
"uniqueAnchor": {
"ancestors": [
"div",
"div",
"body",
"html"
],
"baseRef": "cldx-20220630x10q.htm",
"contextRef": "Duration_1_1_2022_To_6_30_2022_KHKWq_OTTUqEPCrEoEzJ4w",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:BasisOfAccounting",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
}
},
"R7": {
"firstAnchor": {
"ancestors": [
"div",
"div",
"body",
"html"
],
"baseRef": "cldx-20220630x10q.htm",
"contextRef": "Duration_1_1_2022_To_6_30_2022_KHKWq_OTTUqEPCrEoEzJ4w",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:SignificantAccountingPoliciesTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "10201 - Disclosure - Significant Accounting Policies",
"role": "http://www.celldextherapeutics.com/role/DisclosureSignificantAccountingPolicies",
"shortName": "Significant Accounting Policies",
"subGroupType": "",
"uniqueAnchor": {
"ancestors": [
"div",
"div",
"body",
"html"
],
"baseRef": "cldx-20220630x10q.htm",
"contextRef": "Duration_1_1_2022_To_6_30_2022_KHKWq_OTTUqEPCrEoEzJ4w",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:SignificantAccountingPoliciesTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
}
},
"R8": {
"firstAnchor": {
"ancestors": [
"div",
"div",
"body",
"html"
],
"baseRef": "cldx-20220630x10q.htm",
"contextRef": "Duration_1_1_2022_To_6_30_2022_KHKWq_OTTUqEPCrEoEzJ4w",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:FairValueDisclosuresTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "10301 - Disclosure - Fair Value Measurements",
"role": "http://www.celldextherapeutics.com/role/DisclosureFairValueMeasurements",
"shortName": "Fair Value Measurements",
"subGroupType": "",
"uniqueAnchor": {
"ancestors": [
"div",
"div",
"body",
"html"
],
"baseRef": "cldx-20220630x10q.htm",
"contextRef": "Duration_1_1_2022_To_6_30_2022_KHKWq_OTTUqEPCrEoEzJ4w",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:FairValueDisclosuresTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
}
},
"R9": {
"firstAnchor": {
"ancestors": [
"div",
"div",
"body",
"html"
],
"baseRef": "cldx-20220630x10q.htm",
"contextRef": "Duration_1_1_2022_To_6_30_2022_KHKWq_OTTUqEPCrEoEzJ4w",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "10401 - Disclosure - Marketable Securities",
"role": "http://www.celldextherapeutics.com/role/DisclosureMarketableSecurities",
"shortName": "Marketable Securities",
"subGroupType": "",
"uniqueAnchor": {
"ancestors": [
"div",
"div",
"body",
"html"
],
"baseRef": "cldx-20220630x10q.htm",
"contextRef": "Duration_1_1_2022_To_6_30_2022_KHKWq_OTTUqEPCrEoEzJ4w",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
}
}
},
"segmentCount": 25,
"tag": {
"cldx_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughThreeYearsAmortizedCost": {
"auth_ref": [
],
"calculation": {
"http://www.celldextherapeutics.com/role/DisclosureMarketableSecuritiesDetails": {
"order": 2.0,
"parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of available-for-sale debt securities at cost, net of adjustments, maturing in the second fiscal year through the third fiscal year following the latest fiscal year.",
"label": "Available For Sale Securities, Debt Maturities after One Through Three Years, Amortized Cost",
"terseLabel": "Maturing after one year through three years"
}
}
},
"localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughThreeYearsAmortizedCost",
"nsuri": "http://www.celldextherapeutics.com/20220630",
"presentation": [
"http://www.celldextherapeutics.com/role/DisclosureMarketableSecuritiesDetails"
],
"xbrltype": "monetaryItemType"
},
"cldx_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughThreeYearsFairValue": {
"auth_ref": [
],
"calculation": {
"http://www.celldextherapeutics.com/role/DisclosureMarketableSecuritiesDetails": {
"order": 2.0,
"parentTag": "us-gaap_MarketableSecuritiesCurrent",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of available-for-sale debt securities at fair value maturing in the second fiscal year through the third fiscal year following the latest fiscal year.",
"label": "Available For Sale Securities, Debt Maturities after One Through Three Years, Fair Value",
"terseLabel": "Maturing after one year through three years"
}
}
},
"localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughThreeYearsFairValue",
"nsuri": "http://www.celldextherapeutics.com/20220630",
"presentation": [
"http://www.celldextherapeutics.com/role/DisclosureMarketableSecuritiesDetails"
],
"xbrltype": "monetaryItemType"
},
"cldx_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughThreeYearsGrossUnrealizedGain": {
"auth_ref": [
],
"calculation": {
"http://www.celldextherapeutics.com/role/DisclosureMarketableSecuritiesDetails": {
"order": 2.0,
"parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Represents the gross unrealized gains on securities, at a point in time, for those securities which are expected to mature after one year and through three years from the balance sheet date, and which are categorized neither as held-to-maturity nor as trading securities.",
"label": "Available For Sale Securities, Debt Maturities after One Through Three Years, Gross Unrealized Gain",
"terseLabel": "Maturing after one year through three years"
}
}
},
"localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughThreeYearsGrossUnrealizedGain",
"nsuri": "http://www.celldextherapeutics.com/20220630",
"presentation": [
"http://www.celldextherapeutics.com/role/DisclosureMarketableSecuritiesDetails"
],
"xbrltype": "monetaryItemType"
},
"cldx_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughThreeYearsGrossUnrealizedLosses": {
"auth_ref": [
],
"calculation": {
"http://www.celldextherapeutics.com/role/DisclosureMarketableSecuritiesDetails": {
"order": 2.0,
"parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Represents the gross unrealized losses on securities, at a point in time, which are expected to mature after one year and through three years from the balance sheet date, and which are categorized neither as held-to-maturity nor as trading securities.",
"label": "Available For Sale Securities, Debt Maturities after One Through Three Years, Gross Unrealized Losses",
"negatedLabel": "Maturing after one year through three years"
}
}
},
"localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughThreeYearsGrossUnrealizedLosses",
"nsuri": "http://www.celldextherapeutics.com/20220630",
"presentation": [
"http://www.celldextherapeutics.com/role/DisclosureMarketableSecuritiesDetails"
],
"xbrltype": "monetaryItemType"
},
"cldx_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearGrossUnrealizedGain": {
"auth_ref": [
],
"calculation": {
"http://www.celldextherapeutics.com/role/DisclosureMarketableSecuritiesDetails": {
"order": 1.0,
"parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Represents the gross unrealized gains on securities, at a point in time, for those securities which are expected to mature within one year of the balance sheet date, and which are categorized neither as held-to-maturity nor as trading securities.",
"label": "Available For Sale Securities, Debt Maturities within One Year Gross Unrealized Gain",
"terseLabel": "Maturing in one year or less"
}
}
},
"localname": "AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearGrossUnrealizedGain",
"nsuri": "http://www.celldextherapeutics.com/20220630",
"presentation": [
"http://www.celldextherapeutics.com/role/DisclosureMarketableSecuritiesDetails"
],
"xbrltype": "monetaryItemType"
},
"cldx_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearGrossUnrealizedLosses": {
"auth_ref": [
],
"calculation": {
"http://www.celldextherapeutics.com/role/DisclosureMarketableSecuritiesDetails": {
"order": 1.0,
"parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Represents the gross unrealized losses on securities, at a point in time, which are expected to mature within one year of the balance sheet date, and which are categorized neither as held-to-maturity nor as trading securities.",
"label": "Available For Sale Securities, Debt Maturities within One Year, Gross Unrealized Losses",
"negatedLabel": "Maturing in one year or less"
}
}
},
"localname": "AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearGrossUnrealizedLosses",
"nsuri": "http://www.celldextherapeutics.com/20220630",
"presentation": [
"http://www.celldextherapeutics.com/role/DisclosureMarketableSecuritiesDetails"
],
"xbrltype": "monetaryItemType"
},
"cldx_AvailableForSaleSecuritiesGrossUnrealizedLossesAbstract": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"label": "Available For Sale Securities, Gross Unrealized Losses [Abstract]",
"terseLabel": "Gross Unrealized Losses"
}
}
},
"localname": "AvailableForSaleSecuritiesGrossUnrealizedLossesAbstract",
"nsuri": "http://www.celldextherapeutics.com/20220630",
"presentation": [
"http://www.celldextherapeutics.com/role/DisclosureMarketableSecuritiesDetails"
],
"xbrltype": "stringItemType"
},
"cldx_BusinessCombinationContingentConsiderationContractualCreditInMergerAgreement": {
"auth_ref": [
],
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Represents the Business Combination Contingent Consideration Contractual Credit In Merger Agreement.",
"label": "Business Combination Contingent Consideration Contractual Credit In Merger Agreement",
"terseLabel": "Contractual credit merger agreement"
}
}
},
"localname": "BusinessCombinationContingentConsiderationContractualCreditInMergerAgreement",
"nsuri": "http://www.celldextherapeutics.com/20220630",
"presentation": [
"http://www.celldextherapeutics.com/role/DisclosureKolltanAcquisitionDetails"
],
"xbrltype": "monetaryItemType"
},
"cldx_BusinessCombinationContingentConsiderationSettlementAgreementAmountPaid": {
"auth_ref": [
],
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Represents the Business combination contingent consideration settlement agreement amount paid.",
"label": "Business Combination Contingent Consideration Settlement Agreement Amount Paid",
"terseLabel": "Execution of the settlement agreement"
}
}
},
"localname": "BusinessCombinationContingentConsiderationSettlementAgreementAmountPaid",
"nsuri": "http://www.celldextherapeutics.com/20220630",
"presentation": [
"http://www.celldextherapeutics.com/role/DisclosureKolltanAcquisitionDetails"
],
"xbrltype": "monetaryItemType"
},
"cldx_BusinessCombinationContingentConsiderationSettlementAgreementAmountPayable": {
"auth_ref": [
],
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Represents the Business Combination Contingent Consideration Settlement Agreement Amount Payable.",
"label": "Business Combination Contingent Consideration Settlement Agreement Amount Payable",
"terseLabel": "Business contingent amount payable"
}
}
},
"localname": "BusinessCombinationContingentConsiderationSettlementAgreementAmountPayable",
"nsuri": "http://www.celldextherapeutics.com/20220630",
"presentation": [
"http://www.celldextherapeutics.com/role/DisclosureKolltanAcquisitionDetails"
],
"xbrltype": "monetaryItemType"
},
"cldx_ClinicalTrailMember": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Represents the Clinical Trail Member.",
"label": "Clinical Trail [Member]"
}
}
},
"localname": "ClinicalTrailMember",
"nsuri": "http://www.celldextherapeutics.com/20220630",
"presentation": [
"http://www.celldextherapeutics.com/role/DisclosureKolltanAcquisitionDetails"
],
"xbrltype": "domainItemType"
},
"cldx_ContingentMilestoneMember": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Represents the contingent milestone related to achievement of specific development, regulatory approvals or sales-based milestones.",
"label": "Specified development, regulatory approvals or sales-based milestones"
}
}
},
"localname": "ContingentMilestoneMember",
"nsuri": "http://www.celldextherapeutics.com/20220630",
"presentation": [
"http://www.celldextherapeutics.com/role/DisclosureKolltanAcquisitionDetails"
],
"xbrltype": "domainItemType"
},
"cldx_DeferredIncomeFromSaleOfTaxBenefits": {
"auth_ref": [
],
"calculation": {
"http://www.celldextherapeutics.com/role/DisclosureOtherLongTermLiabilitiesDetails": {
"order": 2.0,
"parentTag": "us-gaap_OtherLiabilities",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Represents the deferred income from the sale of tax benefit.",
"label": "Deferred Income from Sale of Tax Benefits",
"terseLabel": "Deferred Income From Sale of Tax Benefits"
}
}
},
"localname": "DeferredIncomeFromSaleOfTaxBenefits",
"nsuri": "http://www.celldextherapeutics.com/20220630",
"presentation": [
"http://www.celldextherapeutics.com/role/DisclosureOtherLongTermLiabilitiesDetails"
],
"xbrltype": "monetaryItemType"
},
"cldx_EuropeanMedicinesAgencyMember": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Represents the European medicines agency member.",
"label": "European medicines agency"
}
}
},
"localname": "EuropeanMedicinesAgencyMember",
"nsuri": "http://www.celldextherapeutics.com/20220630",
"presentation": [
"http://www.celldextherapeutics.com/role/DisclosureKolltanAcquisitionDetails"
],
"xbrltype": "domainItemType"
},
"cldx_KolltanPharmaceuticalsMember": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Represents information pertaining to Kolltan, a privately-held, clinical-stage biopharmaceutical company.",
"label": "Kolltan"
}
}
},
"localname": "KolltanPharmaceuticalsMember",
"nsuri": "http://www.celldextherapeutics.com/20220630",
"presentation": [
"http://www.celldextherapeutics.com/role/DisclosureKolltanAcquisitionDetails"
],
"xbrltype": "domainItemType"
},
"cldx_LitigationSettlementPayable": {
"auth_ref": [
],
"calculation": {
"http://www.celldextherapeutics.com/role/StatementCondensedConsolidatedBalanceSheets": {
"order": 3.0,
"parentTag": "us-gaap_LiabilitiesCurrent",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of litigation expense, including but not limited to legal, forensic, accounting, and investigative fees.",
"label": "Litigation Settlement Payable",
"terseLabel": "Litigation settlement payable"
}
}
},
"localname": "LitigationSettlementPayable",
"nsuri": "http://www.celldextherapeutics.com/20220630",
"presentation": [
"http://www.celldextherapeutics.com/role/StatementCondensedConsolidatedBalanceSheets"
],
"xbrltype": "monetaryItemType"
},
"cldx_PeriodForWhichBaseOfOperationsMustBeMaintained": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Represents period for which base of operations must be maintained in New Jersey.",
"label": "Period for which Base of Operations Must be Maintained",
"terseLabel": "Base of operations requirement (in years)"
}
}
},
"localname": "PeriodForWhichBaseOfOperationsMustBeMaintained",
"nsuri": "http://www.celldextherapeutics.com/20220630",
"presentation": [
"http://www.celldextherapeutics.com/role/DisclosureOtherLongTermLiabilitiesNewJerseyTaxBenefitsDetails"
],
"xbrltype": "durationItemType"
},
"cldx_ProceedsFromSaleOfOperatingLossesAndTaxCredits": {
"auth_ref": [
],
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "The amount of net proceeds received or will be received from the sale of net operating losses and research and development tax credits under New Jersey.",
"label": "Proceeds from sale of operating losses and tax credits",
"terseLabel": "Proceeds from sale of tax credits"
}
}
},
"localname": "ProceedsFromSaleOfOperatingLossesAndTaxCredits",
"nsuri": "http://www.celldextherapeutics.com/20220630",
"presentation": [
"http://www.celldextherapeutics.com/role/DisclosureOtherLongTermLiabilitiesNewJerseyTaxBenefitsDetails"
],
"xbrltype": "monetaryItemType"
},
"cldx_RockefellerUniversityAndGileadSciencesMember": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Rockefeller University And Gilead Sciences [Member]",
"label": "Rockefeller University And Gilead Sciences [Member]",
"terseLabel": "Rockefeller University And Gilead Sciences"
}
}
},
"localname": "RockefellerUniversityAndGileadSciencesMember",
"nsuri": "http://www.celldextherapeutics.com/20220630",
"presentation": [
"http://www.celldextherapeutics.com/role/DisclosureRevenueDetails"
],
"xbrltype": "domainItemType"
},
"cldx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"label": "Share Based Compensation Arrangement by Share Based Payment Award, Options, Weighted Average Remaining Contractual Term [Abstract]",
"terseLabel": "Weighted Average Remaining Contractual Term (In Years)"
}
}
},
"localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract",
"nsuri": "http://www.celldextherapeutics.com/20220630",
"presentation": [
"http://www.celldextherapeutics.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails"
],
"xbrltype": "stringItemType"
},
"cldx_StockIssuedRemainingAuthorizedAmount": {
"auth_ref": [
],
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount remaining of stock issued authorized.",
"label": "Stock Issued Remaining Authorized Amount",
"terseLabel": "Aggregate gross offering price available"
}
}
},
"localname": "StockIssuedRemainingAuthorizedAmount",
"nsuri": "http://www.celldextherapeutics.com/20220630",
"presentation": [
"http://www.celldextherapeutics.com/role/DisclosureStockholdersEquityDetails"
],
"xbrltype": "monetaryItemType"
},
"dei_AmendmentFlag": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
"label": "Amendment Flag"
}
}
},
"localname": "AmendmentFlag",
"nsuri": "http://xbrl.sec.gov/dei/2022",
"presentation": [
"http://www.celldextherapeutics.com/role/DocumentDocumentAndEntityInformation"
],
"xbrltype": "booleanItemType"
},
"dei_CityAreaCode": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Area code of city",
"label": "City Area Code"
}
}
},
"localname": "CityAreaCode",
"nsuri": "http://xbrl.sec.gov/dei/2022",
"presentation": [
"http://www.celldextherapeutics.com/role/DocumentDocumentAndEntityInformation"
],
"xbrltype": "normalizedStringItemType"
},
"dei_CoverAbstract": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Cover page.",
"label": "Document and Entity Information"
}
}
},
"localname": "CoverAbstract",
"nsuri": "http://xbrl.sec.gov/dei/2022",
"xbrltype": "stringItemType"
},
"dei_CurrentFiscalYearEndDate": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "End date of current fiscal year in the format --MM-DD.",
"label": "Current Fiscal Year End Date"
}
}
},
"localname": "CurrentFiscalYearEndDate",
"nsuri": "http://xbrl.sec.gov/dei/2022",
"presentation": [
"http://www.celldextherapeutics.com/role/DocumentDocumentAndEntityInformation"
],
"xbrltype": "gMonthDayItemType"
},
"dei_DocumentFiscalPeriodFocus": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
"label": "Document Fiscal Period Focus"
}
}
},
"localname": "DocumentFiscalPeriodFocus",
"nsuri": "http://xbrl.sec.gov/dei/2022",
"presentation": [
"http://www.celldextherapeutics.com/role/DocumentDocumentAndEntityInformation"
],
"xbrltype": "fiscalPeriodItemType"
},
"dei_DocumentFiscalYearFocus": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
"label": "Document Fiscal Year Focus"
}
}
},
"localname": "DocumentFiscalYearFocus",
"nsuri": "http://xbrl.sec.gov/dei/2022",
"presentation": [
"http://www.celldextherapeutics.com/role/DocumentDocumentAndEntityInformation"
],
"xbrltype": "gYearItemType"
},
"dei_DocumentPeriodEndDate": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.",
"label": "Document Period End Date"
}
}
},
"localname": "DocumentPeriodEndDate",
"nsuri": "http://xbrl.sec.gov/dei/2022",
"presentation": [
"http://www.celldextherapeutics.com/role/DocumentDocumentAndEntityInformation"
],
"xbrltype": "dateItemType"
},
"dei_DocumentQuarterlyReport": {
"auth_ref": [
"r397"
],
"lang": {
"en-us": {
"role": {
"documentation": "Boolean flag that is true only for a form used as an quarterly report.",
"label": "Document Quarterly Report"
}
}
},
"localname": "DocumentQuarterlyReport",
"nsuri": "http://xbrl.sec.gov/dei/2022",
"presentation": [
"http://www.celldextherapeutics.com/role/DocumentDocumentAndEntityInformation"
],
"xbrltype": "booleanItemType"
},
"dei_DocumentTransitionReport": {
"auth_ref": [
"r398"
],
"lang": {
"en-us": {
"role": {
"documentation": "Boolean flag that is true only for a form used as a transition report.",
"label": "Document Transition Report"
}
}
},
"localname": "DocumentTransitionReport",
"nsuri": "http://xbrl.sec.gov/dei/2022",
"presentation": [
"http://www.celldextherapeutics.com/role/DocumentDocumentAndEntityInformation"
],
"xbrltype": "booleanItemType"
},
"dei_DocumentType": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
"label": "Document Type"
}
}
},
"localname": "DocumentType",
"nsuri": "http://xbrl.sec.gov/dei/2022",
"presentation": [
"http://www.celldextherapeutics.com/role/DocumentDocumentAndEntityInformation"
],
"xbrltype": "submissionTypeItemType"
},
"dei_EntityAddressAddressLine1": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Address Line 1 such as Attn, Building Name, Street Name",
"label": "Entity Address, Address Line One"
}
}
},
"localname": "EntityAddressAddressLine1",
"nsuri": "http://xbrl.sec.gov/dei/2022",
"presentation": [
"http://www.celldextherapeutics.com/role/DocumentDocumentAndEntityInformation"
],
"xbrltype": "normalizedStringItemType"
},
"dei_EntityAddressAddressLine2": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Address Line 2 such as Street or Suite number",
"label": "Entity Address, Address Line Two"
}
}
},
"localname": "EntityAddressAddressLine2",
"nsuri": "http://xbrl.sec.gov/dei/2022",
"presentation": [
"http://www.celldextherapeutics.com/role/DocumentDocumentAndEntityInformation"
],
"xbrltype": "normalizedStringItemType"
},
"dei_EntityAddressAddressLine3": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Address Line 3 such as an Office Park",
"label": "Entity Address, Address Line Three"
}
}
},
"localname": "EntityAddressAddressLine3",
"nsuri": "http://xbrl.sec.gov/dei/2022",
"presentation": [
"http://www.celldextherapeutics.com/role/DocumentDocumentAndEntityInformation"
],
"xbrltype": "normalizedStringItemType"
},
"dei_EntityAddressCityOrTown": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Name of the City or Town",
"label": "Entity Address, City or Town"
}
}
},
"localname": "EntityAddressCityOrTown",
"nsuri": "http://xbrl.sec.gov/dei/2022",
"presentation": [
"http://www.celldextherapeutics.com/role/DocumentDocumentAndEntityInformation"
],
"xbrltype": "normalizedStringItemType"
},
"dei_EntityAddressPostalZipCode": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Code for the postal or zip code",
"label": "Entity Address, Postal Zip Code"
}
}
},
"localname": "EntityAddressPostalZipCode",
"nsuri": "http://xbrl.sec.gov/dei/2022",
"presentation": [
"http://www.celldextherapeutics.com/role/DocumentDocumentAndEntityInformation"
],
"xbrltype": "normalizedStringItemType"
},
"dei_EntityAddressStateOrProvince": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Name of the state or province.",
"label": "Entity Address, State or Province"
}
}
},
"localname": "EntityAddressStateOrProvince",
"nsuri": "http://xbrl.sec.gov/dei/2022",
"presentation": [
"http://www.celldextherapeutics.com/role/DocumentDocumentAndEntityInformation"
],
"xbrltype": "stateOrProvinceItemType"
},
"dei_EntityCentralIndexKey": {
"auth_ref": [
"r395"
],
"lang": {
"en-us": {
"role": {
"documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
"label": "Entity Central Index Key"
}
}
},
"localname": "EntityCentralIndexKey",
"nsuri": "http://xbrl.sec.gov/dei/2022",
"presentation": [
"http://www.celldextherapeutics.com/role/DocumentDocumentAndEntityInformation"
],
"xbrltype": "centralIndexKeyItemType"
},
"dei_EntityCommonStockSharesOutstanding": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
"label": "Entity Common Stock, Shares Outstanding"
}
}
},
"localname": "EntityCommonStockSharesOutstanding",
"nsuri": "http://xbrl.sec.gov/dei/2022",
"presentation": [
"http://www.celldextherapeutics.com/role/DocumentDocumentAndEntityInformation"
],
"xbrltype": "sharesItemType"
},
"dei_EntityCurrentReportingStatus": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
"label": "Entity Current Reporting Status"
}
}
},
"localname": "EntityCurrentReportingStatus",
"nsuri": "http://xbrl.sec.gov/dei/2022",
"presentation": [
"http://www.celldextherapeutics.com/role/DocumentDocumentAndEntityInformation"
],
"xbrltype": "yesNoItemType"
},
"dei_EntityEmergingGrowthCompany": {
"auth_ref": [
"r395"
],
"lang": {
"en-us": {
"role": {
"documentation": "Indicate if registrant meets the emerging growth company criteria.",
"label": "Entity Emerging Growth Company"
}
}
},
"localname": "EntityEmergingGrowthCompany",
"nsuri": "http://xbrl.sec.gov/dei/2022",
"presentation": [
"http://www.celldextherapeutics.com/role/DocumentDocumentAndEntityInformation"
],
"xbrltype": "booleanItemType"
},
"dei_EntityFileNumber": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
"label": "Entity File Number"
}
}
},
"localname": "EntityFileNumber",
"nsuri": "http://xbrl.sec.gov/dei/2022",
"presentation": [
"http://www.celldextherapeutics.com/role/DocumentDocumentAndEntityInformation"
],
"xbrltype": "fileNumberItemType"
},
"dei_EntityFilerCategory": {
"auth_ref": [
"r395"
],
"lang": {
"en-us": {
"role": {
"documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
"label": "Entity Filer Category"
}
}
},
"localname": "EntityFilerCategory",
"nsuri": "http://xbrl.sec.gov/dei/2022",
"presentation": [
"http://www.celldextherapeutics.com/role/DocumentDocumentAndEntityInformation"
],
"xbrltype": "filerCategoryItemType"
},
"dei_EntityIncorporationStateCountryCode": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Two-character EDGAR code representing the state or country of incorporation.",
"label": "Entity Incorporation, State or Country Code"
}
}
},
"localname": "EntityIncorporationStateCountryCode",
"nsuri": "http://xbrl.sec.gov/dei/2022",
"presentation": [
"http://www.celldextherapeutics.com/role/DocumentDocumentAndEntityInformation"
],
"xbrltype": "edgarStateCountryItemType"
},
"dei_EntityInteractiveDataCurrent": {
"auth_ref": [
"r407"
],
"lang": {
"en-us": {
"role": {
"documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
"label": "Entity Interactive Data Current"
}
}
},
"localname": "EntityInteractiveDataCurrent",
"nsuri": "http://xbrl.sec.gov/dei/2022",
"presentation": [
"http://www.celldextherapeutics.com/role/DocumentDocumentAndEntityInformation"
],
"xbrltype": "yesNoItemType"
},
"dei_EntityRegistrantName": {
"auth_ref": [
"r395"
],
"lang": {
"en-us": {
"role": {
"documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
"label": "Entity Registrant Name"
}
}
},
"localname": "EntityRegistrantName",
"nsuri": "http://xbrl.sec.gov/dei/2022",
"presentation": [
"http://www.celldextherapeutics.com/role/DocumentDocumentAndEntityInformation"
],
"xbrltype": "normalizedStringItemType"
},
"dei_EntityShellCompany": {
"auth_ref": [
"r395"
],
"lang": {
"en-us": {
"role": {
"documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
"label": "Entity Shell Company"
}
}
},
"localname": "EntityShellCompany",
"nsuri": "http://xbrl.sec.gov/dei/2022",
"presentation": [
"http://www.celldextherapeutics.com/role/DocumentDocumentAndEntityInformation"
],
"xbrltype": "booleanItemType"
},
"dei_EntitySmallBusiness": {
"auth_ref": [
"r395"
],
"lang": {
"en-us": {
"role": {
"documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
"label": "Entity Small Business"
}
}
},
"localname": "EntitySmallBusiness",
"nsuri": "http://xbrl.sec.gov/dei/2022",
"presentation": [
"http://www.celldextherapeutics.com/role/DocumentDocumentAndEntityInformation"
],
"xbrltype": "booleanItemType"
},
"dei_EntityTaxIdentificationNumber": {
"auth_ref": [
"r395"
],
"lang": {
"en-us": {
"role": {
"documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
"label": "Entity Tax Identification Number"
}
}
},
"localname": "EntityTaxIdentificationNumber",
"nsuri": "http://xbrl.sec.gov/dei/2022",
"presentation": [
"http://www.celldextherapeutics.com/role/DocumentDocumentAndEntityInformation"
],
"xbrltype": "employerIdItemType"
},
"dei_LocalPhoneNumber": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Local phone number for entity.",
"label": "Local Phone Number"
}
}
},
"localname": "LocalPhoneNumber",
"nsuri": "http://xbrl.sec.gov/dei/2022",
"presentation": [
"http://www.celldextherapeutics.com/role/DocumentDocumentAndEntityInformation"
],
"xbrltype": "normalizedStringItemType"
},
"dei_Security12bTitle": {
"auth_ref": [
"r394"
],
"lang": {
"en-us": {
"role": {
"documentation": "Title of a 12(b) registered security.",
"label": "Title of 12(b) Security"
}
}
},
"localname": "Security12bTitle",
"nsuri": "http://xbrl.sec.gov/dei/2022",
"presentation": [
"http://www.celldextherapeutics.com/role/DocumentDocumentAndEntityInformation"
],
"xbrltype": "securityTitleItemType"
},
"dei_SecurityExchangeName": {
"auth_ref": [
"r396"
],
"lang": {
"en-us": {
"role": {
"documentation": "Name of the Exchange on which a security is registered.",
"label": "Security Exchange Name"
}
}
},
"localname": "SecurityExchangeName",
"nsuri": "http://xbrl.sec.gov/dei/2022",
"presentation": [
"http://www.celldextherapeutics.com/role/DocumentDocumentAndEntityInformation"
],
"xbrltype": "edgarExchangeCodeItemType"
},
"dei_TradingSymbol": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Trading symbol of an instrument as listed on an exchange.",
"label": "Trading Symbol"
}
}
},
"localname": "TradingSymbol",
"nsuri": "http://xbrl.sec.gov/dei/2022",
"presentation": [
"http://www.celldextherapeutics.com/role/DocumentDocumentAndEntityInformation"
],
"xbrltype": "tradingSymbolItemType"
},
"srt_MajorCustomersAxis": {
"auth_ref": [
"r110",
"r192",
"r197",
"r384"
],
"lang": {
"en-us": {
"role": {
"label": "Customer [Axis]"
}
}
},
"localname": "MajorCustomersAxis",
"nsuri": "http://fasb.org/srt/2022",
"presentation": [
"http://www.celldextherapeutics.com/role/DisclosureRevenueDetails"
],
"xbrltype": "stringItemType"
},
"srt_NameOfMajorCustomerDomain": {
"auth_ref": [
"r110",
"r192",
"r197",
"r384"
],
"lang": {
"en-us": {
"role": {
"label": "Customer [Domain]"
}
}
},
"localname": "NameOfMajorCustomerDomain",
"nsuri": "http://fasb.org/srt/2022",
"presentation": [
"http://www.celldextherapeutics.com/role/DisclosureRevenueDetails"
],
"xbrltype": "domainItemType"
},
"srt_ProductOrServiceAxis": {
"auth_ref": [
"r108",
"r146",
"r147",
"r192",
"r196",
"r354",
"r382",
"r383"
],
"lang": {
"en-us": {
"role": {
"label": "Products and Services [Axis]"
}
}
},
"localname": "ProductOrServiceAxis",
"nsuri": "http://fasb.org/srt/2022",
"presentation": [
"http://www.celldextherapeutics.com/role/DisclosureRevenueDetails",
"http://www.celldextherapeutics.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"
],
"xbrltype": "stringItemType"
},
"srt_ProductsAndServicesDomain": {
"auth_ref": [
"r108",
"r146",
"r147",
"r192",
"r196",
"r354",
"r382",
"r383"
],
"lang": {
"en-us": {
"role": {
"label": "Products and Services [Domain]"
}
}
},
"localname": "ProductsAndServicesDomain",
"nsuri": "http://fasb.org/srt/2022",
"presentation": [
"http://www.celldextherapeutics.com/role/DisclosureRevenueDetails",
"http://www.celldextherapeutics.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"
],
"xbrltype": "domainItemType"
},
"us-gaap_AccountingPoliciesAbstract": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"label": "Significant Accounting Policies"
}
}
},
"localname": "AccountingPoliciesAbstract",
"nsuri": "http://fasb.org/us-gaap/2022",
"xbrltype": "stringItemType"
},
"us-gaap_AccountsAndOtherReceivablesNetCurrent": {
"auth_ref": [
],
"calculation": {
"http://www.celldextherapeutics.com/role/StatementCondensedConsolidatedBalanceSheets": {
"order": 3.0,
"parentTag": "us-gaap_AssetsCurrent",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount, after allowance, receivable from customers, clients, or other third-parties, and receivables classified as other due within one year or the normal operating cycle, if longer.",
"label": "Accounts and Other Receivables, Net, Current",
"terseLabel": "Accounts and other receivables"
}
}
},
"localname": "AccountsAndOtherReceivablesNetCurrent",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.celldextherapeutics.com/role/StatementCondensedConsolidatedBalanceSheets"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_AccountsPayableCurrent": {
"auth_ref": [
"r17",
"r322"
],
"calculation": {
"http://www.celldextherapeutics.com/role/StatementCondensedConsolidatedBalanceSheets": {
"order": 1.0,
"parentTag": "us-gaap_LiabilitiesCurrent",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
"label": "Accounts Payable, Current",
"terseLabel": "Accounts payable"
}
}
},
"localname": "AccountsPayableCurrent",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.celldextherapeutics.com/role/StatementCondensedConsolidatedBalanceSheets"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments": {
"auth_ref": [
"r56"
],
"calculation": {
"http://www.celldextherapeutics.com/role/StatementCondensedConsolidatedStatementsOfCashFlow": {
"order": 3.0,
"parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
"weight": -1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method.",
"label": "Accretion (Amortization) of Discounts and Premiums, Investments",
"negatedLabel": "Amortization and premium of marketable securities, net"
}
}
},
"localname": "AccretionAmortizationOfDiscountsAndPremiumsInvestments",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.celldextherapeutics.com/role/StatementCondensedConsolidatedStatementsOfCashFlow"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_AccruedLiabilitiesCurrent": {
"auth_ref": [
"r19"
],
"calculation": {
"http://www.celldextherapeutics.com/role/StatementCondensedConsolidatedBalanceSheets": {
"order": 2.0,
"parentTag": "us-gaap_LiabilitiesCurrent",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
"label": "Accrued Liabilities, Current",
"terseLabel": "Accrued expenses"
}
}
},
"localname": "AccruedLiabilitiesCurrent",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.celldextherapeutics.com/role/StatementCondensedConsolidatedBalanceSheets"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember": {
"auth_ref": [
"r26",
"r27",
"r28",
"r32",
"r37",
"r38",
"r39"
],
"lang": {
"en-us": {
"role": {
"documentation": "Accumulated unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), attributable to parent.",
"label": "Unrealized Gain (Loss) on Marketable Securities, net of tax"
}
}
},
"localname": "AccumulatedNetUnrealizedInvestmentGainLossMember",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.celldextherapeutics.com/role/DisclosureAccumulatedOtherComprehensiveIncomeDetails"
],
"xbrltype": "domainItemType"
},
"us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
"label": "Accumulated Other Comprehensive Income (Loss) [Line Items]",
"terseLabel": "Accumulated Other Comprehensive Income"
}
}
},
"localname": "AccumulatedOtherComprehensiveIncomeLossLineItems",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.celldextherapeutics.com/role/DisclosureAccumulatedOtherComprehensiveIncomeDetails"
],
"xbrltype": "stringItemType"
},
"us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
"auth_ref": [
"r12",
"r30",
"r31",
"r32",
"r372",
"r389",
"r390"
],
"calculation": {
"http://www.celldextherapeutics.com/role/StatementCondensedConsolidatedBalanceSheets": {
"order": 4.0,
"parentTag": "us-gaap_StockholdersEquity",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
"label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
"terseLabel": "Accumulated other comprehensive income"
}
}
},
"localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.celldextherapeutics.com/role/StatementCondensedConsolidatedBalanceSheets"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_AccumulatedOtherComprehensiveIncomeLossTable": {
"auth_ref": [
"r37",
"r38",
"r310",
"r311",
"r312",
"r313",
"r314",
"r316"
],
"lang": {
"en-us": {
"role": {
"documentation": "Disclosure of information about components of accumulated other comprehensive income (loss).",
"label": "Accumulated Other Comprehensive Income (Loss) [Table]"
}
}
},
"localname": "AccumulatedOtherComprehensiveIncomeLossTable",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.celldextherapeutics.com/role/DisclosureAccumulatedOtherComprehensiveIncomeDetails"
],
"xbrltype": "stringItemType"
},
"us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
"auth_ref": [
"r29",
"r32",
"r37",
"r38",
"r39",
"r68",
"r69",
"r70",
"r287",
"r319",
"r385",
"r386"
],
"lang": {
"en-us": {
"role": {
"documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
"label": "Accumulated Other Comprehensive Income."
}
}
},
"localname": "AccumulatedOtherComprehensiveIncomeMember",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.celldextherapeutics.com/role/DisclosureAccumulatedOtherComprehensiveIncomeDetails",
"http://www.celldextherapeutics.com/role/DisclosureStockholdersEquityDetails"
],
"xbrltype": "domainItemType"
},
"us-gaap_AccumulatedTranslationAdjustmentMember": {
"auth_ref": [
"r25",
"r32",
"r37",
"r38",
"r39",
"r287",
"r311",
"r312",
"r313",
"r314",
"r316"
],
"lang": {
"en-us": {
"role": {
"documentation": "Accumulated other comprehensive income (loss) resulting from foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to the parent.",
"label": "Foreign Currency Items"
}
}
},
"localname": "AccumulatedTranslationAdjustmentMember",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.celldextherapeutics.com/role/DisclosureAccumulatedOtherComprehensiveIncomeDetails"
],
"xbrltype": "domainItemType"
},
"us-gaap_AdditionalPaidInCapitalCommonStock": {
"auth_ref": [
"r10"
],
"calculation": {
"http://www.celldextherapeutics.com/role/StatementCondensedConsolidatedBalanceSheets": {
"order": 3.0,
"parentTag": "us-gaap_StockholdersEquity",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.",
"label": "Additional Paid in Capital, Common Stock",
"terseLabel": "Additional paid-in capital"
}
}
},
"localname": "AdditionalPaidInCapitalCommonStock",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.celldextherapeutics.com/role/StatementCondensedConsolidatedBalanceSheets"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_AdditionalPaidInCapitalMember": {
"auth_ref": [
"r68",
"r69",
"r70",
"r250",
"r251",
"r252",
"r293"
],
"lang": {
"en-us": {
"role": {
"documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
"label": "Additional Paid-In Capital"
}
}
},
"localname": "AdditionalPaidInCapitalMember",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.celldextherapeutics.com/role/DisclosureStockholdersEquityDetails"
],
"xbrltype": "domainItemType"
},
"us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
"auth_ref": [
"r210",
"r254",
"r255"
],
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
"label": "Adjustments to Additional Paid in Capital, Share-based Compensation, Requisite Service Period Recognition",
"terseLabel": "Stock-based compensation"
}
}
},
"localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.celldextherapeutics.com/role/DisclosureStockholdersEquityDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
"terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:"
}
}
},
"localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.celldextherapeutics.com/role/StatementCondensedConsolidatedStatementsOfCashFlow"
],
"xbrltype": "stringItemType"
},
"us-gaap_AllocatedShareBasedCompensationExpense": {
"auth_ref": [
"r244"
],
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
"label": "Allocated Share-based Compensation Expense",
"terseLabel": "Total stock-based compensation expense"
}
}
},
"localname": "AllocatedShareBasedCompensationExpense",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.celldextherapeutics.com/role/DisclosureStockBasedCompensationExpensesDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
"auth_ref": [
"r87"
],
"lang": {
"en-us": {
"role": {
"documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
"label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
"terseLabel": "Potentially dilutive common shares not been included in net loss per common share calculations because the effect would have been anti-dilutive"
}
}
},
"localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.celldextherapeutics.com/role/DisclosureNetLossPerShareDetails"
],
"xbrltype": "sharesItemType"
},
"us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
"auth_ref": [
"r87"
],
"lang": {
"en-us": {
"role": {
"documentation": "Information by type of antidilutive security.",
"label": "Antidilutive Securities [Axis]"
}
}
},
"localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.celldextherapeutics.com/role/DisclosureNetLossPerShareDetails"
],
"xbrltype": "stringItemType"
},
"us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
"label": "Anti-dilutive securities"
}
}
},
"localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.celldextherapeutics.com/role/DisclosureNetLossPerShareDetails"
],
"xbrltype": "stringItemType"
},
"us-gaap_AntidilutiveSecuritiesNameDomain": {
"auth_ref": [
"r87"
],
"lang": {
"en-us": {
"role": {
"documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.",
"label": "Antidilutive Securities, Name [Domain]"
}
}
},
"localname": "AntidilutiveSecuritiesNameDomain",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.celldextherapeutics.com/role/DisclosureNetLossPerShareDetails"
],
"xbrltype": "domainItemType"
},
"us-gaap_Assets": {
"auth_ref": [
"r6",
"r64",
"r97",
"r100",
"r106",
"r126",
"r148",
"r149",
"r150",
"r151",
"r152",
"r153",
"r154",
"r155",
"r156",
"r157",
"r158",
"r285",
"r288",
"r308",
"r320",
"r322",
"r357",
"r371"
],
"calculation": {
"http://www.celldextherapeutics.com/role/StatementCondensedConsolidatedBalanceSheets": {
"order": null,
"parentTag": null,
"root": true,
"weight": null
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
"label": "Assets",
"totalLabel": "Total assets"
}
}
},
"localname": "Assets",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.celldextherapeutics.com/role/StatementCondensedConsolidatedBalanceSheets"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_AssetsAbstract": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"label": "Assets [Abstract]",
"terseLabel": "Assets"
}
}
},
"localname": "AssetsAbstract",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.celldextherapeutics.com/role/StatementCondensedConsolidatedBalanceSheets"
],
"xbrltype": "stringItemType"
},
"us-gaap_AssetsCurrent": {
"auth_ref": [
"r2",
"r16",
"r64",
"r126",
"r148",
"r149",
"r150",
"r151",
"r152",
"r153",
"r154",
"r155",
"r156",
"r157",
"r158",
"r285",
"r288",
"r308",
"r320",
"r322"
],
"calculation": {
"http://www.celldextherapeutics.com/role/StatementCondensedConsolidatedBalanceSheets": {
"order": 1.0,
"parentTag": "us-gaap_Assets",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
"label": "Assets, Current",
"totalLabel": "Total current assets"
}
}
},
"localname": "AssetsCurrent",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.celldextherapeutics.com/role/StatementCondensedConsolidatedBalanceSheets"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_AssetsCurrentAbstract": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"label": "Assets, Current [Abstract]",
"terseLabel": "Current assets:"
}
}
},
"localname": "AssetsCurrentAbstract",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.celldextherapeutics.com/role/StatementCondensedConsolidatedBalanceSheets"
],
"xbrltype": "stringItemType"
},
"us-gaap_AssetsFairValueDisclosure": {
"auth_ref": [
"r296"
],
"calculation": {
"http://www.celldextherapeutics.com/role/DisclosureFairValueMeasurementsDetails": {
"order": null,
"parentTag": null,
"root": true,
"weight": null
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
"label": "Assets, Fair Value Disclosure",
"totalLabel": "Total financial assets at fair value"
}
}
},
"localname": "AssetsFairValueDisclosure",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.celldextherapeutics.com/role/DisclosureFairValueMeasurementsDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_AssetsFairValueDisclosureAbstract": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"label": "Assets:"
}
}
},
"localname": "AssetsFairValueDisclosureAbstract",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.celldextherapeutics.com/role/DisclosureFairValueMeasurementsDetails"
],
"xbrltype": "stringItemType"
},
"us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": {
"auth_ref": [
"r114"
],
"calculation": {
"http://www.celldextherapeutics.com/role/DisclosureMarketableSecuritiesDetails": {
"order": null,
"parentTag": null,
"root": true,
"weight": null
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
"label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax",
"totalLabel": "Gross Unrealized Gains"
}
}
},
"localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.celldextherapeutics.com/role/DisclosureMarketableSecuritiesDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": {
"auth_ref": [
"r115"
],
"calculation": {
"http://www.celldextherapeutics.com/role/DisclosureMarketableSecuritiesDetails": {
"order": null,
"parentTag": null,
"root": true,
"weight": null
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
"label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax",
"negatedTotalLabel": "Gross Unrealized Losses"
}
}
},
"localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.celldextherapeutics.com/role/DisclosureMarketableSecuritiesDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": {
"auth_ref": [
"r113",
"r133"
],
"calculation": {
"http://www.celldextherapeutics.com/role/DisclosureMarketableSecuritiesDetails": {
"order": null,
"parentTag": null,
"root": true,
"weight": null
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
"label": "Available-for-sale Debt Securities, Amortized Cost Basis",
"totalLabel": "Amortized Cost"
}
}
},
"localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.celldextherapeutics.com/role/DisclosureMarketableSecuritiesDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"label": "Available-for-sale Securities, Debt Maturities, Amortized Cost Basis, Fiscal Year Maturity [Abstract]",
"terseLabel": "Amortized Cost"
}
}
},
"localname": "AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.celldextherapeutics.com/role/DisclosureMarketableSecuritiesDetails"
],
"xbrltype": "stringItemType"
},
"us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"label": "Available-for-sale Securities, Debt Maturities, Fair Value, Fiscal Year Maturity [Abstract]",
"terseLabel": "Fair Value"
}
}
},
"localname": "AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.celldextherapeutics.com/role/DisclosureMarketableSecuritiesDetails"
],
"xbrltype": "stringItemType"
},
"us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost": {
"auth_ref": [
"r117"
],
"calculation": {
"http://www.celldextherapeutics.com/role/DisclosureMarketableSecuritiesDetails": {
"order": 1.0,
"parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
"label": "Available-for-sale Securities, Debt Maturities, Next Twelve Months, Amortized Cost Basis",
"terseLabel": "Maturing in one year or less"
}
}
},
"localname": "AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.celldextherapeutics.com/role/DisclosureMarketableSecuritiesDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue": {
"auth_ref": [
"r116",
"r117",
"r368"
],
"calculation": {
"http://www.celldextherapeutics.com/role/DisclosureMarketableSecuritiesDetails": {
"order": 1.0,
"parentTag": "us-gaap_MarketableSecuritiesCurrent",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
"label": "Available-for-sale Securities, Debt Maturities, Next Twelve Months, Fair Value",
"terseLabel": "Maturing in one year or less"
}
}
},
"localname": "AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.celldextherapeutics.com/role/DisclosureMarketableSecuritiesDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_AvailableForSaleSecuritiesGrossUnrealizedGainLossAbstract": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"label": "Available-for-sale Securities, Gross Unrealized Gain [Abstract]",
"terseLabel": "Gross Unrealized Gains"
}
}
},
"localname": "AvailableForSaleSecuritiesGrossUnrealizedGainLossAbstract",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.celldextherapeutics.com/role/DisclosureMarketableSecuritiesDetails"
],
"xbrltype": "stringItemType"
},
"us-gaap_AwardTypeAxis": {
"auth_ref": [
"r213",
"r214",
"r215",
"r217",
"r218",
"r219",
"r220",
"r221",
"r222",
"r223",
"r224",
"r225",
"r226",
"r227",
"r228",
"r229",
"r230",
"r232",
"r233",
"r235",
"r236",
"r238",
"r239",
"r240",
"r241",
"r242"
],
"lang": {
"en-us": {
"role": {
"documentation": "Information by type of award under share-based payment arrangement.",
"label": "Award Type [Axis]"
}
}
},
"localname": "AwardTypeAxis",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.celldextherapeutics.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails",
"http://www.celldextherapeutics.com/role/DisclosureStockBasedCompensationValuationDetails"
],
"xbrltype": "stringItemType"
},
"us-gaap_BasisOfAccounting": {
"auth_ref": [
"r67"
],
"lang": {
"en-us": {
"role": {
"documentation": "The entire disclosure for the basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
"label": "Basis of Accounting [Text Block]",
"terseLabel": "Basis of Presentation"
}
}
},
"localname": "BasisOfAccounting",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.celldextherapeutics.com/role/DisclosureBasisOfPresentation"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_BusinessAcquisitionAcquireeDomain": {
"auth_ref": [
"r207",
"r208",
"r275"
],
"lang": {
"en-us": {
"role": {
"documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree.",
"label": "Business Acquisition, Acquiree [Domain]"
}
}
},
"localname": "BusinessAcquisitionAcquireeDomain",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.celldextherapeutics.com/role/DisclosureKolltanAcquisitionDetails"
],
"xbrltype": "domainItemType"
},
"us-gaap_BusinessAcquisitionAxis": {
"auth_ref": [
"r207",
"r208",
"r273",
"r274",
"r275"
],
"lang": {
"en-us": {
"role": {
"documentation": "Information by business combination or series of individually immaterial business combinations.",
"label": "Business Acquisition [Axis]"
}
}
},
"localname": "BusinessAcquisitionAxis",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.celldextherapeutics.com/role/DisclosureKolltanAcquisitionDetails"
],
"xbrltype": "stringItemType"
},
"us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued": {
"auth_ref": [
"r279"
],
"lang": {
"en-us": {
"role": {
"documentation": "Number of shares of equity interests issued or issuable to acquire entity.",
"label": "Business Acquisition, Equity Interest Issued or Issuable, Number of Shares",
"terseLabel": "Shares issued as part of consideration (in shares)"
}
}
},
"localname": "BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.celldextherapeutics.com/role/DisclosureKolltanAcquisitionDetails"
],
"xbrltype": "sharesItemType"
},
"us-gaap_BusinessAcquisitionLineItems": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
"label": "Business Acquisition [Line Items]",
"terseLabel": "Kolltan Acquisition"
}
}
},
"localname": "BusinessAcquisitionLineItems",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.celldextherapeutics.com/role/DisclosureKolltanAcquisitionDetails"
],
"xbrltype": "stringItemType"
},
"us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1": {
"auth_ref": [
"r54",
"r282"
],
"calculation": {
"http://www.celldextherapeutics.com/role/StatementCondensedConsolidatedStatementsOfCashFlow": {
"order": 5.0,
"parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
"weight": -1.0
},
"http://www.celldextherapeutics.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
"order": 4.0,
"parentTag": "us-gaap_CostsAndExpenses",
"weight": -1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of increase (decrease) in the value of right to a contingent consideration asset.",
"label": "Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Asset",
"negatedLabel": "(Gain) loss on fair value remeasurement of contingent consideration",
"negatedTerseLabel": "(Gain) loss on fair value remeasurement of contingent consideration",
"verboseLabel": "Gain on Fair Value Remeasurement of Contingent Consideration"
}
}
},
"localname": "BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.celldextherapeutics.com/role/DisclosureFairValueMeasurementsAdditionalInformationDetails",
"http://www.celldextherapeutics.com/role/StatementCondensedConsolidatedStatementsOfCashFlow",
"http://www.celldextherapeutics.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1": {
"auth_ref": [
"r54",
"r282"
],
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.",
"label": "Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability",
"verboseLabel": "Fair value adjustments included in operating expenses"
}
}
},
"localname": "BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.celldextherapeutics.com/role/DisclosureFairValueMeasurementsContingentConsiderationLiabilitiesDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh": {
"auth_ref": [
"r281"
],
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "For contingent consideration arrangements recognized in connection with a business combination, this element represents an estimate of the high-end of the potential range (undiscounted) of the consideration which may be paid.",
"label": "Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High",
"terseLabel": "Potential milestone payments"
}
}
},
"localname": "BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.celldextherapeutics.com/role/DisclosureKolltanAcquisitionDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_BusinessCombinationContingentConsiderationLiability": {
"auth_ref": [
"r277",
"r278",
"r280"
],
"calculation": {
"http://www.celldextherapeutics.com/role/DisclosureFairValueMeasurementsDetails": {
"order": 1.0,
"parentTag": "us-gaap_LiabilitiesFairValueDisclosure",
"weight": 1.0
},
"http://www.celldextherapeutics.com/role/DisclosureOtherLongTermLiabilitiesDetails": {
"order": 3.0,
"parentTag": "us-gaap_OtherLiabilities",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of liability recognized arising from contingent consideration in a business combination.",
"label": "Business Combination, Contingent Consideration, Liability",
"periodEndLabel": "Balance at end of period",
"periodStartLabel": "Balance at beginning of period",
"terseLabel": "Contingent milestones (Note 3 and Note 13)",
"verboseLabel": "Kolltan acquisition contingent consideration"
}
}
},
"localname": "BusinessCombinationContingentConsiderationLiability",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.celldextherapeutics.com/role/DisclosureFairValueMeasurementsContingentConsiderationLiabilitiesDetails",
"http://www.celldextherapeutics.com/role/DisclosureFairValueMeasurementsDetails",
"http://www.celldextherapeutics.com/role/DisclosureOtherLongTermLiabilitiesDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_BusinessCombinationDisclosureTextBlock": {
"auth_ref": [
"r276",
"r283"
],
"lang": {
"en-us": {
"role": {
"documentation": "The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).",
"label": "Business Combination Disclosure [Text Block]",
"terseLabel": "Kolltan Acquisition"
}
}
},
"localname": "BusinessCombinationDisclosureTextBlock",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.celldextherapeutics.com/role/DisclosureKolltanAcquisition"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_BusinessCombinationsAbstract": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"label": "Kolltan Acquisition"
}
}
},
"localname": "BusinessCombinationsAbstract",
"nsuri": "http://fasb.org/us-gaap/2022",
"xbrltype": "stringItemType"
},
"us-gaap_CashAndCashEquivalentsAtCarryingValue": {
"auth_ref": [
"r1",
"r4",
"r57"
],
"calculation": {
"http://www.celldextherapeutics.com/role/StatementCondensedConsolidatedBalanceSheets": {
"order": 1.0,
"parentTag": "us-gaap_AssetsCurrent",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
"label": "Cash and Cash Equivalents, at Carrying Value",
"terseLabel": "Cash and cash equivalents"
}
}
},
"localname": "CashAndCashEquivalentsAtCarryingValue",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.celldextherapeutics.com/role/StatementCondensedConsolidatedBalanceSheets"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_CashAndCashEquivalentsFairValueDisclosure": {
"auth_ref": [
],
"calculation": {
"http://www.celldextherapeutics.com/role/DisclosureFairValueMeasurementsDetails": {
"order": 1.0,
"parentTag": "us-gaap_AssetsFairValueDisclosure",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
"label": "Cash and Cash Equivalents, Fair Value Disclosure",
"terseLabel": "Money market funds and cash equivalents"
}
}
},
"localname": "CashAndCashEquivalentsFairValueDisclosure",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.celldextherapeutics.com/role/DisclosureFairValueMeasurementsDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
"auth_ref": [
"r52",
"r57",
"r61"
],
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
"label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
"periodEndLabel": "Cash and cash equivalents at end of period",
"periodStartLabel": "Cash and cash equivalents at beginning of period"
}
}
},
"localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.celldextherapeutics.com/role/StatementCondensedConsolidatedStatementsOfCashFlow"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
"auth_ref": [
"r52",
"r309"
],
"calculation": {
"http://www.celldextherapeutics.com/role/StatementCondensedConsolidatedStatementsOfCashFlow": {
"order": null,
"parentTag": null,
"root": true,
"weight": null
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
"label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
"totalLabel": "Net decrease in cash and cash equivalents"
}
}
},
"localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.celldextherapeutics.com/role/StatementCondensedConsolidatedStatementsOfCashFlow"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"label": "Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]",
"terseLabel": "Non-cash investing activities"
}
}
},
"localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.celldextherapeutics.com/role/StatementCondensedConsolidatedStatementsOfCashFlow"
],
"xbrltype": "stringItemType"
},
"us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
"label": "Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]",
"verboseLabel": "Revenue"
}
}
},
"localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.celldextherapeutics.com/role/DisclosureRevenueDetails"
],
"xbrltype": "stringItemType"
},
"us-gaap_CommitmentsAndContingencies": {
"auth_ref": [
"r23",
"r360",
"r376"
],
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
"label": "Commitments and Contingencies.",
"terseLabel": "Commitments and contingent liabilities"
}
}
},
"localname": "CommitmentsAndContingencies",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.celldextherapeutics.com/role/StatementCondensedConsolidatedBalanceSheets"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_CommonStockMember": {
"auth_ref": [
"r68",
"r69",
"r293"
],
"lang": {
"en-us": {
"role": {
"documentation": "Stock that is subordinate to all other stock of the issuer.",
"label": "Common Stock"
}
}
},
"localname": "CommonStockMember",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.celldextherapeutics.com/role/DisclosureStockholdersEquityDetails"
],
"xbrltype": "domainItemType"
},
"us-gaap_CommonStockParOrStatedValuePerShare": {
"auth_ref": [
"r8"
],
"lang": {
"en-us": {
"role": {
"documentation": "Face amount or stated value per share of common stock.",
"label": "Common Stock, Par or Stated Value Per Share",
"terseLabel": "Common Stock, Par Value (in dollars per share)"
}
}
},
"localname": "CommonStockParOrStatedValuePerShare",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.celldextherapeutics.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical"
],
"xbrltype": "perShareItemType"
},
"us-gaap_CommonStockSharesAuthorized": {
"auth_ref": [
"r8"
],
"lang": {
"en-us": {
"role": {
"documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
"label": "Common Stock, Shares Authorized",
"terseLabel": "Common Stock, Shares Authorized"
}
}
},
"localname": "CommonStockSharesAuthorized",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.celldextherapeutics.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical"
],
"xbrltype": "sharesItemType"
},
"us-gaap_CommonStockSharesIssued": {
"auth_ref": [
"r8"
],
"lang": {
"en-us": {
"role": {
"documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
"label": "Common Stock, Shares, Issued",
"periodEndLabel": "Balance (in shares)",
"periodStartLabel": "Balance (in shares)",
"terseLabel": "Common Stock, Shares Issued"
}
}
},
"localname": "CommonStockSharesIssued",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.celldextherapeutics.com/role/DisclosureStockholdersEquityDetails",
"http://www.celldextherapeutics.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical"
],
"xbrltype": "sharesItemType"
},
"us-gaap_CommonStockSharesOutstanding": {
"auth_ref": [
"r8",
"r177"
],
"lang": {
"en-us": {
"role": {
"documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
"label": "Common Stock, Shares, Outstanding",
"terseLabel": "Common Stock, Shares Outstanding"
}
}
},
"localname": "CommonStockSharesOutstanding",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.celldextherapeutics.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical"
],
"xbrltype": "sharesItemType"
},
"us-gaap_CommonStockValue": {
"auth_ref": [
"r8",
"r322"
],
"calculation": {
"http://www.celldextherapeutics.com/role/StatementCondensedConsolidatedBalanceSheets": {
"order": 2.0,
"parentTag": "us-gaap_StockholdersEquity",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
"label": "Common Stock, Value, Issued",
"verboseLabel": "Common stock, $.001 par value; 297,000,000 shares authorized; 46,764,703 and 46,730,198 shares issued and outstanding at June 30, 2022 and December 31, 2021, respectively"
}
}
},
"localname": "CommonStockValue",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.celldextherapeutics.com/role/StatementCondensedConsolidatedBalanceSheets"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_ComprehensiveIncomeNetOfTax": {
"auth_ref": [
"r34",
"r35",
"r36",
"r43",
"r364",
"r379"
],
"calculation": {
"http://www.celldextherapeutics.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
"order": null,
"parentTag": null,
"root": true,
"weight": null
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
"label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
"totalLabel": "Comprehensive loss"
}
}
},
"localname": "ComprehensiveIncomeNetOfTax",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.celldextherapeutics.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_ComprehensiveIncomeNetOfTaxAbstract": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"label": "Accumulated Other Comprehensive Income",
"terseLabel": "Comprehensive loss:"
}
}
},
"localname": "ComprehensiveIncomeNetOfTaxAbstract",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.celldextherapeutics.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"
],
"xbrltype": "stringItemType"
},
"us-gaap_ComprehensiveIncomeNoteTextBlock": {
"auth_ref": [
"r42",
"r48",
"r363",
"r378"
],
"lang": {
"en-us": {
"role": {
"documentation": "The entire disclosure for comprehensive income, which includes, but is not limited to, 1) the amount of income tax expense or benefit allocated to each component of other comprehensive income, including reclassification adjustments, 2) the reclassification adjustments for each classification of other comprehensive income and 3) the ending accumulated balances for each component of comprehensive income.",
"label": "Comprehensive Income (Loss) Note [Text Block]",
"terseLabel": "Accumulated Other Comprehensive Income"
}
}
},
"localname": "ComprehensiveIncomeNoteTextBlock",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.celldextherapeutics.com/role/DisclosureAccumulatedOtherComprehensiveIncome"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_ConstructionInProgressExpendituresIncurredButNotYetPaid": {
"auth_ref": [
"r58",
"r59",
"r60"
],
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Future cash outflow to pay for construction in progress expenditures that have occurred.",
"label": "Construction in Progress Expenditures Incurred but Not yet Paid",
"terseLabel": "Accrued construction in progress"
}
}
},
"localname": "ConstructionInProgressExpendituresIncurredButNotYetPaid",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.celldextherapeutics.com/role/StatementCondensedConsolidatedStatementsOfCashFlow"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_ContingentConsiderationByTypeAxis": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Information by type of contingent consideration.",
"label": "Contingent Consideration by Type [Axis]"
}
}
},
"localname": "ContingentConsiderationByTypeAxis",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.celldextherapeutics.com/role/DisclosureKolltanAcquisitionDetails"
],
"xbrltype": "stringItemType"
},
"us-gaap_ContingentConsiderationTypeDomain": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Description of contingent payment arrangement.",
"label": "Contingent Consideration Type [Domain]"
}
}
},
"localname": "ContingentConsiderationTypeDomain",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.celldextherapeutics.com/role/DisclosureKolltanAcquisitionDetails"
],
"xbrltype": "domainItemType"
},
"us-gaap_ContractWithCustomerAssetNet": {
"auth_ref": [
"r180",
"r182",
"r193"
],
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time.",
"label": "Contract with Customer, Asset, after Allowance for Credit Loss",
"verboseLabel": "Contract assets"
}
}
},
"localname": "ContractWithCustomerAssetNet",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.celldextherapeutics.com/role/DisclosureRevenueDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_ContractWithCustomerLiability": {
"auth_ref": [
"r180",
"r181",
"r193"
],
"calculation": {
"http://www.celldextherapeutics.com/role/DisclosureOtherLongTermLiabilitiesDetails": {
"order": 4.0,
"parentTag": "us-gaap_OtherLiabilities",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.",
"label": "Contract with Customer, Liability",
"terseLabel": "Contract liability",
"verboseLabel": "Deferred revenue (Note 10)"
}
}
},
"localname": "ContractWithCustomerLiability",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.celldextherapeutics.com/role/DisclosureOtherLongTermLiabilitiesDetails",
"http://www.celldextherapeutics.com/role/DisclosureRevenueDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_ContractWithCustomerLiabilityRevenueRecognized": {
"auth_ref": [
"r194"
],
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.",
"label": "Contract with Customer, Liability, Revenue Recognized",
"terseLabel": "Revenue, contract liabilities"
}
}
},
"localname": "ContractWithCustomerLiabilityRevenueRecognized",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.celldextherapeutics.com/role/DisclosureRevenueDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_CorporateDebtSecuritiesMember": {
"auth_ref": [
"r199",
"r206",
"r391"
],
"lang": {
"en-us": {
"role": {
"documentation": "Debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment.",
"label": "Corporate debt securities"
}
}
},
"localname": "CorporateDebtSecuritiesMember",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.celldextherapeutics.com/role/DisclosureMarketableSecuritiesDetails"
],
"xbrltype": "domainItemType"
},
"us-gaap_CostsAndExpenses": {
"auth_ref": [
"r46"
],
"calculation": {
"http://www.celldextherapeutics.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
"order": 2.0,
"parentTag": "us-gaap_OperatingIncomeLoss",
"weight": -1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Total costs of sales and operating expenses for the period.",
"label": "Costs and Expenses",
"totalLabel": "Total operating expenses"
}
}
},
"localname": "CostsAndExpenses",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.celldextherapeutics.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_CostsAndExpensesAbstract": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"label": "Costs and Expenses [Abstract]",
"terseLabel": "Operating expenses:"
}
}
},
"localname": "CostsAndExpensesAbstract",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.celldextherapeutics.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"
],
"xbrltype": "stringItemType"
},
"us-gaap_CurrentStateAndLocalTaxExpenseBenefit": {
"auth_ref": [
"r65",
"r264",
"r268"
],
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of current state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.",
"label": "Current State and Local Tax Expense (Benefit)",
"terseLabel": "Amount of tax benefit"
}
}
},
"localname": "CurrentStateAndLocalTaxExpenseBenefit",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.celldextherapeutics.com/role/DisclosureOtherLongTermLiabilitiesNewJerseyTaxBenefitsDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_DebtSecuritiesAvailableForSaleTable": {
"auth_ref": [
"r122"
],
"lang": {
"en-us": {
"role": {
"documentation": "Disclosure of information about investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
"label": "Debt Securities, Available-for-sale [Table]"
}
}
},
"localname": "DebtSecuritiesAvailableForSaleTable",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.celldextherapeutics.com/role/DisclosureMarketableSecuritiesDetails"
],
"xbrltype": "stringItemType"
},
"us-gaap_DeferredTaxLiabilities": {
"auth_ref": [
"r258",
"r262"
],
"calculation": {
"http://www.celldextherapeutics.com/role/DisclosureOtherLongTermLiabilitiesDetails": {
"order": 1.0,
"parentTag": "us-gaap_OtherLiabilities",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting.",
"label": "Deferred Tax Liabilities, Net",
"terseLabel": "Net deferred tax liabilities related to IPR&D (Note 11)",
"verboseLabel": "Net deferred tax liability"
}
}
},
"localname": "DeferredTaxLiabilities",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.celldextherapeutics.com/role/DisclosureIncomeTaxesDetails",
"http://www.celldextherapeutics.com/role/DisclosureOtherLongTermLiabilitiesDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_DepreciationDepletionAndAmortization": {
"auth_ref": [
"r55",
"r96"
],
"calculation": {
"http://www.celldextherapeutics.com/role/StatementCondensedConsolidatedStatementsOfCashFlow": {
"order": 2.0,
"parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.",
"label": ".Depreciation, Depletion and Amortization",
"terseLabel": "Depreciation and amortization"
}
}
},
"localname": "DepreciationDepletionAndAmortization",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.celldextherapeutics.com/role/StatementCondensedConsolidatedStatementsOfCashFlow"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
"auth_ref": [
"r212",
"r213",
"r245",
"r246",
"r248",
"r256"
],
"lang": {
"en-us": {
"role": {
"documentation": "The entire disclosure for share-based payment arrangement.",
"label": "Disclosure of Compensation Related Costs, Share-based Payments [Text Block]",
"terseLabel": "Stock-Based Compensation"
}
}
},
"localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.celldextherapeutics.com/role/DisclosureStockBasedCompensation"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"label": "Stock-Based Compensation"
}
}
},
"localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
"nsuri": "http://fasb.org/us-gaap/2022",
"xbrltype": "stringItemType"
},
"us-gaap_EarningsPerShareAbstract": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"label": "Net Loss Per Share"
}
}
},
"localname": "EarningsPerShareAbstract",
"nsuri": "http://fasb.org/us-gaap/2022",
"xbrltype": "stringItemType"
},
"us-gaap_EarningsPerShareBasic": {
"auth_ref": [
"r44",
"r72",
"r73",
"r74",
"r75",
"r76",
"r79",
"r82",
"r84",
"r85",
"r86",
"r90",
"r91",
"r294",
"r295",
"r365",
"r380"
],
"lang": {
"en-us": {
"role": {
"documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
"label": "Earnings Per Share, Basic",
"terseLabel": "Basic net loss per common share"
}
}
},
"localname": "EarningsPerShareBasic",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.celldextherapeutics.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"
],
"xbrltype": "perShareItemType"
},
"us-gaap_EarningsPerShareDiluted": {
"auth_ref": [
"r44",
"r72",
"r73",
"r74",
"r75",
"r76",
"r82",
"r84",
"r85",
"r86",
"r90",
"r91",
"r294",
"r295",
"r365",
"r380"
],
"lang": {
"en-us": {
"role": {
"documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
"label": "Earnings Per Share, Diluted",
"terseLabel": "Diluted net loss per common share"
}
}
},
"localname": "EarningsPerShareDiluted",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.celldextherapeutics.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"
],
"xbrltype": "perShareItemType"
},
"us-gaap_EarningsPerShareTextBlock": {
"auth_ref": [
"r87",
"r88",
"r89",
"r92"
],
"lang": {
"en-us": {
"role": {
"documentation": "The entire disclosure for earnings per share.",
"label": "Earnings Per Share [Text Block]",
"terseLabel": "Net Loss Per Share"
}
}
},
"localname": "EarningsPerShareTextBlock",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.celldextherapeutics.com/role/DisclosureNetLossPerShare"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
"label": "Valuation and Expenses Information",
"verboseLabel": "Stock-based compensation expense"
}
}
},
"localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.celldextherapeutics.com/role/DisclosureStockBasedCompensationExpensesDetails",
"http://www.celldextherapeutics.com/role/DisclosureStockBasedCompensationValuationDetails"
],
"xbrltype": "stringItemType"
},
"us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
"auth_ref": [
"r247"
],
"lang": {
"en-us": {
"role": {
"documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
"label": "Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition",
"terseLabel": "Weighted average period compensation cost is expected to be recognized (in years)"
}
}
},
"localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.celldextherapeutics.com/role/DisclosureStockBasedCompensationEmployeeStockOptionAndIncentivePlanActivityAdditionalInformationDetails"
],
"xbrltype": "durationItemType"
},
"us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": {
"auth_ref": [
"r247"
],
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of cost to be recognized for option under share-based payment arrangement.",
"label": "Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Stock Options",
"terseLabel": "Compensation cost not yet recognized"
}
}
},
"localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.celldextherapeutics.com/role/DisclosureStockBasedCompensationEmployeeStockOptionAndIncentivePlanActivityAdditionalInformationDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_EmployeeStockOptionMember": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
"label": "Stock Options"
}
}
},
"localname": "EmployeeStockOptionMember",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.celldextherapeutics.com/role/DisclosureNetLossPerShareDetails",
"http://www.celldextherapeutics.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails",
"http://www.celldextherapeutics.com/role/DisclosureStockBasedCompensationValuationDetails"
],
"xbrltype": "domainItemType"
},
"us-gaap_EquityComponentDomain": {
"auth_ref": [
"r0",
"r37",
"r38",
"r39",
"r68",
"r69",
"r70",
"r71",
"r77",
"r78",
"r93",
"r127",
"r177",
"r178",
"r250",
"r251",
"r252",
"r265",
"r266",
"r293",
"r310",
"r311",
"r312",
"r313",
"r314",
"r316",
"r319",
"r385",
"r386",
"r387"
],
"lang": {
"en-us": {
"role": {
"documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
"label": "Equity Component [Domain]"
}
}
},
"localname": "EquityComponentDomain",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.celldextherapeutics.com/role/DisclosureAccumulatedOtherComprehensiveIncomeDetails",
"http://www.celldextherapeutics.com/role/DisclosureStockholdersEquityDetails"
],
"xbrltype": "domainItemType"
},
"us-gaap_EstimateOfFairValueFairValueDisclosureMember": {
"auth_ref": [
"r159",
"r161",
"r162",
"r307"
],
"lang": {
"en-us": {
"role": {
"documentation": "Measured as an estimate of fair value.",
"label": "Fair value"
}
}
},
"localname": "EstimateOfFairValueFairValueDisclosureMember",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.celldextherapeutics.com/role/DisclosureFairValueMeasurementsAdditionalInformationDetails",
"http://www.celldextherapeutics.com/role/DisclosureFairValueMeasurementsContingentConsiderationLiabilitiesDetails",
"http://www.celldextherapeutics.com/role/DisclosureFairValueMeasurementsDetails"
],
"xbrltype": "domainItemType"
},
"us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
"label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
"terseLabel": "Fair value measurements"
}
}
},
"localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.celldextherapeutics.com/role/DisclosureFairValueMeasurementsAdditionalInformationDetails",
"http://www.celldextherapeutics.com/role/DisclosureFairValueMeasurementsContingentConsiderationLiabilitiesDetails",
"http://www.celldextherapeutics.com/role/DisclosureFairValueMeasurementsDetails"
],
"xbrltype": "stringItemType"
},
"us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
"auth_ref": [
"r296",
"r297",
"r303"
],
"lang": {
"en-us": {
"role": {
"documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.",
"label": "Fair Value Measurements, Recurring and Nonrecurring [Table]"
}
}
},
"localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.celldextherapeutics.com/role/DisclosureFairValueMeasurementsAdditionalInformationDetails",
"http://www.celldextherapeutics.com/role/DisclosureFairValueMeasurementsContingentConsiderationLiabilitiesDetails",
"http://www.celldextherapeutics.com/role/DisclosureFairValueMeasurementsDetails"
],
"xbrltype": "stringItemType"
},
"us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock": {
"auth_ref": [
"r296",
"r297"
],
"lang": {
"en-us": {
"role": {
"documentation": "Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).",
"label": "Fair Value, Assets Measured on Recurring Basis [Table Text Block]",
"terseLabel": "Schedule of financial assets and liabilities subject to fair value measurements"
}
}
},
"localname": "FairValueAssetsMeasuredOnRecurringBasisTextBlock",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.celldextherapeutics.com/role/DisclosureFairValueMeasurementsTables"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_FairValueByFairValueHierarchyLevelAxis": {
"auth_ref": [
"r159",
"r161",
"r162",
"r199",
"r200",
"r201",
"r202",
"r203",
"r204",
"r205",
"r206",
"r297",
"r326",
"r327",
"r328"
],
"lang": {
"en-us": {
"role": {
"documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
"label": "Fair Value, Hierarchy [Axis]"
}
}
},
"localname": "FairValueByFairValueHierarchyLevelAxis",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.celldextherapeutics.com/role/DisclosureFairValueMeasurementsContingentConsiderationLiabilitiesDetails",
"http://www.celldextherapeutics.com/role/DisclosureFairValueMeasurementsDetails"
],
"xbrltype": "stringItemType"
},
"us-gaap_FairValueByMeasurementBasisAxis": {
"auth_ref": [
"r159",
"r161",
"r162",
"r296",
"r304"
],
"lang": {
"en-us": {
"role": {
"documentation": "Information by measurement basis.",
"label": "Measurement Basis [Axis]"
}
}
},
"localname": "FairValueByMeasurementBasisAxis",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.celldextherapeutics.com/role/DisclosureFairValueMeasurementsAdditionalInformationDetails",
"http://www.celldextherapeutics.com/role/DisclosureFairValueMeasurementsContingentConsiderationLiabilitiesDetails",
"http://www.celldextherapeutics.com/role/DisclosureFairValueMeasurementsDetails"
],
"xbrltype": "stringItemType"
},
"us-gaap_FairValueByMeasurementFrequencyAxis": {
"auth_ref": [
"r296",
"r297",
"r298",
"r299",
"r305"
],
"lang": {
"en-us": {
"role": {
"documentation": "Information by measurement frequency.",
"label": "Measurement Frequency [Axis]"
}
}
},
"localname": "FairValueByMeasurementFrequencyAxis",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.celldextherapeutics.com/role/DisclosureFairValueMeasurementsDetails"
],
"xbrltype": "stringItemType"
},
"us-gaap_FairValueDisclosuresAbstract": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"label": "Fair Value Measurements"
}
}
},
"localname": "FairValueDisclosuresAbstract",
"nsuri": "http://fasb.org/us-gaap/2022",
"xbrltype": "stringItemType"
},
"us-gaap_FairValueDisclosuresTextBlock": {
"auth_ref": [
"r302"
],
"lang": {
"en-us": {
"role": {
"documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.",
"label": "Fair Value Disclosures [Text Block]",
"terseLabel": "Fair Value Measurements"
}
}
},
"localname": "FairValueDisclosuresTextBlock",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.celldextherapeutics.com/role/DisclosureFairValueMeasurements"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_FairValueInputsLevel1Member": {
"auth_ref": [
"r159",
"r199",
"r200",
"r205",
"r206",
"r297",
"r326"
],
"lang": {
"en-us": {
"role": {
"documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
"label": "Level 1"
}
}
},
"localname": "FairValueInputsLevel1Member",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.celldextherapeutics.com/role/DisclosureFairValueMeasurementsDetails"
],
"xbrltype": "domainItemType"
},
"us-gaap_FairValueInputsLevel2Member": {
"auth_ref": [
"r159",
"r161",
"r162",
"r199",
"r200",
"r205",
"r206",
"r297",
"r327"
],
"lang": {
"en-us": {
"role": {
"documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
"label": "Level 2"
}
}
},
"localname": "FairValueInputsLevel2Member",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.celldextherapeutics.com/role/DisclosureFairValueMeasurementsDetails"
],
"xbrltype": "domainItemType"
},
"us-gaap_FairValueInputsLevel3Member": {
"auth_ref": [
"r159",
"r161",
"r162",
"r199",
"r200",
"r201",
"r202",
"r203",
"r204",
"r205",
"r206",
"r297",
"r328"
],
"lang": {
"en-us": {
"role": {
"documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
"label": "Level 3"
}
}
},
"localname": "FairValueInputsLevel3Member",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.celldextherapeutics.com/role/DisclosureFairValueMeasurementsContingentConsiderationLiabilitiesDetails",
"http://www.celldextherapeutics.com/role/DisclosureFairValueMeasurementsDetails"
],
"xbrltype": "domainItemType"
},
"us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
"label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]",
"terseLabel": "Contingent consideration liabilities measured at fair value"
}
}
},
"localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.celldextherapeutics.com/role/DisclosureFairValueMeasurementsContingentConsiderationLiabilitiesDetails"
],
"xbrltype": "stringItemType"
},
"us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": {
"auth_ref": [
"r300",
"r303"
],
"lang": {
"en-us": {
"role": {
"documentation": "Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.",
"label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]",
"terseLabel": "Schedule of the contingent consideration liabilities measured at fair value using Level 3 inputs"
}
}
},
"localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.celldextherapeutics.com/role/DisclosureFairValueMeasurementsTables"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_FairValueMeasurementFrequencyDomain": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Measurement frequency.",
"label": "Fair Value, Measurement Frequency [Domain]"
}
}
},
"localname": "FairValueMeasurementFrequencyDomain",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.celldextherapeutics.com/role/DisclosureFairValueMeasurementsDetails"
],
"xbrltype": "domainItemType"
},
"us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3": {
"auth_ref": [
"r301"
],
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of transfers of financial instrument classified as a liability out of level 3 of the fair value hierarchy.",
"label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Liability, Transfers out of Level 3",
"terseLabel": "Liabilities transfers out of level 3"
}
}
},
"localname": "FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.celldextherapeutics.com/role/DisclosureFairValueMeasurementsAdditionalInformationDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3": {
"auth_ref": [
"r301"
],
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of transfer of financial instrument classified as an asset into level 3 of the fair value hierarchy.",
"label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset Transfers Into Level 3",
"terseLabel": "Asset transfer into level 3"
}
}
},
"localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.celldextherapeutics.com/role/DisclosureFairValueMeasurementsAdditionalInformationDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3": {
"auth_ref": [
"r301"
],
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of transfers of financial instrument classified as an asset out of level 3 of the fair value hierarchy.",
"label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Transfers out of Level 3",
"terseLabel": "Asset transfer out of level 3"
}
}
},
"localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.celldextherapeutics.com/role/DisclosureFairValueMeasurementsAdditionalInformationDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
"auth_ref": [
"r159",
"r161",
"r162",
"r199",
"r200",
"r201",
"r202",
"r203",
"r204",
"r205",
"r206",
"r326",
"r327",
"r328"
],
"lang": {
"en-us": {
"role": {
"documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
"label": "Fair Value Hierarchy [Domain]"
}
}
},
"localname": "FairValueMeasurementsFairValueHierarchyDomain",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.celldextherapeutics.com/role/DisclosureFairValueMeasurementsContingentConsiderationLiabilitiesDetails",
"http://www.celldextherapeutics.com/role/DisclosureFairValueMeasurementsDetails"
],
"xbrltype": "domainItemType"
},
"us-gaap_FairValueMeasurementsRecurringMember": {
"auth_ref": [
"r302",
"r305"
],
"lang": {
"en-us": {
"role": {
"documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.",
"label": "Fair Value Measurements."
}
}
},
"localname": "FairValueMeasurementsRecurringMember",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.celldextherapeutics.com/role/DisclosureFairValueMeasurementsDetails"
],
"xbrltype": "domainItemType"
},
"us-gaap_FinancialInstrumentAxis": {
"auth_ref": [
"r118",
"r119",
"r123",
"r124",
"r125",
"r128",
"r129",
"r130",
"r131",
"r132",
"r134",
"r135",
"r136",
"r137",
"r160",
"r175",
"r291",
"r323",
"r324",
"r325",
"r326",
"r327",
"r328",
"r329",
"r330",
"r331",
"r332",
"r333",
"r334",
"r335",
"r336",
"r337",
"r338",
"r339",
"r340",
"r341",
"r342",
"r343",
"r344",
"r345",
"r346",
"r347",
"r348",
"r349",
"r350",
"r351",
"r352",
"r399",
"r400",
"r401",
"r402",
"r403",
"r404",
"r405"
],
"lang": {
"en-us": {
"role": {
"documentation": "Information by type of financial instrument.",
"label": "Financial Instrument [Axis]"
}
}
},
"localname": "FinancialInstrumentAxis",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.celldextherapeutics.com/role/DisclosureKolltanAcquisitionDetails",
"http://www.celldextherapeutics.com/role/DisclosureMarketableSecuritiesDetails"
],
"xbrltype": "stringItemType"
},
"us-gaap_GainLossOnSaleOfPropertyPlantEquipment": {
"auth_ref": [
"r55"
],
"calculation": {
"http://www.celldextherapeutics.com/role/StatementCondensedConsolidatedStatementsOfCashFlow": {
"order": 4.0,
"parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
"weight": -1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property.",
"label": "Gain (Loss) on Disposition of Property Plant Equipment",
"negatedTerseLabel": "Loss (gain) on sale or disposal of assets"
}
}
},
"localname": "GainLossOnSaleOfPropertyPlantEquipment",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.celldextherapeutics.com/role/StatementCondensedConsolidatedStatementsOfCashFlow"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_GainLossRelatedToLitigationSettlement": {
"auth_ref": [
"r145"
],
"calculation": {
"http://www.celldextherapeutics.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
"order": 3.0,
"parentTag": "us-gaap_CostsAndExpenses",
"weight": -1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of gain (loss) recognized in settlement of litigation and insurance claims. Excludes claims within an insurance entity's normal claims settlement process.",
"label": "Gain (Loss) Related to Litigation Settlement",
"negatedLabel": "Litigation settlement related loss"
}
}
},
"localname": "GainLossRelatedToLitigationSettlement",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.celldextherapeutics.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_GeneralAndAdministrativeExpense": {
"auth_ref": [
"r47"
],
"calculation": {
"http://www.celldextherapeutics.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
"order": 2.0,
"parentTag": "us-gaap_CostsAndExpenses",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
"label": "General and Administrative Expense",
"terseLabel": "General and administrative"
}
}
},
"localname": "GeneralAndAdministrativeExpense",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.celldextherapeutics.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_GeneralAndAdministrativeExpenseMember": {
"auth_ref": [
"r45"
],
"lang": {
"en-us": {
"role": {
"documentation": "Primary financial statement caption encompassing general and administrative expense.",
"label": "General and administrative"
}
}
},
"localname": "GeneralAndAdministrativeExpenseMember",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.celldextherapeutics.com/role/DisclosureStockBasedCompensationExpensesDetails"
],
"xbrltype": "domainItemType"
},
"us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"label": "Intangible Assets"
}
}
},
"localname": "GoodwillAndIntangibleAssetsDisclosureAbstract",
"nsuri": "http://fasb.org/us-gaap/2022",
"xbrltype": "stringItemType"
},
"us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock": {
"auth_ref": [
"r141"
],
"lang": {
"en-us": {
"role": {
"documentation": "The entire disclosure for goodwill and intangible assets.",
"label": "Goodwill and Intangible Assets Disclosure [Text Block]",
"terseLabel": "Intangible Assets"
}
}
},
"localname": "GoodwillAndIntangibleAssetsDisclosureTextBlock",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.celldextherapeutics.com/role/DisclosureIntangibleAssets"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_GrantMember": {
"auth_ref": [
"r196"
],
"lang": {
"en-us": {
"role": {
"documentation": "Award of money not required to be repaid.",
"label": "Contracts and grants"
}
}
},
"localname": "GrantMember",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.celldextherapeutics.com/role/DisclosureRevenueDetails",
"http://www.celldextherapeutics.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"
],
"xbrltype": "domainItemType"
},
"us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
"auth_ref": [
"r41",
"r97",
"r99",
"r102",
"r105",
"r107",
"r355",
"r362",
"r366",
"r381"
],
"calculation": {
"http://www.celldextherapeutics.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
"order": 1.0,
"parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.",
"label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
"totalLabel": "Net loss"
}
}
},
"localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.celldextherapeutics.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_IncomeStatementAbstract": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"label": "CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS"
}
}
},
"localname": "IncomeStatementAbstract",
"nsuri": "http://fasb.org/us-gaap/2022",
"xbrltype": "stringItemType"
},
"us-gaap_IncomeStatementLocationAxis": {
"auth_ref": [
"r143",
"r144"
],
"lang": {
"en-us": {
"role": {
"documentation": "Information by location in the income statement.",
"label": "Income Statement Location [Axis]"
}
}
},
"localname": "IncomeStatementLocationAxis",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.celldextherapeutics.com/role/DisclosureStockBasedCompensationExpensesDetails"
],
"xbrltype": "stringItemType"
},
"us-gaap_IncomeStatementLocationDomain": {
"auth_ref": [
"r144"
],
"lang": {
"en-us": {
"role": {
"documentation": "Location in the income statement.",
"label": "Income Statement Location [Domain]"
}
}
},
"localname": "IncomeStatementLocationDomain",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.celldextherapeutics.com/role/DisclosureStockBasedCompensationExpensesDetails"
],
"xbrltype": "domainItemType"
},
"us-gaap_IncomeTaxAuthorityNameAxis": {
"auth_ref": [
"r260"
],
"lang": {
"en-us": {
"role": {
"documentation": "Information by name of taxing authority.",
"label": "Income Tax Authority, Name [Axis]"
}
}
},
"localname": "IncomeTaxAuthorityNameAxis",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.celldextherapeutics.com/role/DisclosureOtherLongTermLiabilitiesNewJerseyTaxBenefitsDetails"
],
"xbrltype": "stringItemType"
},
"us-gaap_IncomeTaxAuthorityNameDomain": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Named agency, division or body that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes.",
"label": "Income Tax Authority, Name [Domain]"
}
}
},
"localname": "IncomeTaxAuthorityNameDomain",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.celldextherapeutics.com/role/DisclosureOtherLongTermLiabilitiesNewJerseyTaxBenefitsDetails"
],
"xbrltype": "domainItemType"
},
"us-gaap_IncomeTaxDisclosureAbstract": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"label": "Income Taxes"
}
}
},
"localname": "IncomeTaxDisclosureAbstract",
"nsuri": "http://fasb.org/us-gaap/2022",
"xbrltype": "stringItemType"
},
"us-gaap_IncomeTaxDisclosureTextBlock": {
"auth_ref": [
"r66",
"r259",
"r261",
"r263",
"r267",
"r269",
"r270",
"r271",
"r272"
],
"lang": {
"en-us": {
"role": {
"documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
"label": "Income Tax Disclosure [Text Block]",
"terseLabel": "Income Taxes"
}
}
},
"localname": "IncomeTaxDisclosureTextBlock",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.celldextherapeutics.com/role/DisclosureIncomeTaxes"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables": {
"auth_ref": [
"r54"
],
"calculation": {
"http://www.celldextherapeutics.com/role/StatementCondensedConsolidatedStatementsOfCashFlow": {
"order": 7.0,
"parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
"weight": -1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "The increase (decrease) during the reporting period in the amount due from customers for the credit sale of goods and services; includes accounts receivable and other types of receivables.",
"label": "Increase (Decrease) in Accounts and Other Receivables",
"negatedLabel": "Accounts and other receivables"
}
}
},
"localname": "IncreaseDecreaseInAccountsAndOtherReceivables",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.celldextherapeutics.com/role/StatementCondensedConsolidatedStatementsOfCashFlow"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": {
"auth_ref": [
"r54"
],
"calculation": {
"http://www.celldextherapeutics.com/role/StatementCondensedConsolidatedStatementsOfCashFlow": {
"order": 9.0,
"parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.",
"label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities",
"terseLabel": "Accounts payable and accrued expenses"
}
}
},
"localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.celldextherapeutics.com/role/StatementCondensedConsolidatedStatementsOfCashFlow"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"label": "Increase (Decrease) in Operating Capital [Abstract]",
"terseLabel": "Changes in operating assets and liabilities:"
}
}
},
"localname": "IncreaseDecreaseInOperatingCapitalAbstract",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.celldextherapeutics.com/role/StatementCondensedConsolidatedStatementsOfCashFlow"
],
"xbrltype": "stringItemType"
},
"us-gaap_IncreaseDecreaseInOtherOperatingLiabilities": {
"auth_ref": [
"r54"
],
"calculation": {
"http://www.celldextherapeutics.com/role/StatementCondensedConsolidatedStatementsOfCashFlow": {
"order": 11.0,
"parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of increase (decrease) in operating liabilities classified as other.",
"label": "Increase (Decrease) in Other Operating Liabilities",
"terseLabel": "Other liabilities"
}
}
},
"localname": "IncreaseDecreaseInOtherOperatingLiabilities",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.celldextherapeutics.com/role/StatementCondensedConsolidatedStatementsOfCashFlow"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
"auth_ref": [
"r54"
],
"calculation": {
"http://www.celldextherapeutics.com/role/StatementCondensedConsolidatedStatementsOfCashFlow": {
"order": 8.0,
"parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
"weight": -1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
"label": "Increase (Decrease) in Prepaid Expense and Other Assets",
"negatedLabel": "Prepaid and other current assets"
}
}
},
"localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.celldextherapeutics.com/role/StatementCondensedConsolidatedStatementsOfCashFlow"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill": {
"auth_ref": [
"r140"
],
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.",
"label": "Indefinite-Lived Intangible Assets (Excluding Goodwill)",
"verboseLabel": "Indefinite-lived intangible assets"
}
}
},
"localname": "IndefiniteLivedIntangibleAssetsExcludingGoodwill",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.celldextherapeutics.com/role/DisclosureBasisOfPresentationDetails",
"http://www.celldextherapeutics.com/role/DisclosureIntangibleAssetsDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_IntangibleAssetsNetExcludingGoodwill": {
"auth_ref": [
"r138",
"r139"
],
"calculation": {
"http://www.celldextherapeutics.com/role/StatementCondensedConsolidatedBalanceSheets": {
"order": 4.0,
"parentTag": "us-gaap_Assets",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.",
"label": "Intangible Assets, Net (Excluding Goodwill)",
"terseLabel": "Intangible assets, net"
}
}
},
"localname": "IntangibleAssetsNetExcludingGoodwill",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.celldextherapeutics.com/role/StatementCondensedConsolidatedBalanceSheets"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_InterestAndOtherIncome": {
"auth_ref": [
],
"calculation": {
"http://www.celldextherapeutics.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
"order": 2.0,
"parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "The amount of interest income and other income recognized during the period. Included in this element is interest derived from investments in debt securities, cash and cash equivalents, and other investments which reflect the time value of money or transactions in which the payments are for the use or forbearance of money and other income from ancillary business-related activities (that is, excluding major activities considered part of the normal operations of the business).",
"label": "Interest and Other Income",
"terseLabel": "Investment and other income, net"
}
}
},
"localname": "InterestAndOtherIncome",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.celldextherapeutics.com/role/DisclosureOtherLongTermLiabilitiesNewJerseyTaxBenefitsDetails",
"http://www.celldextherapeutics.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_InterestReceivable": {
"auth_ref": [
"r9"
],
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Carrying amount as of the balance sheet date of interest earned but not received. Also called accrued interest or accrued interest receivable.",
"label": "Interest Receivable",
"terseLabel": "Accrued interest"
}
}
},
"localname": "InterestReceivable",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.celldextherapeutics.com/role/DisclosureMarketableSecuritiesAdditionalInformationDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_InvestmentsAndCash": {
"auth_ref": [
"r377"
],
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Sum of investments and unrestricted cash as of the balance sheet date.",
"label": "Cash, cash equivalents and marketable securities"
}
}
},
"localname": "InvestmentsAndCash",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.celldextherapeutics.com/role/DisclosureBasisOfPresentationDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"label": "Marketable Securities"
}
}
},
"localname": "InvestmentsDebtAndEquitySecuritiesAbstract",
"nsuri": "http://fasb.org/us-gaap/2022",
"xbrltype": "stringItemType"
},
"us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock": {
"auth_ref": [
"r122",
"r356",
"r369",
"r392",
"r406"
],
"lang": {
"en-us": {
"role": {
"documentation": "The entire disclosure for investments in certain debt and equity securities.",
"label": "Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]",
"terseLabel": "Marketable Securities"
}
}
},
"localname": "InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.celldextherapeutics.com/role/DisclosureMarketableSecurities"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_Liabilities": {
"auth_ref": [
"r18",
"r64",
"r101",
"r126",
"r148",
"r149",
"r150",
"r152",
"r153",
"r154",
"r155",
"r156",
"r157",
"r158",
"r286",
"r288",
"r289",
"r308",
"r320",
"r321"
],
"calculation": {
"http://www.celldextherapeutics.com/role/StatementCondensedConsolidatedBalanceSheets": {
"order": 1.0,
"parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
"label": "Liabilities",
"totalLabel": "Total liabilities"
}
}
},
"localname": "Liabilities",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.celldextherapeutics.com/role/StatementCondensedConsolidatedBalanceSheets"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_LiabilitiesAndStockholdersEquity": {
"auth_ref": [
"r15",
"r64",
"r126",
"r308",
"r322",
"r358",
"r374"
],
"calculation": {
"http://www.celldextherapeutics.com/role/StatementCondensedConsolidatedBalanceSheets": {
"order": null,
"parentTag": null,
"root": true,
"weight": null
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
"label": "Liabilities and Equity",
"totalLabel": "Total liabilities and stockholders' equity"
}
}
},
"localname": "LiabilitiesAndStockholdersEquity",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.celldextherapeutics.com/role/StatementCondensedConsolidatedBalanceSheets"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"label": "Liabilities and Equity [Abstract]",
"terseLabel": "Liabilities and stockholders' equity"
}
}
},
"localname": "LiabilitiesAndStockholdersEquityAbstract",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.celldextherapeutics.com/role/StatementCondensedConsolidatedBalanceSheets"
],
"xbrltype": "stringItemType"
},
"us-gaap_LiabilitiesCurrent": {
"auth_ref": [
"r3",
"r21",
"r64",
"r126",
"r148",
"r149",
"r150",
"r152",
"r153",
"r154",
"r155",
"r156",
"r157",
"r158",
"r286",
"r288",
"r289",
"r308",
"r320",
"r321",
"r322"
],
"calculation": {
"http://www.celldextherapeutics.com/role/StatementCondensedConsolidatedBalanceSheets": {
"order": 1.0,
"parentTag": "us-gaap_Liabilities",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
"label": "Liabilities, Current",
"totalLabel": "Total current liabilities"
}
}
},
"localname": "LiabilitiesCurrent",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.celldextherapeutics.com/role/StatementCondensedConsolidatedBalanceSheets"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_LiabilitiesCurrentAbstract": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"label": "Liabilities, Current [Abstract]",
"terseLabel": "Current liabilities:"
}
}
},
"localname": "LiabilitiesCurrentAbstract",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.celldextherapeutics.com/role/StatementCondensedConsolidatedBalanceSheets"
],
"xbrltype": "stringItemType"
},
"us-gaap_LiabilitiesFairValueDisclosure": {
"auth_ref": [
"r296"
],
"calculation": {
"http://www.celldextherapeutics.com/role/DisclosureFairValueMeasurementsDetails": {
"order": null,
"parentTag": null,
"root": true,
"weight": null
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Fair value of financial and nonfinancial obligations.",
"label": "Financial and Nonfinancial Liabilities, Fair Value Disclosure",
"totalLabel": "Total financial liabilities at fair value"
}
}
},
"localname": "LiabilitiesFairValueDisclosure",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.celldextherapeutics.com/role/DisclosureFairValueMeasurementsDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_LiabilitiesFairValueDisclosureAbstract": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"label": "Liabilities:"
}
}
},
"localname": "LiabilitiesFairValueDisclosureAbstract",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.celldextherapeutics.com/role/DisclosureFairValueMeasurementsDetails"
],
"xbrltype": "stringItemType"
},
"us-gaap_LitigationSettlementExpense": {
"auth_ref": [
],
"calculation": {
"http://www.celldextherapeutics.com/role/StatementCondensedConsolidatedStatementsOfCashFlow": {
"order": 10.0,
"parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of litigation expense, including but not limited to legal, forensic, accounting, and investigative fees.",
"label": "Litigation Settlement, Expense",
"terseLabel": "Litigation settlement payable"
}
}
},
"localname": "LitigationSettlementExpense",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.celldextherapeutics.com/role/DisclosureKolltanAcquisitionDetails",
"http://www.celldextherapeutics.com/role/StatementCondensedConsolidatedStatementsOfCashFlow"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_MarketableSecurities": {
"auth_ref": [
"r361"
],
"calculation": {
"http://www.celldextherapeutics.com/role/DisclosureFairValueMeasurementsDetails": {
"order": 2.0,
"parentTag": "us-gaap_AssetsFairValueDisclosure",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of investment in marketable security.",
"label": "Available-for-sale Securities",
"terseLabel": "Marketable securities"
}
}
},
"localname": "MarketableSecurities",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.celldextherapeutics.com/role/DisclosureFairValueMeasurementsDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_MarketableSecuritiesCurrent": {
"auth_ref": [
],
"calculation": {
"http://www.celldextherapeutics.com/role/DisclosureMarketableSecuritiesDetails": {
"order": null,
"parentTag": null,
"root": true,
"weight": null
},
"http://www.celldextherapeutics.com/role/StatementCondensedConsolidatedBalanceSheets": {
"order": 2.0,
"parentTag": "us-gaap_AssetsCurrent",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of investment in marketable security, classified as current.",
"label": "Available-for-sale Securities, Debt Securities, Current",
"terseLabel": "Marketable securities",
"totalLabel": "Fair Value"
}
}
},
"localname": "MarketableSecuritiesCurrent",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.celldextherapeutics.com/role/DisclosureMarketableSecuritiesDetails",
"http://www.celldextherapeutics.com/role/StatementCondensedConsolidatedBalanceSheets"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_NetCashProvidedByUsedInFinancingActivities": {
"auth_ref": [
"r52"
],
"calculation": {
"http://www.celldextherapeutics.com/role/StatementCondensedConsolidatedStatementsOfCashFlow": {
"order": 3.0,
"parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
"label": "Net Cash Provided by (Used in) Financing Activities",
"totalLabel": "Net cash provided by financing activities"
}
}
},
"localname": "NetCashProvidedByUsedInFinancingActivities",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.celldextherapeutics.com/role/StatementCondensedConsolidatedStatementsOfCashFlow"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"label": "Net Cash Provided by (Used in) Financing Activities, Continuing Operations [Abstract]",
"terseLabel": "Cash flows from financing activities:"
}
}
},
"localname": "NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.celldextherapeutics.com/role/StatementCondensedConsolidatedStatementsOfCashFlow"
],
"xbrltype": "stringItemType"
},
"us-gaap_NetCashProvidedByUsedInInvestingActivities": {
"auth_ref": [
"r52"
],
"calculation": {
"http://www.celldextherapeutics.com/role/StatementCondensedConsolidatedStatementsOfCashFlow": {
"order": 2.0,
"parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
"label": "Net Cash Provided by (Used in) Investing Activities, Continuing Operations",
"totalLabel": "Net cash provided by investing activities"
}
}
},
"localname": "NetCashProvidedByUsedInInvestingActivities",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.celldextherapeutics.com/role/StatementCondensedConsolidatedStatementsOfCashFlow"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"label": "Net Cash Provided by (Used in) Investing Activities, Continuing Operations [Abstract]",
"terseLabel": "Cash flows from investing activities:"
}
}
},
"localname": "NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.celldextherapeutics.com/role/StatementCondensedConsolidatedStatementsOfCashFlow"
],
"xbrltype": "stringItemType"
},
"us-gaap_NetCashProvidedByUsedInOperatingActivities": {
"auth_ref": [
"r52",
"r53",
"r56"
],
"calculation": {
"http://www.celldextherapeutics.com/role/StatementCondensedConsolidatedStatementsOfCashFlow": {
"order": 1.0,
"parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
"weight": 1.0
}
},
"lang": {
"en-us": {
"role": {
"documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
"label": "Net Cash Provided by (Used in) Operating Activities",
"terseLabel": "Net cash used in operations",
"totalLabel": "Net cash used in operating activities"
}
}
},
"localname": "NetCashProvidedByUsedInOperatingActivities",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.celldextherapeutics.com/role/DisclosureBasisOfPresentationDetails",
"http://www.celldextherapeutics.com/role/StatementCondensedConsolidatedStatementsOfCashFlow"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"label": "Net Cash Provided by (Used in) Operating Activities, Continuing Operations [Abstract]",
"terseLabel": "Cash flows from operating activities:"
}
}
},
"localname": "NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.celldextherapeutics.com/role/StatementCondensedConsolidatedStatementsOfCashFlow"
],
"xbrltype": "stringItemType"
},
"us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": {
"auth_ref": [
"r72",
"r73",
"r74",
"r75",
"r79",
"r80",
"r83",
"r86",
"r97",
"r99",
"r102",
"r105",
"r107"
],
"calculation": {
"http://www.celldextherapeutics.com/role/StatementCondensedConsolidatedStatementsOfCashFlow": {
"order": 1.0,
"parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
"weight": 1.0
},
"http://www.celldextherapeutics.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
"order": 1.0,
"parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.",
"label": "Net Income (Loss) Available to Common Stockholders, Basic",
"terseLabel": "Net loss",
"totalLabel": "Net loss"
}
}
},
"localname": "NetIncomeLossAvailableToCommonStockholdersBasic",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.celldextherapeutics.com/role/DisclosureBasisOfPresentationDetails",
"http://www.celldextherapeutics.com/role/DisclosureStockholdersEquityDetails",
"http://www.celldextherapeutics.com/role/StatementCondensedConsolidatedStatementsOfCashFlow",
"http://www.celldextherapeutics.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
"label": "New Accounting Pronouncements, Policy [Policy Text Block]",
"terseLabel": "Recent Accounting Pronouncements"
}
}
},
"localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.celldextherapeutics.com/role/DisclosureSignificantAccountingPoliciesPolicies"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_NewJerseyDivisionOfTaxationMember": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Designated tax department of the government of the state of New Jersey.",
"label": "New Jersey tax benefits"
}
}
},
"localname": "NewJerseyDivisionOfTaxationMember",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.celldextherapeutics.com/role/DisclosureOtherLongTermLiabilitiesNewJerseyTaxBenefitsDetails"
],
"xbrltype": "domainItemType"
},
"us-gaap_OperatingIncomeLoss": {
"auth_ref": [
"r97",
"r99",
"r102",
"r105",
"r107"
],
"calculation": {
"http://www.celldextherapeutics.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
"order": 1.0,
"parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "The net result for the period of deducting operating expenses from operating revenues.",
"label": "Operating Income (Loss)",
"totalLabel": "Operating loss"
}
}
},
"localname": "OperatingIncomeLoss",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.celldextherapeutics.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_OperatingLeaseLiabilityCurrent": {
"auth_ref": [
"r318"
],
"calculation": {
"http://www.celldextherapeutics.com/role/StatementCondensedConsolidatedBalanceSheets": {
"order": 4.0,
"parentTag": "us-gaap_LiabilitiesCurrent",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
"label": "Operating Lease, Liability, Current",
"terseLabel": "Current portion of operating lease liabilities"
}
}
},
"localname": "OperatingLeaseLiabilityCurrent",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.celldextherapeutics.com/role/StatementCondensedConsolidatedBalanceSheets"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_OperatingLeaseLiabilityNoncurrent": {
"auth_ref": [
"r318"
],
"calculation": {
"http://www.celldextherapeutics.com/role/StatementCondensedConsolidatedBalanceSheets": {
"order": 3.0,
"parentTag": "us-gaap_Liabilities",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
"label": "Operating Lease, Liability, Noncurrent",
"terseLabel": "Long-term portion of operating lease liabilities"
}
}
},
"localname": "OperatingLeaseLiabilityNoncurrent",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.celldextherapeutics.com/role/StatementCondensedConsolidatedBalanceSheets"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_OperatingLeaseRightOfUseAsset": {
"auth_ref": [
"r317"
],
"calculation": {
"http://www.celldextherapeutics.com/role/StatementCondensedConsolidatedBalanceSheets": {
"order": 3.0,
"parentTag": "us-gaap_Assets",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of lessee's right to use underlying asset under operating lease.",
"label": "Operating Lease, Right-of-Use Asset",
"terseLabel": "Operating lease right-of-use assets, net"
}
}
},
"localname": "OperatingLeaseRightOfUseAsset",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.celldextherapeutics.com/role/StatementCondensedConsolidatedBalanceSheets"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"label": "Basis of Presentation"
}
}
},
"localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
"nsuri": "http://fasb.org/us-gaap/2022",
"xbrltype": "stringItemType"
},
"us-gaap_OtherAssetsNoncurrent": {
"auth_ref": [
"r5"
],
"calculation": {
"http://www.celldextherapeutics.com/role/StatementCondensedConsolidatedBalanceSheets": {
"order": 5.0,
"parentTag": "us-gaap_Assets",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of noncurrent assets classified as other.",
"label": "Other Assets, Noncurrent",
"terseLabel": "Other assets"
}
}
},
"localname": "OtherAssetsNoncurrent",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.celldextherapeutics.com/role/StatementCondensedConsolidatedBalanceSheets"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_OtherComprehensiveIncomeLossNetOfTax": {
"auth_ref": [
"r33",
"r35",
"r37",
"r38",
"r40",
"r42",
"r177",
"r310",
"r315",
"r316",
"r363",
"r378"
],
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount after tax and reclassification adjustments of other comprehensive income (loss).",
"label": "Other Comprehensive Income (Loss), Net of Tax",
"terseLabel": "Other comprehensive loss"
}
}
},
"localname": "OtherComprehensiveIncomeLossNetOfTax",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.celldextherapeutics.com/role/DisclosureAccumulatedOtherComprehensiveIncomeDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]",
"terseLabel": "Other comprehensive income (loss):"
}
}
},
"localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.celldextherapeutics.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"
],
"xbrltype": "stringItemType"
},
"us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax": {
"auth_ref": [
"r26",
"r30"
],
"calculation": {
"http://www.celldextherapeutics.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
"order": 2.0,
"parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.",
"label": "Other Comprehensive Income (Loss), Unrealized Holding Gain (Loss) on Securities Arising During Period, Net of Tax",
"terseLabel": "Unrealized loss on marketable securities",
"verboseLabel": "Unrealized (loss) gain on marketable securities"
}
}
},
"localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.celldextherapeutics.com/role/DisclosureStockholdersEquityDetails",
"http://www.celldextherapeutics.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_OtherLiabilities": {
"auth_ref": [
"r359"
],
"calculation": {
"http://www.celldextherapeutics.com/role/DisclosureOtherLongTermLiabilitiesDetails": {
"order": null,
"parentTag": null,
"root": true,
"weight": null
},
"http://www.celldextherapeutics.com/role/DisclosureOtherLongTermLiabilitiesDetailsCalc2": {
"order": null,
"parentTag": null,
"root": true,
"weight": null
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of liabilities classified as other.",
"label": "Other Liabilities",
"totalLabel": "Total"
}
}
},
"localname": "OtherLiabilities",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.celldextherapeutics.com/role/DisclosureOtherLongTermLiabilitiesDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_OtherLiabilitiesCurrent": {
"auth_ref": [
"r19",
"r322"
],
"calculation": {
"http://www.celldextherapeutics.com/role/DisclosureOtherLongTermLiabilitiesDetailsCalc2": {
"order": 1.0,
"parentTag": "us-gaap_OtherLiabilities",
"weight": 1.0
},
"http://www.celldextherapeutics.com/role/StatementCondensedConsolidatedBalanceSheets": {
"order": 5.0,
"parentTag": "us-gaap_LiabilitiesCurrent",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.",
"label": "Other Liabilities, Current",
"negatedLabel": "Less current portion",
"terseLabel": "Current portion of other long-term liabilities"
}
}
},
"localname": "OtherLiabilitiesCurrent",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.celldextherapeutics.com/role/DisclosureOtherLongTermLiabilitiesDetails",
"http://www.celldextherapeutics.com/role/StatementCondensedConsolidatedBalanceSheets"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_OtherLiabilitiesDisclosureAbstract": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"label": "Other Long-Term Liabilities"
}
}
},
"localname": "OtherLiabilitiesDisclosureAbstract",
"nsuri": "http://fasb.org/us-gaap/2022",
"xbrltype": "stringItemType"
},
"us-gaap_OtherLiabilitiesDisclosureTextBlock": {
"auth_ref": [
"r20"
],
"lang": {
"en-us": {
"role": {
"documentation": "The entire disclosure for other liabilities.",
"label": "Other Liabilities Disclosure [Text Block]",
"terseLabel": "Other Long-Term Liabilities"
}
}
},
"localname": "OtherLiabilitiesDisclosureTextBlock",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.celldextherapeutics.com/role/DisclosureOtherLongTermLiabilities"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_OtherLiabilitiesNoncurrent": {
"auth_ref": [
"r22"
],
"calculation": {
"http://www.celldextherapeutics.com/role/DisclosureOtherLongTermLiabilitiesDetailsCalc2": {
"order": 2.0,
"parentTag": "us-gaap_OtherLiabilities",
"weight": 1.0
},
"http://www.celldextherapeutics.com/role/StatementCondensedConsolidatedBalanceSheets": {
"order": 2.0,
"parentTag": "us-gaap_Liabilities",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.",
"label": "Other Liabilities, Noncurrent",
"terseLabel": "Other long-term liabilities",
"verboseLabel": "Long-term portion"
}
}
},
"localname": "OtherLiabilitiesNoncurrent",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.celldextherapeutics.com/role/DisclosureOtherLongTermLiabilitiesDetails",
"http://www.celldextherapeutics.com/role/StatementCondensedConsolidatedBalanceSheets"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_OtherNoncurrentLiabilitiesTableTextBlock": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Tabular disclosure of other noncurrent liabilities.",
"label": "Schedule of Other Long Term Liabilities [Table Text Block]",
"terseLabel": "Schedule of other long-term liabilities"
}
}
},
"localname": "OtherNoncurrentLiabilitiesTableTextBlock",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.celldextherapeutics.com/role/DisclosureOtherLongTermLiabilitiesTables"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCreditLossesOnDebtSecuritiesHeld": {
"auth_ref": [
"r120",
"r121"
],
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "The cumulative amount of credit losses recognized in earnings related to debt securities held for which a portion of an other than temporary impairment (OTTI) was recognized in other comprehensive income (a component of shareholders' equity).",
"label": "Other than Temporary Impairment, Credit Losses Recognized in Earnings, Credit Losses on Debt Securities Held",
"terseLabel": "Number of investment-grade securities in unrealized loss position over 12 months"
}
}
},
"localname": "OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCreditLossesOnDebtSecuritiesHeld",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.celldextherapeutics.com/role/DisclosureMarketableSecuritiesAdditionalInformationDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_PaymentsToAcquireMarketableSecurities": {
"auth_ref": [
"r112"
],
"calculation": {
"http://www.celldextherapeutics.com/role/StatementCondensedConsolidatedStatementsOfCashFlow": {
"order": 2.0,
"parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
"weight": -1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of cash outflow for purchase of marketable security.",
"label": "Payments to Acquire Marketable Securities",
"negatedLabel": "Purchases of marketable securities"
}
}
},
"localname": "PaymentsToAcquireMarketableSecurities",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.celldextherapeutics.com/role/StatementCondensedConsolidatedStatementsOfCashFlow"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
"auth_ref": [
"r50"
],
"calculation": {
"http://www.celldextherapeutics.com/role/StatementCondensedConsolidatedStatementsOfCashFlow": {
"order": 3.0,
"parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
"weight": -1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
"label": "Payments to Acquire Property, Plant, and Equipment",
"negatedLabel": "Acquisition of property and equipment"
}
}
},
"localname": "PaymentsToAcquirePropertyPlantAndEquipment",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.celldextherapeutics.com/role/StatementCondensedConsolidatedStatementsOfCashFlow"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_PortionAtFairValueFairValueDisclosureMember": {
"auth_ref": [
"r306"
],
"lang": {
"en-us": {
"role": {
"documentation": "Measured at fair value for financial reporting purposes.",
"label": "Portion at Fair Value Measurement [Member]"
}
}
},
"localname": "PortionAtFairValueFairValueDisclosureMember",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.celldextherapeutics.com/role/DisclosureFairValueMeasurementsAdditionalInformationDetails",
"http://www.celldextherapeutics.com/role/DisclosureFairValueMeasurementsContingentConsiderationLiabilitiesDetails",
"http://www.celldextherapeutics.com/role/DisclosureFairValueMeasurementsDetails"
],
"xbrltype": "domainItemType"
},
"us-gaap_PreferredStockParOrStatedValuePerShare": {
"auth_ref": [
"r7",
"r163"
],
"lang": {
"en-us": {
"role": {
"documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
"label": "Preferred Stock, Par or Stated Value Per Share",
"terseLabel": "Convertible Preferred Stock, Par Value (in dollars per share)"
}
}
},
"localname": "PreferredStockParOrStatedValuePerShare",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.celldextherapeutics.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical"
],
"xbrltype": "perShareItemType"
},
"us-gaap_PreferredStockSharesAuthorized": {
"auth_ref": [
"r7"
],
"lang": {
"en-us": {
"role": {
"documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
"label": "Preferred Stock, Shares Authorized",
"terseLabel": "Convertible Preferred Stock, Shares Authorized"
}
}
},
"localname": "PreferredStockSharesAuthorized",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.celldextherapeutics.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical"
],
"xbrltype": "sharesItemType"
},
"us-gaap_PreferredStockSharesIssued": {
"auth_ref": [
"r7",
"r163"
],
"lang": {
"en-us": {
"role": {
"documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.",
"label": "Preferred Stock, Shares Issued",
"terseLabel": "Convertible Preferred Stock, Shares Issued"
}
}
},
"localname": "PreferredStockSharesIssued",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.celldextherapeutics.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical"
],
"xbrltype": "sharesItemType"
},
"us-gaap_PreferredStockSharesOutstanding": {
"auth_ref": [
"r7"
],
"lang": {
"en-us": {
"role": {
"documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.",
"label": "Preferred Stock, Shares Outstanding",
"terseLabel": "Convertible Preferred Stock, Shares Outstanding"
}
}
},
"localname": "PreferredStockSharesOutstanding",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.celldextherapeutics.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical"
],
"xbrltype": "sharesItemType"
},
"us-gaap_PreferredStockValue": {
"auth_ref": [
"r7",
"r322"
],
"calculation": {
"http://www.celldextherapeutics.com/role/StatementCondensedConsolidatedBalanceSheets": {
"order": 1.0,
"parentTag": "us-gaap_StockholdersEquity",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.",
"label": "Preferred Stock, Value, Issued",
"terseLabel": "Convertible preferred stock, $.01 par value; 3,000,000 shares authorized; no shares issued and outstanding at June 30, 2022 and December 31, 2021"
}
}
},
"localname": "PreferredStockValue",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.celldextherapeutics.com/role/StatementCondensedConsolidatedBalanceSheets"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
"auth_ref": [
"r16"
],
"calculation": {
"http://www.celldextherapeutics.com/role/StatementCondensedConsolidatedBalanceSheets": {
"order": 4.0,
"parentTag": "us-gaap_AssetsCurrent",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
"label": "Prepaid Expense and Other Assets, Current",
"terseLabel": "Prepaid and other current assets"
}
}
},
"localname": "PrepaidExpenseAndOtherAssetsCurrent",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.celldextherapeutics.com/role/StatementCondensedConsolidatedBalanceSheets"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities": {
"auth_ref": [
],
"calculation": {
"http://www.celldextherapeutics.com/role/StatementCondensedConsolidatedStatementsOfCashFlow": {
"order": 1.0,
"parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities (held-to-maturity or available-for-sale) during the period.",
"label": "Proceeds from Sale and Maturity of Marketable Securities",
"terseLabel": "Sales and maturities of marketable securities"
}
}
},
"localname": "ProceedsFromSaleAndMaturityOfMarketableSecurities",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.celldextherapeutics.com/role/StatementCondensedConsolidatedStatementsOfCashFlow"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_ProceedsFromSaleOfProductiveAssets": {
"auth_ref": [
"r49"
],
"calculation": {
"http://www.celldextherapeutics.com/role/StatementCondensedConsolidatedStatementsOfCashFlow": {
"order": 4.0,
"parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "The cash inflow from the sale of property, plant and equipment (capital expenditures), software, and other intangible assets.",
"label": "Proceeds from Sale of Productive Assets",
"terseLabel": "Proceeds from sale or disposal of assets"
}
}
},
"localname": "ProceedsFromSaleOfProductiveAssets",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.celldextherapeutics.com/role/StatementCondensedConsolidatedStatementsOfCashFlow"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_ProceedsFromStockPlans": {
"auth_ref": [
"r51"
],
"calculation": {
"http://www.celldextherapeutics.com/role/StatementCondensedConsolidatedStatementsOfCashFlow": {
"order": 1.0,
"parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "The cash inflow associated with the amount received from the stock plan during the period.",
"label": "Proceeds from Stock Plans",
"terseLabel": "Proceeds from issuance of stock from employee benefit plans"
}
}
},
"localname": "ProceedsFromStockPlans",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.celldextherapeutics.com/role/StatementCondensedConsolidatedStatementsOfCashFlow"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_PropertyPlantAndEquipmentNet": {
"auth_ref": [
"r142",
"r322",
"r370",
"r375"
],
"calculation": {
"http://www.celldextherapeutics.com/role/StatementCondensedConsolidatedBalanceSheets": {
"order": 2.0,
"parentTag": "us-gaap_Assets",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
"label": "Property, Plant and Equipment, Net",
"terseLabel": "Property and equipment, net"
}
}
},
"localname": "PropertyPlantAndEquipmentNet",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.celldextherapeutics.com/role/StatementCondensedConsolidatedBalanceSheets"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax": {
"auth_ref": [
"r32",
"r37",
"r38",
"r40",
"r310",
"r314",
"r316"
],
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount after tax of reclassification adjustments of other comprehensive income (loss).",
"label": "Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax",
"terseLabel": "Amounts reclassified from AOCI"
}
}
},
"localname": "ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.celldextherapeutics.com/role/DisclosureAccumulatedOtherComprehensiveIncomeDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_ResearchAndDevelopmentExpense": {
"auth_ref": [
"r257",
"r353",
"r393"
],
"calculation": {
"http://www.celldextherapeutics.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
"order": 1.0,
"parentTag": "us-gaap_CostsAndExpenses",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
"label": "Research and Development Expense",
"terseLabel": "Research and development"
}
}
},
"localname": "ResearchAndDevelopmentExpense",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.celldextherapeutics.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_ResearchAndDevelopmentExpenseMember": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
"label": "Research and development"
}
}
},
"localname": "ResearchAndDevelopmentExpenseMember",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.celldextherapeutics.com/role/DisclosureStockBasedCompensationExpensesDetails"
],
"xbrltype": "domainItemType"
},
"us-gaap_RetainedEarningsAccumulatedDeficit": {
"auth_ref": [
"r11",
"r178",
"r322",
"r373",
"r388",
"r390"
],
"calculation": {
"http://www.celldextherapeutics.com/role/StatementCondensedConsolidatedBalanceSheets": {
"order": 5.0,
"parentTag": "us-gaap_StockholdersEquity",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
"label": "Retained Earnings (Accumulated Deficit)",
"terseLabel": "Accumulated deficit"
}
}
},
"localname": "RetainedEarningsAccumulatedDeficit",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.celldextherapeutics.com/role/StatementCondensedConsolidatedBalanceSheets"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_RetainedEarningsMember": {
"auth_ref": [
"r0",
"r68",
"r69",
"r70",
"r71",
"r77",
"r78",
"r127",
"r250",
"r251",
"r252",
"r265",
"r266",
"r293",
"r385",
"r387"
],
"lang": {
"en-us": {
"role": {
"documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
"label": "Accumulated Deficit"
}
}
},
"localname": "RetainedEarningsMember",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.celldextherapeutics.com/role/DisclosureStockholdersEquityDetails"
],
"xbrltype": "domainItemType"
},
"us-gaap_RevenueFromContractWithCustomerAbstract": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"label": "Revenue."
}
}
},
"localname": "RevenueFromContractWithCustomerAbstract",
"nsuri": "http://fasb.org/us-gaap/2022",
"xbrltype": "stringItemType"
},
"us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
"auth_ref": [
"r94",
"r95",
"r98",
"r103",
"r104",
"r108",
"r109",
"r110",
"r191",
"r192",
"r354"
],
"calculation": {
"http://www.celldextherapeutics.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
"order": 1.0,
"parentTag": "us-gaap_OperatingIncomeLoss",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.",
"label": "Revenue from Contract with Customer, Excluding Assessed Tax",
"terseLabel": "Total revenues",
"verboseLabel": "Revenues"
}
}
},
"localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.celldextherapeutics.com/role/DisclosureRevenueDetails",
"http://www.celldextherapeutics.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_RevenueFromContractWithCustomerTextBlock": {
"auth_ref": [
"r183",
"r184",
"r185",
"r186",
"r187",
"r188",
"r189",
"r190",
"r195",
"r198"
],
"lang": {
"en-us": {
"role": {
"documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.",
"label": "Revenue from Contract with Customer [Text Block]",
"terseLabel": "Revenue"
}
}
},
"localname": "RevenueFromContractWithCustomerTextBlock",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.celldextherapeutics.com/role/DisclosureRevenue"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_RevenuesAbstract": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"label": "Revenues [Abstract].",
"terseLabel": "Revenues:"
}
}
},
"localname": "RevenuesAbstract",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.celldextherapeutics.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"
],
"xbrltype": "stringItemType"
},
"us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock": {
"auth_ref": [
"r32",
"r315",
"r316"
],
"lang": {
"en-us": {
"role": {
"documentation": "Tabular disclosure of the components of accumulated other comprehensive income (loss).",
"label": "Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]",
"terseLabel": "Schedule of changes in accumulated other comprehensive income"
}
}
},
"localname": "ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.celldextherapeutics.com/role/DisclosureAccumulatedOtherComprehensiveIncomeTables"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
"auth_ref": [
"r87"
],
"lang": {
"en-us": {
"role": {
"documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.",
"label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]"
}
}
},
"localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.celldextherapeutics.com/role/DisclosureNetLossPerShareDetails"
],
"xbrltype": "stringItemType"
},
"us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
"auth_ref": [
"r87"
],
"lang": {
"en-us": {
"role": {
"documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.",
"label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
"terseLabel": "Schedule of potentially dilutive common shares that have not been included in the net loss per common share calculations because the effect would have been anti-dilutive"
}
}
},
"localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.celldextherapeutics.com/role/DisclosureNetLossPerShareTables"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
"label": "Schedule of Available-for-sale Securities [Line Items]",
"terseLabel": "Marketable Securities"
}
}
},
"localname": "ScheduleOfAvailableForSaleSecuritiesLineItems",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.celldextherapeutics.com/role/DisclosureMarketableSecuritiesDetails"
],
"xbrltype": "stringItemType"
},
"us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Tabular disclosure of the reconciliation of available-for-sale securities from cost basis to fair value.",
"label": "Schedule of Available-for-sale Securities Reconciliation [Table Text Block]",
"terseLabel": "Schedule of marketable debt securities, classified as available-for-sale"
}
}
},
"localname": "ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.celldextherapeutics.com/role/DisclosureMarketableSecuritiesTables"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable": {
"auth_ref": [
"r273",
"r274",
"r275"
],
"lang": {
"en-us": {
"role": {
"documentation": "Schedule reflecting each material business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities.",
"label": "Schedule of Business Acquisitions, by Acquisition [Table]"
}
}
},
"localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTable",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.celldextherapeutics.com/role/DisclosureKolltanAcquisitionDetails"
],
"xbrltype": "stringItemType"
},
"us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": {
"auth_ref": [
"r284"
],
"lang": {
"en-us": {
"role": {
"documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
"label": "Schedule of Collaborative Arrangements and Non-collaborative Arrangement Transactions [Table]"
}
}
},
"localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.celldextherapeutics.com/role/DisclosureRevenueDetails"
],
"xbrltype": "stringItemType"
},
"us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": {
"auth_ref": [
"r243",
"r253"
],
"lang": {
"en-us": {
"role": {
"documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements.",
"label": "Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table]"
}
}
},
"localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.celldextherapeutics.com/role/DisclosureStockBasedCompensationExpensesDetails",
"http://www.celldextherapeutics.com/role/DisclosureStockBasedCompensationValuationDetails"
],
"xbrltype": "stringItemType"
},
"us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
"auth_ref": [
"r243"
],
"lang": {
"en-us": {
"role": {
"documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.",
"label": "Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block]",
"terseLabel": "Schedule of stock-based compensation expense"
}
}
},
"localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.celldextherapeutics.com/role/DisclosureStockBasedCompensationTables"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
"auth_ref": [
"r209",
"r211",
"r213",
"r214",
"r215",
"r217",
"r218",
"r219",
"r220",
"r221",
"r222",
"r223",
"r224",
"r225",
"r226",
"r227",
"r228",
"r229",
"r230",
"r232",
"r233",
"r235",
"r236",
"r238",
"r239",
"r240",
"r241",
"r242"
],
"lang": {
"en-us": {
"role": {
"documentation": "Disclosure of information about share-based payment arrangement.",
"label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]"
}
}
},
"localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.celldextherapeutics.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails"
],
"xbrltype": "stringItemType"
},
"us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
"auth_ref": [
"r216",
"r231",
"r234"
],
"lang": {
"en-us": {
"role": {
"documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
"label": "Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]",
"terseLabel": "Schedule of stock option activity"
}
}
},
"localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.celldextherapeutics.com/role/DisclosureStockBasedCompensationTables"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
"auth_ref": [
"r237"
],
"lang": {
"en-us": {
"role": {
"documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
"label": "Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
"terseLabel": "Schedule of assumptions used for the fair value of employee stock options granted"
}
}
},
"localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.celldextherapeutics.com/role/DisclosureStockBasedCompensationTables"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_ScheduleOfStockholdersEquityTableTextBlock": {
"auth_ref": [
"r177"
],
"lang": {
"en-us": {
"role": {
"documentation": "Tabular disclosure of changes in the separate accounts comprising stockholders' equity (in addition to retained earnings) and of the changes in the number of shares of equity securities during at least the most recent annual fiscal period and any subsequent interim period presented is required to make the financial statements sufficiently informative if both financial position and results of operations are presented.",
"label": "Schedule of Stockholders Equity [Table Text Block]",
"terseLabel": "Schedule of Shareholder's equity"
}
}
},
"localname": "ScheduleOfStockholdersEquityTableTextBlock",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.celldextherapeutics.com/role/DisclosureStockholdersEquityTables"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_ServiceMember": {
"auth_ref": [
"r196"
],
"lang": {
"en-us": {
"role": {
"documentation": "Assistance, including, but not limited to, technology, license and maintenance, license and service, maintenance, oil and gas, and financial service.",
"label": "Product development and licensing agreements"
}
}
},
"localname": "ServiceMember",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.celldextherapeutics.com/role/DisclosureRevenueDetails",
"http://www.celldextherapeutics.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"
],
"xbrltype": "domainItemType"
},
"us-gaap_ShareBasedCompensation": {
"auth_ref": [
"r54"
],
"calculation": {
"http://www.celldextherapeutics.com/role/StatementCondensedConsolidatedStatementsOfCashFlow": {
"order": 6.0,
"parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of noncash expense for share-based payment arrangement.",
"label": "Share-based Compensation",
"terseLabel": "Stock-based compensation expense"
}
}
},
"localname": "ShareBasedCompensation",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.celldextherapeutics.com/role/StatementCondensedConsolidatedStatementsOfCashFlow"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"label": "Share-based Compensation Arrangement by Share-based Payment Award, Additional General Disclosures [Abstract]",
"terseLabel": "Additional information"
}
}
},
"localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.celldextherapeutics.com/role/DisclosureStockBasedCompensationEmployeeStockOptionAndIncentivePlanActivityAdditionalInformationDetails"
],
"xbrltype": "stringItemType"
},
"us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions and Methodology [Abstract]",
"verboseLabel": "Black-Scholes option with following assumptions:"
}
}
},
"localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.celldextherapeutics.com/role/DisclosureStockBasedCompensationValuationDetails"
],
"xbrltype": "stringItemType"
},
"us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
"auth_ref": [
"r240"
],
"lang": {
"en-us": {
"role": {
"documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.",
"label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
"terseLabel": "Expected dividend yield (as a percent)"
}
}
},
"localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.celldextherapeutics.com/role/DisclosureStockBasedCompensationValuationDetails"
],
"xbrltype": "percentItemType"
},
"us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
"label": "Expected stock price volatility, maximum (as a percent)",
"terseLabel": "Expected stock price volatility, maximum (as a percent)"
}
}
},
"localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.celldextherapeutics.com/role/DisclosureStockBasedCompensationValuationDetails"
],
"xbrltype": "percentItemType"
},
"us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
"label": "Expected stock price volatility, minimum (as a percent)",
"verboseLabel": "Expected stock price volatility, minimum (as a percent)"
}
}
},
"localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.celldextherapeutics.com/role/DisclosureStockBasedCompensationValuationDetails"
],
"xbrltype": "percentItemType"
},
"us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.",
"label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum",
"terseLabel": "Risk-free interest rate, maximum (as a percent)"
}
}
},
"localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.celldextherapeutics.com/role/DisclosureStockBasedCompensationValuationDetails"
],
"xbrltype": "percentItemType"
},
"us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.",
"label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum",
"terseLabel": "Risk-free interest rate, minimum (as a percent)"
}
}
},
"localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.celldextherapeutics.com/role/DisclosureStockBasedCompensationValuationDetails"
],
"xbrltype": "percentItemType"
},
"us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
"label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]",
"terseLabel": "Stock-Based Compensation"
}
}
},
"localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.celldextherapeutics.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails"
],
"xbrltype": "stringItemType"
},
"us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
"auth_ref": [
"r249"
],
"lang": {
"en-us": {
"role": {
"documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.",
"label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant",
"terseLabel": "Shares available for grant under the 2021 Plan"
}
}
},
"localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.celldextherapeutics.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails"
],
"xbrltype": "sharesItemType"
},
"us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
"auth_ref": [
"r219"
],
"lang": {
"en-us": {
"role": {
"documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.",
"label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number",
"terseLabel": "Options exercisable at the end of the period (in shares)"
}
}
},
"localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.celldextherapeutics.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails"
],
"xbrltype": "sharesItemType"
},
"us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
"auth_ref": [
"r219"
],
"lang": {
"en-us": {
"role": {
"documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.",
"label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
"terseLabel": "Options exercisable at the end of the period (in dollars per share)"
}
}
},
"localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.celldextherapeutics.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails"
],
"xbrltype": "perShareItemType"
},
"us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
"auth_ref": [
"r223"
],
"lang": {
"en-us": {
"role": {
"documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.",
"label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period",
"negatedLabel": "Canceled (in shares)"
}
}
},
"localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.celldextherapeutics.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails"
],
"xbrltype": "sharesItemType"
},
"us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
"auth_ref": [
"r221"
],
"lang": {
"en-us": {
"role": {
"documentation": "Gross number of share options (or share units) granted during the period.",
"label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross",
"terseLabel": "Granted (in shares)"
}
}
},
"localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.celldextherapeutics.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails"
],
"xbrltype": "sharesItemType"
},
"us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
"auth_ref": [
"r232"
],
"lang": {
"en-us": {
"role": {
"documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.",
"label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
"terseLabel": "Weighted average grant-date fair value (in dollars per share)"
}
}
},
"localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.celldextherapeutics.com/role/DisclosureStockBasedCompensationEmployeeStockOptionAndIncentivePlanActivityAdditionalInformationDetails"
],
"xbrltype": "perShareItemType"
},
"us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
"auth_ref": [
"r217",
"r218"
],
"lang": {
"en-us": {
"role": {
"documentation": "Number of options outstanding, including both vested and non-vested options.",
"label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number",
"periodEndLabel": "Options outstanding at the end of the period (in shares)",
"periodStartLabel": "Options outstanding at beginning of the period (in shares)"
}
}
},
"localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.celldextherapeutics.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails"
],
"xbrltype": "sharesItemType"
},
"us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
"label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]",
"terseLabel": "Shares"
}
}
},
"localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.celldextherapeutics.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails"
],
"xbrltype": "stringItemType"
},
"us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
"auth_ref": [
"r217",
"r218"
],
"lang": {
"en-us": {
"role": {
"documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
"label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
"periodEndLabel": "Options outstanding at the end of the period (in dollars per share)",
"periodStartLabel": "Options outstanding at beginning of the period (in dollars per share)"
}
}
},
"localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.celldextherapeutics.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails"
],
"xbrltype": "perShareItemType"
},
"us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]",
"terseLabel": "Weighted Average Exercise Price Per Share"
}
}
},
"localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.celldextherapeutics.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails"
],
"xbrltype": "stringItemType"
},
"us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue": {
"auth_ref": [
"r236"
],
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
"label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value",
"terseLabel": "Intrinsic value of options vested and expected to vest"
}
}
},
"localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.celldextherapeutics.com/role/DisclosureStockBasedCompensationEmployeeStockOptionAndIncentivePlanActivityAdditionalInformationDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": {
"auth_ref": [
"r235"
],
"lang": {
"en-us": {
"role": {
"documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
"label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number",
"terseLabel": "Options vested and expected to vest at the end of the period (in shares)"
}
}
},
"localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.celldextherapeutics.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails"
],
"xbrltype": "sharesItemType"
},
"us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": {
"auth_ref": [
"r235"
],
"lang": {
"en-us": {
"role": {
"documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
"label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price",
"terseLabel": "Options vested and expected to Vest at the end of the period (in dollars per share)"
}
}
},
"localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.celldextherapeutics.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails"
],
"xbrltype": "perShareItemType"
},
"us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
"auth_ref": [
"r213",
"r214",
"r215",
"r217",
"r218",
"r219",
"r220",
"r221",
"r222",
"r223",
"r224",
"r225",
"r226",
"r227",
"r228",
"r229",
"r230",
"r232",
"r233",
"r235",
"r236",
"r238",
"r239",
"r240",
"r241",
"r242"
],
"lang": {
"en-us": {
"role": {
"documentation": "Award under share-based payment arrangement.",
"label": "Equity Award [Domain]"
}
}
},
"localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.celldextherapeutics.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails",
"http://www.celldextherapeutics.com/role/DisclosureStockBasedCompensationValuationDetails"
],
"xbrltype": "domainItemType"
},
"us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
"auth_ref": [
"r222"
],
"lang": {
"en-us": {
"role": {
"documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
"label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
"terseLabel": "Exercised (in dollars per share)"
}
}
},
"localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.celldextherapeutics.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails"
],
"xbrltype": "perShareItemType"
},
"us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
"auth_ref": [
"r223"
],
"lang": {
"en-us": {
"role": {
"documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.",
"label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price",
"terseLabel": "Canceled (in dollars per share)"
}
}
},
"localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.celldextherapeutics.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails"
],
"xbrltype": "perShareItemType"
},
"us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
"auth_ref": [
"r221"
],
"lang": {
"en-us": {
"role": {
"documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
"label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
"terseLabel": "Granted (in dollars per share)"
}
}
},
"localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.celldextherapeutics.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails"
],
"xbrltype": "perShareItemType"
},
"us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
"auth_ref": [
"r238"
],
"lang": {
"en-us": {
"role": {
"documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
"label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term",
"terseLabel": "Expected option term"
}
}
},
"localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.celldextherapeutics.com/role/DisclosureStockBasedCompensationValuationDetails"
],
"xbrltype": "durationItemType"
},
"us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
"auth_ref": [
"r249"
],
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.",
"label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value",
"terseLabel": "Intrinsic value of options exercisable"
}
}
},
"localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.celldextherapeutics.com/role/DisclosureStockBasedCompensationEmployeeStockOptionAndIncentivePlanActivityAdditionalInformationDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
"auth_ref": [
"r249"
],
"lang": {
"en-us": {
"role": {
"documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
"label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
"terseLabel": "Options exercisable at the end of the period"
}
}
},
"localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.celldextherapeutics.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails"
],
"xbrltype": "durationItemType"
},
"us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
"auth_ref": [
"r235"
],
"lang": {
"en-us": {
"role": {
"documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
"label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
"verboseLabel": "Options outstanding at the end of the period"
}
}
},
"localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.celldextherapeutics.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails"
],
"xbrltype": "durationItemType"
},
"us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1": {
"auth_ref": [
"r236"
],
"lang": {
"en-us": {
"role": {
"documentation": "Weighted average remaining contractual term for fully vested and expected to vest exercisable or convertible options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
"label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term",
"terseLabel": "Options vested and expected to vest at the end of the period"
}
}
},
"localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.celldextherapeutics.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails"
],
"xbrltype": "durationItemType"
},
"us-gaap_SignificantAccountingPoliciesTextBlock": {
"auth_ref": [
"r62",
"r67"
],
"lang": {
"en-us": {
"role": {
"documentation": "The entire disclosure for all significant accounting policies of the reporting entity.",
"label": "Significant Accounting Policies [Text Block]",
"terseLabel": "Significant Accounting Policies"
}
}
},
"localname": "SignificantAccountingPoliciesTextBlock",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.celldextherapeutics.com/role/DisclosureSignificantAccountingPolicies"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_StatementEquityComponentsAxis": {
"auth_ref": [
"r0",
"r24",
"r37",
"r38",
"r39",
"r68",
"r69",
"r70",
"r71",
"r77",
"r78",
"r93",
"r127",
"r177",
"r178",
"r250",
"r251",
"r252",
"r265",
"r266",
"r293",
"r310",
"r311",
"r312",
"r313",
"r314",
"r316",
"r319",
"r385",
"r386",
"r387"
],
"lang": {
"en-us": {
"role": {
"documentation": "Information by component of equity.",
"label": "Equity Components [Axis]"
}
}
},
"localname": "StatementEquityComponentsAxis",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.celldextherapeutics.com/role/DisclosureAccumulatedOtherComprehensiveIncomeDetails",
"http://www.celldextherapeutics.com/role/DisclosureStockholdersEquityDetails"
],
"xbrltype": "stringItemType"
},
"us-gaap_StatementLineItems": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
"label": "Common Stock.",
"terseLabel": "Income Taxes",
"verboseLabel": "New Jersey Tax Benefits"
}
}
},
"localname": "StatementLineItems",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.celldextherapeutics.com/role/DisclosureOtherLongTermLiabilitiesNewJerseyTaxBenefitsDetails",
"http://www.celldextherapeutics.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"
],
"xbrltype": "stringItemType"
},
"us-gaap_StatementOfCashFlowsAbstract": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"label": "CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOW"
}
}
},
"localname": "StatementOfCashFlowsAbstract",
"nsuri": "http://fasb.org/us-gaap/2022",
"xbrltype": "stringItemType"
},
"us-gaap_StatementOfFinancialPositionAbstract": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"label": "CONDENSED CONSOLIDATED BALANCE SHEETS"
}
}
},
"localname": "StatementOfFinancialPositionAbstract",
"nsuri": "http://fasb.org/us-gaap/2022",
"xbrltype": "stringItemType"
},
"us-gaap_StatementTable": {
"auth_ref": [
"r68",
"r69",
"r70",
"r93",
"r354"
],
"lang": {
"en-us": {
"role": {
"documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
"label": "Statement [Table]"
}
}
},
"localname": "StatementTable",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.celldextherapeutics.com/role/DisclosureOtherLongTermLiabilitiesNewJerseyTaxBenefitsDetails",
"http://www.celldextherapeutics.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"
],
"xbrltype": "stringItemType"
},
"us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": {
"auth_ref": [
"r7",
"r8",
"r177",
"r178"
],
"lang": {
"en-us": {
"role": {
"documentation": "Number of shares issued during the period as a result of an employee stock purchase plan.",
"label": "Stock Issued During Period, Shares, Employee Stock Purchase Plans",
"terseLabel": "Shares issued under stock option and employee stock purchase plans (in shares)"
}
}
},
"localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.celldextherapeutics.com/role/DisclosureStockholdersEquityDetails"
],
"xbrltype": "sharesItemType"
},
"us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
"auth_ref": [
"r7",
"r8",
"r177",
"r178",
"r222"
],
"lang": {
"en-us": {
"role": {
"documentation": "Number of share options (or share units) exercised during the current period.",
"label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period",
"negatedLabel": "Exercised (in shares)"
}
}
},
"localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.celldextherapeutics.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails"
],
"xbrltype": "sharesItemType"
},
"us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan": {
"auth_ref": [
"r7",
"r8",
"r177",
"r178"
],
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.",
"label": "Stock Issued During Period, Value, Employee Stock Purchase Plan",
"terseLabel": "Shares issued under stock option and employee stock purchase plans"
}
}
},
"localname": "StockIssuedDuringPeriodValueEmployeeStockPurchasePlan",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.celldextherapeutics.com/role/DisclosureStockholdersEquityDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_StockholdersEquity": {
"auth_ref": [
"r8",
"r13",
"r14",
"r64",
"r111",
"r126",
"r308",
"r322"
],
"calculation": {
"http://www.celldextherapeutics.com/role/StatementCondensedConsolidatedBalanceSheets": {
"order": 2.0,
"parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
"label": "Stockholders Equity",
"periodEndLabel": "Balance",
"periodStartLabel": "Balance",
"totalLabel": "Total stockholders' equity"
}
}
},
"localname": "StockholdersEquity",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.celldextherapeutics.com/role/DisclosureAccumulatedOtherComprehensiveIncomeDetails",
"http://www.celldextherapeutics.com/role/DisclosureStockholdersEquityDetails",
"http://www.celldextherapeutics.com/role/StatementCondensedConsolidatedBalanceSheets"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_StockholdersEquityAbstract": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"label": "Stockholders' Equity Attributable to Parent [Abstract]",
"terseLabel": "Stockholders' equity:"
}
}
},
"localname": "StockholdersEquityAbstract",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.celldextherapeutics.com/role/StatementCondensedConsolidatedBalanceSheets"
],
"xbrltype": "stringItemType"
},
"us-gaap_StockholdersEquityNoteAbstract": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"label": "Stockholders' Equity"
}
}
},
"localname": "StockholdersEquityNoteAbstract",
"nsuri": "http://fasb.org/us-gaap/2022",
"xbrltype": "stringItemType"
},
"us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
"auth_ref": [
"r63",
"r164",
"r165",
"r166",
"r167",
"r168",
"r169",
"r170",
"r171",
"r172",
"r173",
"r174",
"r176",
"r178",
"r179",
"r292"
],
"lang": {
"en-us": {
"role": {
"documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
"label": "Stockholders' Equity Note Disclosure [Text Block]",
"terseLabel": "Stockholders' Equity"
}
}
},
"localname": "StockholdersEquityNoteDisclosureTextBlock",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.celldextherapeutics.com/role/DisclosureStockholdersEquity"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Different names of stock transactions and the different attributes of each transaction.",
"label": "Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]"
}
}
},
"localname": "SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.celldextherapeutics.com/role/DisclosureStockholdersEquityDetails"
],
"xbrltype": "stringItemType"
},
"us-gaap_SubsidiarySaleOfStockLineItems": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
"label": "Subsidiary, Sale of Stock [Line Items]",
"terseLabel": "Common Stock"
}
}
},
"localname": "SubsidiarySaleOfStockLineItems",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.celldextherapeutics.com/role/DisclosureStockholdersEquityDetails"
],
"xbrltype": "stringItemType"
},
"us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
"auth_ref": [
"r118",
"r119",
"r123",
"r124",
"r125",
"r160",
"r175",
"r291",
"r323",
"r324",
"r325",
"r326",
"r327",
"r328",
"r329",
"r330",
"r331",
"r332",
"r333",
"r334",
"r335",
"r336",
"r337",
"r338",
"r339",
"r340",
"r341",
"r342",
"r343",
"r344",
"r345",
"r346",
"r347",
"r348",
"r349",
"r350",
"r351",
"r352",
"r399",
"r400",
"r401",
"r402",
"r403",
"r404",
"r405"
],
"lang": {
"en-us": {
"role": {
"documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.",
"label": "Financial Instruments [Domain]"
}
}
},
"localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.celldextherapeutics.com/role/DisclosureKolltanAcquisitionDetails",
"http://www.celldextherapeutics.com/role/DisclosureMarketableSecuritiesDetails"
],
"xbrltype": "domainItemType"
},
"us-gaap_USTreasuryAndGovernmentMember": {
"auth_ref": [
"r199",
"r367",
"r391"
],
"lang": {
"en-us": {
"role": {
"documentation": "This category includes investments in debt securities issued by the United States Department of the Treasury, US Government Agencies and US Government-sponsored Enterprises. Such securities may include treasury bills (short-term maturities - one year or less), treasury notes (intermediate term maturities - two to ten years), and treasury bonds (long-term maturities - ten to thirty years), debt securities issued by the Government National Mortgage Association (Ginnie Mae) and debt securities issued by the Federal National Mortgage Association (Fannie Mae) or the Federal Home Loan Mortgage Corporation (Freddie Mac).",
"label": "U.S. government and municipal obligations"
}
}
},
"localname": "USTreasuryAndGovernmentMember",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.celldextherapeutics.com/role/DisclosureMarketableSecuritiesDetails"
],
"xbrltype": "domainItemType"
},
"us-gaap_UnderlyingAssetClassAxis": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Information by underlying asset class.",
"label": "Underlying Asset Class [Axis]"
}
}
},
"localname": "UnderlyingAssetClassAxis",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.celldextherapeutics.com/role/DisclosureKolltanAcquisitionDetails"
],
"xbrltype": "stringItemType"
},
"us-gaap_UnderlyingAssetClassDomain": {
"auth_ref": [
"r290"
],
"lang": {
"en-us": {
"role": {
"documentation": "Major types of referenced/underlying asset classes (for example, corporate debt, sovereign debt, and structured finance).",
"label": "Underlying Asset Class [Domain]"
}
}
},
"localname": "UnderlyingAssetClassDomain",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.celldextherapeutics.com/role/DisclosureKolltanAcquisitionDetails"
],
"xbrltype": "domainItemType"
},
"us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
"auth_ref": [
"r81",
"r86"
],
"lang": {
"en-us": {
"role": {
"documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
"label": "Weighted Average Number of Shares Outstanding, Diluted",
"terseLabel": "Shares used in calculating diluted net loss per share"
}
}
},
"localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.celldextherapeutics.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"
],
"xbrltype": "sharesItemType"
},
"us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
"auth_ref": [
"r79",
"r86"
],
"lang": {
"en-us": {
"role": {
"documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
"label": "Weighted Average Number of Shares Outstanding, Basic",
"terseLabel": "Shares used in calculating basic net loss per share"
}
}
},
"localname": "WeightedAverageNumberOfSharesOutstandingBasic",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.celldextherapeutics.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"
],
"xbrltype": "sharesItemType"
}
},
"unitCount": 4
}
},
"std_ref": {
"r0": {
"Name": "Accounting Standards Codification",
"Paragraph": "6",
"Publisher": "FASB",
"Section": "65",
"SubTopic": "10",
"Subparagraph": "(c)",
"Topic": "105",
"URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695"
},
"r1": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Subparagraph": "(a)",
"Topic": "210",
"URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
},
"r10": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02(30)(a)(1))",
"Topic": "210",
"URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r100": {
"Name": "Accounting Standards Codification",
"Paragraph": "30",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(c)",
"Topic": "280",
"URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599"
},
"r101": {
"Name": "Accounting Standards Codification",
"Paragraph": "30",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(d)",
"Topic": "280",
"URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599"
},
"r102": {
"Name": "Accounting Standards Codification",
"Paragraph": "31",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "280",
"URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599"
},
"r103": {
"Name": "Accounting Standards Codification",
"Paragraph": "32",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(a)",
"Topic": "280",
"URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
},
"r104": {
"Name": "Accounting Standards Codification",
"Paragraph": "32",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(b)",
"Topic": "280",
"URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
},
"r105": {
"Name": "Accounting Standards Codification",
"Paragraph": "32",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(c)",
"Topic": "280",
"URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
},
"r106": {
"Name": "Accounting Standards Codification",
"Paragraph": "32",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(d)",
"Topic": "280",
"URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
},
"r107": {
"Name": "Accounting Standards Codification",
"Paragraph": "32",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(f)",
"Topic": "280",
"URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
},
"r108": {
"Name": "Accounting Standards Codification",
"Paragraph": "40",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "280",
"URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599"
},
"r109": {
"Name": "Accounting Standards Codification",
"Paragraph": "41",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(a)",
"Topic": "280",
"URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599"
},
"r11": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02(30)(a)(3))",
"Topic": "210",
"URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r110": {
"Name": "Accounting Standards Codification",
"Paragraph": "42",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "280",
"URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599"
},
"r111": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SAB Topic 4.E)",
"Topic": "310",
"URI": "https://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707"
},
"r112": {
"Name": "Accounting Standards Codification",
"Paragraph": "11",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Topic": "320",
"URI": "https://asc.fasb.org/extlink&oid=124260329&loc=d3e26853-111562"
},
"r113": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(a)",
"Topic": "320",
"URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563"
},
"r114": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(b)",
"Topic": "320",
"URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563"
},
"r115": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(c)",
"Topic": "320",
"URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563"
},
"r116": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(d)",
"Topic": "320",
"URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563"
},
"r117": {
"Name": "Accounting Standards Codification",
"Paragraph": "3",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(a)",
"Topic": "320",
"URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27198-111563"
},
"r118": {
"Name": "Accounting Standards Codification",
"Paragraph": "5",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "320",
"URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27232-111563"
},
"r119": {
"Name": "Accounting Standards Codification",
"Paragraph": "5A",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "320",
"URI": "https://asc.fasb.org/extlink&oid=126970911&loc=SL120269820-111563"
},
"r12": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02(30)(a)(4))",
"Topic": "210",
"URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r120": {
"Name": "Accounting Standards Codification",
"Paragraph": "8B",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(a)",
"Topic": "320",
"URI": "https://asc.fasb.org/extlink&oid=126970911&loc=SL6284393-111563"
},
"r121": {
"Name": "Accounting Standards Codification",
"Paragraph": "8B",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(g)",
"Topic": "320",
"URI": "https://asc.fasb.org/extlink&oid=126970911&loc=SL6284393-111563"
},
"r122": {
"Name": "Accounting Standards Codification",
"Publisher": "FASB",
"Topic": "320",
"URI": "https://asc.fasb.org/topic&trid=2196928"
},
"r123": {
"Name": "Accounting Standards Codification",
"Paragraph": "3",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(a)",
"Topic": "321",
"URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714"
},
"r124": {
"Name": "Accounting Standards Codification",
"Paragraph": "3",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(b)",
"Topic": "321",
"URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714"
},
"r125": {
"Name": "Accounting Standards Codification",
"Paragraph": "3",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(c)",
"Topic": "321",
"URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714"
},
"r126": {
"Name": "Accounting Standards Codification",
"Paragraph": "3",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(c)",
"Topic": "323",
"URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
},
"r127": {
"Name": "Accounting Standards Codification",
"Paragraph": "4",
"Publisher": "FASB",
"Section": "65",
"SubTopic": "10",
"Subparagraph": "(d)",
"Topic": "326",
"URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
},
"r128": {
"Name": "Accounting Standards Codification",
"Paragraph": "11",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Topic": "326",
"URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919244-210447"
},
"r129": {
"Name": "Accounting Standards Codification",
"Paragraph": "13",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Topic": "326",
"URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447"
},
"r13": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02(30))",
"Topic": "210",
"URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r130": {
"Name": "Accounting Standards Codification",
"Paragraph": "14",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Topic": "326",
"URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919253-210447"
},
"r131": {
"Name": "Accounting Standards Codification",
"Paragraph": "16",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Topic": "326",
"URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919258-210447"
},
"r132": {
"Name": "Accounting Standards Codification",
"Paragraph": "5",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Topic": "326",
"URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919230-210447"
},
"r133": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "30",
"Topic": "326",
"URI": "https://asc.fasb.org/extlink&oid=124258926&loc=SL82898722-210454"
},
"r134": {
"Name": "Accounting Standards Codification",
"Paragraph": "4",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "30",
"Topic": "326",
"URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455"
},
"r135": {
"Name": "Accounting Standards Codification",
"Paragraph": "7",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "30",
"Topic": "326",
"URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922895-210455"
},
"r136": {
"Name": "Accounting Standards Codification",
"Paragraph": "9",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "30",
"Topic": "326",
"URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455"
},
"r137": {
"Name": "Accounting Standards Codification",
"Paragraph": "8",
"Publisher": "FASB",
"Section": "55",
"SubTopic": "30",
"Topic": "326",
"URI": "https://asc.fasb.org/extlink&oid=121590138&loc=SL82922954-210456"
},
"r138": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "30",
"Topic": "350",
"URI": "https://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274"
},
"r139": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "30",
"Subparagraph": "((a)(1),(b))",
"Topic": "350",
"URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
},
"r14": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02(31))",
"Topic": "210",
"URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r140": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "30",
"Subparagraph": "(b)",
"Topic": "350",
"URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
},
"r141": {
"Name": "Accounting Standards Codification",
"Publisher": "FASB",
"Topic": "350",
"URI": "https://asc.fasb.org/topic&trid=2144416"
},
"r142": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "360",
"URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
},
"r143": {
"Name": "Accounting Standards Codification",
"Paragraph": "3",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(d)",
"Topic": "360",
"URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
},
"r144": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(c)",
"Topic": "420",
"URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
},
"r145": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Topic": "450",
"URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349"
},
"r146": {
"Name": "Accounting Standards Codification",
"Paragraph": "9",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(b)",
"Topic": "450",
"URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349"
},
"r147": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "20",
"Subparagraph": "(SAB Topic 5.Y.Q2)",
"Topic": "450",
"URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751"
},
"r148": {
"Name": "Accounting Standards Codification",
"Paragraph": "1A",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.13-01(a)(4)(i))",
"Topic": "470",
"URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
},
"r149": {
"Name": "Accounting Standards Codification",
"Paragraph": "1A",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.13-01(a)(4)(ii))",
"Topic": "470",
"URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
},
"r15": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02(32))",
"Topic": "210",
"URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r150": {
"Name": "Accounting Standards Codification",
"Paragraph": "1A",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
"Topic": "470",
"URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
},
"r151": {
"Name": "Accounting Standards Codification",
"Paragraph": "1A",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.13-01(a)(4)(iii))",
"Topic": "470",
"URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
},
"r152": {
"Name": "Accounting Standards Codification",
"Paragraph": "1A",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.13-01(a)(4)(iv))",
"Topic": "470",
"URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
},
"r153": {
"Name": "Accounting Standards Codification",
"Paragraph": "1A",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.13-01(a)(5))",
"Topic": "470",
"URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
},
"r154": {
"Name": "Accounting Standards Codification",
"Paragraph": "1B",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.13-02(a)(4)(i))",
"Topic": "470",
"URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
},
"r155": {
"Name": "Accounting Standards Codification",
"Paragraph": "1B",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
"Topic": "470",
"URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
},
"r156": {
"Name": "Accounting Standards Codification",
"Paragraph": "1B",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
"Topic": "470",
"URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
},
"r157": {
"Name": "Accounting Standards Codification",
"Paragraph": "1B",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.13-02(a)(4)(iv))",
"Topic": "470",
"URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
},
"r158": {
"Name": "Accounting Standards Codification",
"Paragraph": "1B",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.13-02(a)(5))",
"Topic": "470",
"URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
},
"r159": {
"Name": "Accounting Standards Codification",
"Paragraph": "1D",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(c)",
"Topic": "470",
"URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
},
"r16": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02(9))",
"Topic": "210",
"URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r160": {
"Name": "Accounting Standards Codification",
"Paragraph": "1I",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(c)",
"Topic": "470",
"URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
},
"r161": {
"Name": "Accounting Standards Codification",
"Paragraph": "69B",
"Publisher": "FASB",
"Section": "55",
"SubTopic": "20",
"Topic": "470",
"URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612"
},
"r162": {
"Name": "Accounting Standards Codification",
"Paragraph": "69C",
"Publisher": "FASB",
"Section": "55",
"SubTopic": "20",
"Topic": "470",
"URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612"
},
"r163": {
"Name": "Accounting Standards Codification",
"Paragraph": "13",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(a)",
"Topic": "505",
"URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
},
"r164": {
"Name": "Accounting Standards Codification",
"Paragraph": "13",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(b)",
"Topic": "505",
"URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
},
"r165": {
"Name": "Accounting Standards Codification",
"Paragraph": "13",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(g)",
"Topic": "505",
"URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
},
"r166": {
"Name": "Accounting Standards Codification",
"Paragraph": "13",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(h)",
"Topic": "505",
"URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
},
"r167": {
"Name": "Accounting Standards Codification",
"Paragraph": "13",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(i)",
"Topic": "505",
"URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
},
"r168": {
"Name": "Accounting Standards Codification",
"Paragraph": "13",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "505",
"URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
},
"r169": {
"Name": "Accounting Standards Codification",
"Paragraph": "14",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(a)",
"Topic": "505",
"URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644"
},
"r17": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02.19(a))",
"Topic": "210",
"URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r170": {
"Name": "Accounting Standards Codification",
"Paragraph": "14",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(b)",
"Topic": "505",
"URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644"
},
"r171": {
"Name": "Accounting Standards Codification",
"Paragraph": "14",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(c)",
"Topic": "505",
"URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644"
},
"r172": {
"Name": "Accounting Standards Codification",
"Paragraph": "16",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(b)",
"Topic": "505",
"URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496180-112644"
},
"r173": {
"Name": "Accounting Standards Codification",
"Paragraph": "18",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(a)",
"Topic": "505",
"URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644"
},
"r174": {
"Name": "Accounting Standards Codification",
"Paragraph": "18",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(b)",
"Topic": "505",
"URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644"
},
"r175": {
"Name": "Accounting Standards Codification",
"Paragraph": "18",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(c)",
"Topic": "505",
"URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644"
},
"r176": {
"Name": "Accounting Standards Codification",
"Paragraph": "18",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(d)",
"Topic": "505",
"URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644"
},
"r177": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "505",
"URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644"
},
"r178": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.3-04)",
"Topic": "505",
"URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
},
"r179": {
"Name": "Accounting Standards Codification",
"Publisher": "FASB",
"Topic": "505",
"URI": "https://asc.fasb.org/topic&trid=2208762"
},
"r18": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02.19-26)",
"Topic": "210",
"URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r180": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Topic": "606",
"URI": "https://asc.fasb.org/extlink&oid=126919976&loc=SL49130531-203044"
},
"r181": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Topic": "606",
"URI": "https://asc.fasb.org/extlink&oid=126919976&loc=SL49130532-203044"
},
"r182": {
"Name": "Accounting Standards Codification",
"Paragraph": "3",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Topic": "606",
"URI": "https://asc.fasb.org/extlink&oid=126919976&loc=SL49130533-203044"
},
"r183": {
"Name": "Accounting Standards Codification",
"Paragraph": "10",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "606",
"URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130551-203045"
},
"r184": {
"Name": "Accounting Standards Codification",
"Paragraph": "12",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(a)",
"Topic": "606",
"URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045"
},
"r185": {
"Name": "Accounting Standards Codification",
"Paragraph": "12",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(b)",
"Topic": "606",
"URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045"
},
"r186": {
"Name": "Accounting Standards Codification",
"Paragraph": "12",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(c)",
"Topic": "606",
"URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045"
},
"r187": {
"Name": "Accounting Standards Codification",
"Paragraph": "12",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(d)",
"Topic": "606",
"URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045"
},
"r188": {
"Name": "Accounting Standards Codification",
"Paragraph": "12",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(e)",
"Topic": "606",
"URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045"
},
"r189": {
"Name": "Accounting Standards Codification",
"Paragraph": "13",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(b)(2)",
"Topic": "606",
"URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130556-203045"
},
"r19": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02.20)",
"Topic": "210",
"URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r190": {
"Name": "Accounting Standards Codification",
"Paragraph": "15",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "606",
"URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130558-203045"
},
"r191": {
"Name": "Accounting Standards Codification",
"Paragraph": "4",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(a)",
"Topic": "606",
"URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130543-203045"
},
"r192": {
"Name": "Accounting Standards Codification",
"Paragraph": "5",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "606",
"URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045"
},
"r193": {
"Name": "Accounting Standards Codification",
"Paragraph": "8",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(a)",
"Topic": "606",
"URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130549-203045"
},
"r194": {
"Name": "Accounting Standards Codification",
"Paragraph": "8",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(b)",
"Topic": "606",
"URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130549-203045"
},
"r195": {
"Name": "Accounting Standards Codification",
"Paragraph": "9",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "606",
"URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130550-203045"
},
"r196": {
"Name": "Accounting Standards Codification",
"Paragraph": "91",
"Publisher": "FASB",
"Section": "55",
"SubTopic": "10",
"Subparagraph": "(a)",
"Topic": "606",
"URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046"
},
"r197": {
"Name": "Accounting Standards Codification",
"Paragraph": "91",
"Publisher": "FASB",
"Section": "55",
"SubTopic": "10",
"Subparagraph": "(c)",
"Topic": "606",
"URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046"
},
"r198": {
"Name": "Accounting Standards Codification",
"Publisher": "FASB",
"Topic": "606",
"URI": "https://asc.fasb.org/topic&trid=49130388"
},
"r199": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(d)(ii)",
"Topic": "715",
"URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
},
"r2": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Topic": "210",
"URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
},
"r20": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02.20,24)",
"Topic": "210",
"URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r200": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(d)(iv)(01)",
"Topic": "715",
"URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
},
"r201": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(d)(iv)(02)",
"Topic": "715",
"URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
},
"r202": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(d)(iv)(02)(A)",
"Topic": "715",
"URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
},
"r203": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(d)(iv)(02)(B)",
"Topic": "715",
"URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
},
"r204": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(d)(iv)(02)(C)",
"Topic": "715",
"URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
},
"r205": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(d)(iv)(03)",
"Topic": "715",
"URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
},
"r206": {
"Name": "Accounting Standards Codification",
"Paragraph": "17",
"Publisher": "FASB",
"Section": "55",
"SubTopic": "20",
"Topic": "715",
"URI": "https://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921"
},
"r207": {
"Name": "Accounting Standards Codification",
"Paragraph": "11",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "80",
"Subparagraph": "(a)",
"Topic": "715",
"URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947"
},
"r208": {
"Name": "Accounting Standards Codification",
"Paragraph": "6",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "80",
"Subparagraph": "(a)",
"Topic": "715",
"URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947"
},
"r209": {
"Name": "Accounting Standards Codification",
"Paragraph": "1D",
"Publisher": "FASB",
"Section": "35",
"SubTopic": "10",
"Topic": "718",
"URI": "https://asc.fasb.org/extlink&oid=126961718&loc=SL116886442-113899"
},
"r21": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02.21)",
"Topic": "210",
"URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r210": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "35",
"SubTopic": "10",
"Topic": "718",
"URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4534-113899"
},
"r211": {
"Name": "Accounting Standards Codification",
"Paragraph": "3",
"Publisher": "FASB",
"Section": "35",
"SubTopic": "10",
"Topic": "718",
"URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4549-113899"
},
"r212": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(a)",
"Topic": "718",
"URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
},
"r213": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(a)(1)",
"Topic": "718",
"URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
},
"r214": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(a)(2)",
"Topic": "718",
"URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
},
"r215": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(a)(3)",
"Topic": "718",
"URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
},
"r216": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(c)(1)",
"Topic": "718",
"URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
},
"r217": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(c)(1)(i)",
"Topic": "718",
"URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
},
"r218": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(c)(1)(ii)",
"Topic": "718",
"URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
},
"r219": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(c)(1)(iii)",
"Topic": "718",
"URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
},
"r22": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02.24)",
"Topic": "210",
"URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r220": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(c)(1)(iv)",
"Topic": "718",
"URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
},
"r221": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(c)(1)(iv)(01)",
"Topic": "718",
"URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
},
"r222": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(c)(1)(iv)(02)",
"Topic": "718",
"URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
},
"r223": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(c)(1)(iv)(03)",
"Topic": "718",
"URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
},
"r224": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(c)(1)(iv)(04)",
"Topic": "718",
"URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
},
"r225": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(c)(2)(i)",
"Topic": "718",
"URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
},
"r226": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(c)(2)(ii)",
"Topic": "718",
"URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
},
"r227": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(c)(2)(iii)",
"Topic": "718",
"URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
},
"r228": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(c)(2)(iii)(01)",
"Topic": "718",
"URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
},
"r229": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(c)(2)(iii)(02)",
"Topic": "718",
"URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
},
"r23": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02.25)",
"Topic": "210",
"URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r230": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(c)(2)(iii)(03)",
"Topic": "718",
"URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
},
"r231": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(d)",
"Topic": "718",
"URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
},
"r232": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(d)(1)",
"Topic": "718",
"URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
},
"r233": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(d)(2)",
"Topic": "718",
"URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
},
"r234": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(e)",
"Topic": "718",
"URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
},
"r235": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(e)(1)",
"Topic": "718",
"URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
},
"r236": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(e)(2)",
"Topic": "718",
"URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
},
"r237": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(f)(2)",
"Topic": "718",
"URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
},
"r238": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(f)(2)(i)",
"Topic": "718",
"URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
},
"r239": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(f)(2)(ii)",
"Topic": "718",
"URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
},
"r24": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02.29-31)",
"Topic": "210",
"URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r240": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(f)(2)(iii)",
"Topic": "718",
"URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
},
"r241": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(f)(2)(iv)",
"Topic": "718",
"URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
},
"r242": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(f)(2)(v)",
"Topic": "718",
"URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
},
"r243": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(h)(1)",
"Topic": "718",
"URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
},
"r244": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(h)(1)(i)",
"Topic": "718",
"URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
},
"r245": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(h)(2)",
"Topic": "718",
"URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
},
"r246": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(h)(2)(i)",
"Topic": "718",
"URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
},
"r247": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(i)",
"Topic": "718",
"URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
},
"r248": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(l)",
"Topic": "718",
"URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
},
"r249": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "718",
"URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
},
"r25": {
"Name": "Accounting Standards Codification",
"Paragraph": "10A",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Subparagraph": "(a),(b),(c)",
"Topic": "220",
"URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580"
},
"r250": {
"Name": "Accounting Standards Codification",
"Paragraph": "15",
"Publisher": "FASB",
"Section": "65",
"SubTopic": "10",
"Subparagraph": "(e)",
"Topic": "718",
"URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333"
},
"r251": {
"Name": "Accounting Standards Codification",
"Paragraph": "15",
"Publisher": "FASB",
"Section": "65",
"SubTopic": "10",
"Subparagraph": "(f)(1)",
"Topic": "718",
"URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333"
},
"r252": {
"Name": "Accounting Standards Codification",
"Paragraph": "15",
"Publisher": "FASB",
"Section": "65",
"SubTopic": "10",
"Subparagraph": "(f)(2)",
"Topic": "718",
"URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333"
},
"r253": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SAB Topic 14.F)",
"Topic": "718",
"URI": "https://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809"
},
"r254": {
"Name": "Accounting Standards Codification",
"Paragraph": "12",
"Publisher": "FASB",
"Section": "55",
"SubTopic": "20",
"Topic": "718",
"URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11149-113907"
},
"r255": {
"Name": "Accounting Standards Codification",
"Paragraph": "13",
"Publisher": "FASB",
"Section": "55",
"SubTopic": "20",
"Topic": "718",
"URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11178-113907"
},
"r256": {
"Name": "Accounting Standards Codification",
"Publisher": "FASB",
"Topic": "718",
"URI": "https://asc.fasb.org/topic&trid=2228938"
},
"r257": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "730",
"URI": "https://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
},
"r258": {
"Name": "Accounting Standards Codification",
"Paragraph": "6",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Topic": "740",
"URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e31931-109318"
},
"r259": {
"Name": "Accounting Standards Codification",
"Paragraph": "14",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "740",
"URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319"
},
"r26": {
"Name": "Accounting Standards Codification",
"Paragraph": "10A",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Subparagraph": "(e)",
"Topic": "220",
"URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580"
},
"r260": {
"Name": "Accounting Standards Codification",
"Paragraph": "15",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(e)",
"Topic": "740",
"URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319"
},
"r261": {
"Name": "Accounting Standards Codification",
"Paragraph": "17",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(b)",
"Topic": "740",
"URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319"
},
"r262": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "740",
"URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319"
},
"r263": {
"Name": "Accounting Standards Codification",
"Paragraph": "21",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "740",
"URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319"
},
"r264": {
"Name": "Accounting Standards Codification",
"Paragraph": "9",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(a)",
"Topic": "740",
"URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319"
},
"r265": {
"Name": "Accounting Standards Codification",
"Paragraph": "8",
"Publisher": "FASB",
"Section": "65",
"SubTopic": "10",
"Subparagraph": "(d)(2)",
"Topic": "740",
"URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277"
},
"r266": {
"Name": "Accounting Standards Codification",
"Paragraph": "8",
"Publisher": "FASB",
"Section": "65",
"SubTopic": "10",
"Subparagraph": "(d)(3)",
"Topic": "740",
"URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277"
},
"r267": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
"Topic": "740",
"URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
},
"r268": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SAB Topic 6.I.7)",
"Topic": "740",
"URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
},
"r269": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SAB Topic 11.C)",
"Topic": "740",
"URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817"
},
"r27": {
"Name": "Accounting Standards Codification",
"Paragraph": "10A",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Subparagraph": "(f)",
"Topic": "220",
"URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580"
},
"r270": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "270",
"Topic": "740",
"URI": "https://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338"
},
"r271": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "30",
"Subparagraph": "(a)",
"Topic": "740",
"URI": "https://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331"
},
"r272": {
"Name": "Accounting Standards Codification",
"Publisher": "FASB",
"Topic": "740",
"URI": "https://asc.fasb.org/topic&trid=2144680"
},
"r273": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "805",
"URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463"
},
"r274": {
"Name": "Accounting Standards Codification",
"Paragraph": "3",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "805",
"URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463"
},
"r275": {
"Name": "Accounting Standards Codification",
"Paragraph": "5",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(a)",
"Topic": "805",
"URI": "https://asc.fasb.org/extlink&oid=128092470&loc=d3e4946-128472"
},
"r276": {
"Name": "Accounting Standards Codification",
"Paragraph": "5",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(b)",
"Topic": "805",
"URI": "https://asc.fasb.org/extlink&oid=128092470&loc=d3e4946-128472"
},
"r277": {
"Name": "Accounting Standards Codification",
"Paragraph": "6",
"Publisher": "FASB",
"Section": "25",
"SubTopic": "30",
"Topic": "805",
"URI": "https://asc.fasb.org/extlink&oid=6911189&loc=d3e6408-128476"
},
"r278": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "35",
"SubTopic": "30",
"Subparagraph": "(b)",
"Topic": "805",
"URI": "https://asc.fasb.org/extlink&oid=126966325&loc=d3e6819-128478"
},
"r279": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "30",
"Subparagraph": "(b)(4)",
"Topic": "805",
"URI": "https://asc.fasb.org/extlink&oid=126975305&loc=d3e6927-128479"
},
"r28": {
"Name": "Accounting Standards Codification",
"Paragraph": "10A",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Subparagraph": "(h)",
"Topic": "220",
"URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580"
},
"r280": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "30",
"Subparagraph": "(c)(1)",
"Topic": "805",
"URI": "https://asc.fasb.org/extlink&oid=126975305&loc=d3e6927-128479"
},
"r281": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "30",
"Subparagraph": "(c)(3)",
"Topic": "805",
"URI": "https://asc.fasb.org/extlink&oid=126975305&loc=d3e6927-128479"
},
"r282": {
"Name": "Accounting Standards Codification",
"Paragraph": "4",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "30",
"Subparagraph": "(a)(1)",
"Topic": "805",
"URI": "https://asc.fasb.org/extlink&oid=126975305&loc=d3e7008-128479"
},
"r283": {
"Name": "Accounting Standards Codification",
"Publisher": "FASB",
"Topic": "805",
"URI": "https://asc.fasb.org/topic&trid=2303972"
},
"r284": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "808",
"URI": "https://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
},
"r285": {
"Name": "Accounting Standards Codification",
"Paragraph": "25",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Subparagraph": "(a)",
"Topic": "810",
"URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
},
"r286": {
"Name": "Accounting Standards Codification",
"Paragraph": "25",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Subparagraph": "(b)",
"Topic": "810",
"URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
},
"r287": {
"Name": "Accounting Standards Codification",
"Paragraph": "1A",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(c),(3)",
"Topic": "810",
"URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
},
"r288": {
"Name": "Accounting Standards Codification",
"Paragraph": "3",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(bb)",
"Topic": "810",
"URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
},
"r289": {
"Name": "Accounting Standards Codification",
"Paragraph": "3",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(c)",
"Topic": "810",
"URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
},
"r29": {
"Name": "Accounting Standards Codification",
"Paragraph": "10A",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Topic": "220",
"URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580"
},
"r290": {
"Name": "Accounting Standards Codification",
"Paragraph": "4K",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(a)",
"Topic": "815",
"URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5708775-113959"
},
"r291": {
"Name": "Accounting Standards Codification",
"Paragraph": "5",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "40",
"Subparagraph": "(f)",
"Topic": "815",
"URI": "https://asc.fasb.org/extlink&oid=126731327&loc=d3e90205-114008"
},
"r292": {
"Name": "Accounting Standards Codification",
"Paragraph": "6",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "40",
"Subparagraph": "(a)",
"Topic": "815",
"URI": "https://asc.fasb.org/extlink&oid=126731327&loc=SL126733271-114008"
},
"r293": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "65",
"SubTopic": "40",
"Subparagraph": "(e)(3)",
"Topic": "815",
"URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011"
},
"r294": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "65",
"SubTopic": "40",
"Subparagraph": "(e)(4)",
"Topic": "815",
"URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011"
},
"r295": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "65",
"SubTopic": "40",
"Subparagraph": "(f)",
"Topic": "815",
"URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011"
},
"r296": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(a)",
"Topic": "820",
"URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258"
},
"r297": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(b)",
"Topic": "820",
"URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258"
},
"r298": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(bbb)(1)",
"Topic": "820",
"URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258"
},
"r299": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(bbb)(2)",
"Topic": "820",
"URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258"
},
"r3": {
"Name": "Accounting Standards Codification",
"Paragraph": "5",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Topic": "210",
"URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765"
},
"r30": {
"Name": "Accounting Standards Codification",
"Paragraph": "11",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Topic": "220",
"URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e637-108580"
},
"r300": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(c)",
"Topic": "820",
"URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258"
},
"r301": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(c)(3)",
"Topic": "820",
"URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258"
},
"r302": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "820",
"URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258"
},
"r303": {
"Name": "Accounting Standards Codification",
"Paragraph": "3",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "820",
"URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19279-110258"
},
"r304": {
"Name": "Accounting Standards Codification",
"Paragraph": "6A",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(a)",
"Topic": "820",
"URI": "https://asc.fasb.org/extlink&oid=126976982&loc=SL6742756-110258"
},
"r305": {
"Name": "Accounting Standards Codification",
"Paragraph": "6A",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "820",
"URI": "https://asc.fasb.org/extlink&oid=126976982&loc=SL6742756-110258"
},
"r306": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Subparagraph": "(a)",
"Topic": "825",
"URI": "https://asc.fasb.org/extlink&oid=123594809&loc=d3e13220-108610"
},
"r307": {
"Name": "Accounting Standards Codification",
"Paragraph": "10",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "825",
"URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13433-108611"
},
"r308": {
"Name": "Accounting Standards Codification",
"Paragraph": "28",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(f)",
"Topic": "825",
"URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612"
},
"r309": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "230",
"Topic": "830",
"URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906"
},
"r31": {
"Name": "Accounting Standards Codification",
"Paragraph": "14",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Topic": "220",
"URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e681-108580"
},
"r310": {
"Name": "Accounting Standards Codification",
"Paragraph": "17",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "30",
"Topic": "830",
"URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900"
},
"r311": {
"Name": "Accounting Standards Codification",
"Paragraph": "20",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "30",
"Subparagraph": "(a)",
"Topic": "830",
"URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
},
"r312": {
"Name": "Accounting Standards Codification",
"Paragraph": "20",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "30",
"Subparagraph": "(b)",
"Topic": "830",
"URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
},
"r313": {
"Name": "Accounting Standards Codification",
"Paragraph": "20",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "30",
"Subparagraph": "(c)",
"Topic": "830",
"URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
},
"r314": {
"Name": "Accounting Standards Codification",
"Paragraph": "20",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "30",
"Subparagraph": "(d)",
"Topic": "830",
"URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
},
"r315": {
"Name": "Accounting Standards Codification",
"Paragraph": "20",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "30",
"Topic": "830",
"URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
},
"r316": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "30",
"Topic": "830",
"URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
},
"r317": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "20",
"Subparagraph": "(a)",
"Topic": "842",
"URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
},
"r318": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "20",
"Subparagraph": "(b)",
"Topic": "842",
"URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
},
"r319": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "65",
"SubTopic": "10",
"Subparagraph": "(a)(3)(iii)(03)",
"Topic": "848",
"URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846"
},
"r32": {
"Name": "Accounting Standards Codification",
"Paragraph": "14A",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Topic": "220",
"URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669686-108580"
},
"r320": {
"Name": "Accounting Standards Codification",
"Paragraph": "7",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(a)",
"Topic": "852",
"URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
},
"r321": {
"Name": "Accounting Standards Codification",
"Paragraph": "7",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(b)",
"Topic": "852",
"URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
},
"r322": {
"Name": "Accounting Standards Codification",
"Paragraph": "10",
"Publisher": "FASB",
"Section": "55",
"SubTopic": "10",
"Topic": "852",
"URI": "https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766"
},
"r323": {
"Name": "Accounting Standards Codification",
"Paragraph": "3",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(b)(2)(i)",
"Topic": "860",
"URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
},
"r324": {
"Name": "Accounting Standards Codification",
"Paragraph": "3",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(b)(2)(ii)",
"Topic": "860",
"URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
},
"r325": {
"Name": "Accounting Standards Codification",
"Paragraph": "3",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(b)(3)",
"Topic": "860",
"URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
},
"r326": {
"Name": "Accounting Standards Codification",
"Paragraph": "3",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(bb)(1)",
"Topic": "860",
"URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
},
"r327": {
"Name": "Accounting Standards Codification",
"Paragraph": "3",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(bb)(2)",
"Topic": "860",
"URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
},
"r328": {
"Name": "Accounting Standards Codification",
"Paragraph": "3",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(bb)(3)",
"Topic": "860",
"URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
},
"r329": {
"Name": "Accounting Standards Codification",
"Paragraph": "3",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(c)(1)",
"Topic": "860",
"URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
},
"r33": {
"Name": "Accounting Standards Codification",
"Paragraph": "1A",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Subparagraph": "(b)",
"Topic": "220",
"URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580"
},
"r330": {
"Name": "Accounting Standards Codification",
"Paragraph": "3",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(c)(2)",
"Topic": "860",
"URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
},
"r331": {
"Name": "Accounting Standards Codification",
"Paragraph": "3",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(c)(3)",
"Topic": "860",
"URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
},
"r332": {
"Name": "Accounting Standards Codification",
"Paragraph": "4",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(b)(1)",
"Topic": "860",
"URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
},
"r333": {
"Name": "Accounting Standards Codification",
"Paragraph": "4",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(b)(2)",
"Topic": "860",
"URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
},
"r334": {
"Name": "Accounting Standards Codification",
"Paragraph": "4",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(b)(3)",
"Topic": "860",
"URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
},
"r335": {
"Name": "Accounting Standards Codification",
"Paragraph": "4",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(c)",
"Topic": "860",
"URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
},
"r336": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "30",
"Topic": "860",
"URI": "https://asc.fasb.org/extlink&oid=66007379&loc=d3e113888-111728"
},
"r337": {
"Name": "Accounting Standards Codification",
"Paragraph": "7",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "30",
"Subparagraph": "(a)",
"Topic": "860",
"URI": "https://asc.fasb.org/extlink&oid=109249958&loc=SL34722452-111729"
},
"r338": {
"Name": "Accounting Standards Codification",
"Paragraph": "3",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "50",
"Subparagraph": "(a)(1)",
"Topic": "860",
"URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746"
},
"r339": {
"Name": "Accounting Standards Codification",
"Paragraph": "3",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "50",
"Subparagraph": "(a)(2)",
"Topic": "860",
"URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746"
},
"r34": {
"Name": "Accounting Standards Codification",
"Paragraph": "1A",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Subparagraph": "(c)",
"Topic": "220",
"URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580"
},
"r340": {
"Name": "Accounting Standards Codification",
"Paragraph": "3",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "50",
"Subparagraph": "(a)(3)",
"Topic": "860",
"URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746"
},
"r341": {
"Name": "Accounting Standards Codification",
"Paragraph": "3",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "50",
"Subparagraph": "(a)(4)(i)",
"Topic": "860",
"URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746"
},
"r342": {
"Name": "Accounting Standards Codification",
"Paragraph": "4",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "50",
"Subparagraph": "(a)(1)",
"Topic": "860",
"URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746"
},
"r343": {
"Name": "Accounting Standards Codification",
"Paragraph": "4",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "50",
"Subparagraph": "(a)(2)",
"Topic": "860",
"URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746"
},
"r344": {
"Name": "Accounting Standards Codification",
"Paragraph": "4",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "50",
"Subparagraph": "(a)(3)",
"Topic": "860",
"URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746"
},
"r345": {
"Name": "Accounting Standards Codification",
"Paragraph": "4",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "50",
"Subparagraph": "(a)(4)",
"Topic": "860",
"URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746"
},
"r346": {
"Name": "Accounting Standards Codification",
"Paragraph": "4",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "50",
"Subparagraph": "(a)(5)",
"Topic": "860",
"URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746"
},
"r347": {
"Name": "Accounting Standards Codification",
"Paragraph": "4",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "50",
"Subparagraph": "(a)(6)",
"Topic": "860",
"URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746"
},
"r348": {
"Name": "Accounting Standards Codification",
"Paragraph": "4",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "50",
"Subparagraph": "(a)(7)",
"Topic": "860",
"URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746"
},
"r349": {
"Name": "Accounting Standards Codification",
"Paragraph": "4",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "50",
"Subparagraph": "(b)",
"Topic": "860",
"URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746"
},
"r35": {
"Name": "Accounting Standards Codification",
"Paragraph": "1B",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Subparagraph": "(b)",
"Topic": "220",
"URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580"
},
"r350": {
"Name": "Accounting Standards Codification",
"Paragraph": "4",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "50",
"Subparagraph": "(e)(1)",
"Topic": "860",
"URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746"
},
"r351": {
"Name": "Accounting Standards Codification",
"Paragraph": "4",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "50",
"Subparagraph": "(e)(2)",
"Topic": "860",
"URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746"
},
"r352": {
"Name": "Accounting Standards Codification",
"Paragraph": "4",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "50",
"Subparagraph": "(e)(3)",
"Topic": "860",
"URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746"
},
"r353": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "25",
"SubTopic": "730",
"Topic": "912",
"URI": "https://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433"
},
"r354": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SAB Topic 11.L)",
"Topic": "924",
"URI": "https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856"
},
"r355": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "25",
"SubTopic": "20",
"Topic": "940",
"URI": "https://asc.fasb.org/extlink&oid=126941158&loc=d3e41242-110953"
},
"r356": {
"Name": "Accounting Standards Codification",
"Publisher": "FASB",
"SubTopic": "320",
"Topic": "940",
"URI": "https://asc.fasb.org/subtopic&trid=2176304"
},
"r357": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "210",
"Subparagraph": "(SX 210.9-03(11))",
"Topic": "942",
"URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
},
"r358": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "210",
"Subparagraph": "(SX 210.9-03(23))",
"Topic": "942",
"URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
},
"r359": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "210",
"Subparagraph": "(SX 210.9-03.15)",
"Topic": "942",
"URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
},
"r36": {
"Name": "Accounting Standards Codification",
"Paragraph": "5",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Topic": "220",
"URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e557-108580"
},
"r360": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "210",
"Subparagraph": "(SX 210.9-03.17)",
"Topic": "942",
"URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
},
"r361": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "210",
"Subparagraph": "(SX 210.9-03.4)",
"Topic": "942",
"URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
},
"r362": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "220",
"Subparagraph": "(SX 210.9-04(15))",
"Topic": "942",
"URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
},
"r363": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "220",
"Subparagraph": "(SX 210.9-04(23))",
"Topic": "942",
"URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
},
"r364": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "220",
"Subparagraph": "(SX 210.9-04(26))",
"Topic": "942",
"URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
},
"r365": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "220",
"Subparagraph": "(SX 210.9-04(27))",
"Topic": "942",
"URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
},
"r366": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "235",
"Subparagraph": "(SX 210.9-05(b)(2))",
"Topic": "942",
"URI": "https://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884"
},
"r367": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "320",
"Subparagraph": "(b)",
"Topic": "942",
"URI": "https://asc.fasb.org/extlink&oid=126980459&loc=d3e62557-112803"
},
"r368": {
"Name": "Accounting Standards Codification",
"Paragraph": "3A",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "320",
"Subparagraph": "(a)",
"Topic": "942",
"URI": "https://asc.fasb.org/extlink&oid=126980459&loc=SL120269850-112803"
},
"r369": {
"Name": "Accounting Standards Codification",
"Publisher": "FASB",
"SubTopic": "320",
"Topic": "942",
"URI": "https://asc.fasb.org/subtopic&trid=2209399"
},
"r37": {
"Name": "Accounting Standards Codification",
"Paragraph": "4",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "220",
"URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067"
},
"r370": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "360",
"Topic": "942",
"URI": "https://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630"
},
"r371": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "210",
"Subparagraph": "(SX 210.7-03(a)(12))",
"Topic": "944",
"URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
},
"r372": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "210",
"Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
"Topic": "944",
"URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
},
"r373": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "210",
"Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
"Topic": "944",
"URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
},
"r374": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "210",
"Subparagraph": "(SX 210.7-03(a)(25))",
"Topic": "944",
"URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
},
"r375": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "210",
"Subparagraph": "(SX 210.7-03(a)(8))",
"Topic": "944",
"URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
},
"r376": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "210",
"Subparagraph": "(SX 210.7-03.(a),19)",
"Topic": "944",
"URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
},
"r377": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "210",
"Subparagraph": "(SX 210.7-03.1,2)",
"Topic": "944",
"URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
},
"r378": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "220",
"Subparagraph": "(SX 210.7-04(19))",
"Topic": "944",
"URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
},
"r379": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "220",
"Subparagraph": "(SX 210.7-04(22))",
"Topic": "944",
"URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
},
"r38": {
"Name": "Accounting Standards Codification",
"Paragraph": "5",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "220",
"URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067"
},
"r380": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "220",
"Subparagraph": "(SX 210.7-04(23))",
"Topic": "944",
"URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
},
"r381": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "220",
"Subparagraph": "(SX 210.7-04(8))",
"Topic": "944",
"URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
},
"r382": {
"Name": "Accounting Standards Codification",
"Paragraph": "4H",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "40",
"Topic": "944",
"URI": "https://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438"
},
"r383": {
"Name": "Accounting Standards Codification",
"Paragraph": "13H",
"Publisher": "FASB",
"Section": "55",
"SubTopic": "40",
"Subparagraph": "(a)",
"Topic": "944",
"URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441"
},
"r384": {
"Name": "Accounting Standards Codification",
"Paragraph": "13H",
"Publisher": "FASB",
"Section": "55",
"SubTopic": "40",
"Subparagraph": "(c)",
"Topic": "944",
"URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441"
},
"r385": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "65",
"SubTopic": "40",
"Subparagraph": "(e)",
"Topic": "944",
"URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
},
"r386": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "65",
"SubTopic": "40",
"Subparagraph": "(f)(1)",
"Topic": "944",
"URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
},
"r387": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "65",
"SubTopic": "40",
"Subparagraph": "(f)(2)",
"Topic": "944",
"URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
},
"r388": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "65",
"SubTopic": "40",
"Subparagraph": "(g)(2)(i)",
"Topic": "944",
"URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
},
"r389": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "65",
"SubTopic": "40",
"Subparagraph": "(g)(2)(ii)",
"Topic": "944",
"URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
},
"r39": {
"Name": "Accounting Standards Codification",
"Paragraph": "6",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "220",
"URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067"
},
"r390": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "65",
"SubTopic": "40",
"Subparagraph": "(h)(2)",
"Topic": "944",
"URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
},
"r391": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "80",
"Subparagraph": "(e)",
"Topic": "944",
"URI": "https://asc.fasb.org/extlink&oid=124508989&loc=d3e19393-158473"
},
"r392": {
"Name": "Accounting Standards Codification",
"Publisher": "FASB",
"SubTopic": "320",
"Topic": "946",
"URI": "https://asc.fasb.org/subtopic&trid=2324412"
},
"r393": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Topic": "985",
"URI": "https://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756"
},
"r394": {
"Name": "Exchange Act",
"Number": "240",
"Publisher": "SEC",
"Section": "12",
"Subsection": "b"
},
"r395": {
"Name": "Exchange Act",
"Number": "240",
"Publisher": "SEC",
"Section": "12",
"Subsection": "b-2"
},
"r396": {
"Name": "Exchange Act",
"Number": "240",
"Publisher": "SEC",
"Section": "12",
"Subsection": "d1-1"
},
"r397": {
"Name": "Form 10-Q",
"Number": "240",
"Publisher": "SEC",
"Section": "308",
"Subsection": "a"
},
"r398": {
"Name": "Forms 10-K, 10-Q, 20-F",
"Number": "240",
"Publisher": "SEC",
"Section": "13",
"Subsection": "a-1"
},
"r399": {
"Name": "Regulation S-K (SK)",
"Number": "229",
"Paragraph": "(a)",
"Publisher": "SEC",
"Section": "1402"
},
"r4": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02(1))",
"Topic": "210",
"URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r40": {
"Name": "Accounting Standards Codification",
"Paragraph": "15",
"Publisher": "FASB",
"Section": "55",
"SubTopic": "10",
"Topic": "220",
"URI": "https://asc.fasb.org/extlink&oid=124507222&loc=d3e1436-108581"
},
"r400": {
"Name": "Regulation S-K (SK)",
"Number": "229",
"Paragraph": "(b)",
"Publisher": "SEC",
"Section": "1402",
"Subparagraph": "(1)"
},
"r401": {
"Name": "Regulation S-K (SK)",
"Number": "229",
"Paragraph": "(b)",
"Publisher": "SEC",
"Section": "1402",
"Subparagraph": "(2)"
},
"r402": {
"Name": "Regulation S-K (SK)",
"Number": "229",
"Paragraph": "(b)",
"Publisher": "SEC",
"Section": "1402",
"Subparagraph": "(3)"
},
"r403": {
"Name": "Regulation S-K (SK)",
"Number": "229",
"Paragraph": "(c)",
"Publisher": "SEC",
"Section": "1402",
"Subparagraph": "(2)(i)"
},
"r404": {
"Name": "Regulation S-K (SK)",
"Number": "229",
"Paragraph": "(c)",
"Publisher": "SEC",
"Section": "1402",
"Subparagraph": "(2)(ii)"
},
"r405": {
"Name": "Regulation S-K (SK)",
"Number": "229",
"Paragraph": "(c)",
"Publisher": "SEC",
"Section": "1402",
"Subparagraph": "(2)(iii)"
},
"r406": {
"Name": "Regulation S-K (SK)",
"Number": "229",
"Paragraph": "(b)",
"Publisher": "SEC",
"Section": "1403"
},
"r407": {
"Name": "Regulation S-T",
"Number": "232",
"Publisher": "SEC",
"Section": "405"
},
"r41": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-03(10))",
"Topic": "220",
"URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
},
"r42": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-03(21))",
"Topic": "220",
"URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
},
"r43": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-03(24))",
"Topic": "220",
"URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
},
"r44": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-03(25))",
"Topic": "220",
"URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
},
"r45": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-03(4))",
"Topic": "220",
"URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
},
"r46": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-03)",
"Topic": "220",
"URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
},
"r47": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-03.4)",
"Topic": "220",
"URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
},
"r48": {
"Name": "Accounting Standards Codification",
"Publisher": "FASB",
"Topic": "220",
"URI": "https://asc.fasb.org/topic&trid=2134417"
},
"r49": {
"Name": "Accounting Standards Codification",
"Paragraph": "12",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Subparagraph": "(c)",
"Topic": "230",
"URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3179-108585"
},
"r5": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02(17))",
"Topic": "210",
"URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r50": {
"Name": "Accounting Standards Codification",
"Paragraph": "13",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Subparagraph": "(c)",
"Topic": "230",
"URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585"
},
"r51": {
"Name": "Accounting Standards Codification",
"Paragraph": "14",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Subparagraph": "(a)",
"Topic": "230",
"URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585"
},
"r52": {
"Name": "Accounting Standards Codification",
"Paragraph": "24",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Topic": "230",
"URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585"
},
"r53": {
"Name": "Accounting Standards Codification",
"Paragraph": "25",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Topic": "230",
"URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585"
},
"r54": {
"Name": "Accounting Standards Codification",
"Paragraph": "28",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Subparagraph": "(a)",
"Topic": "230",
"URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585"
},
"r55": {
"Name": "Accounting Standards Codification",
"Paragraph": "28",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Subparagraph": "(b)",
"Topic": "230",
"URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585"
},
"r56": {
"Name": "Accounting Standards Codification",
"Paragraph": "28",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Topic": "230",
"URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585"
},
"r57": {
"Name": "Accounting Standards Codification",
"Paragraph": "4",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Topic": "230",
"URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3044-108585"
},
"r58": {
"Name": "Accounting Standards Codification",
"Paragraph": "3",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "230",
"URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4304-108586"
},
"r59": {
"Name": "Accounting Standards Codification",
"Paragraph": "4",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "230",
"URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4313-108586"
},
"r6": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02(18))",
"Topic": "210",
"URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r60": {
"Name": "Accounting Standards Codification",
"Paragraph": "5",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "230",
"URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4332-108586"
},
"r61": {
"Name": "Accounting Standards Codification",
"Paragraph": "8",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "230",
"URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586"
},
"r62": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "235",
"URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18726-107790"
},
"r63": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.4-08(e)(1))",
"Topic": "235",
"URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
},
"r64": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.4-08(g)(1)(ii))",
"Topic": "235",
"URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
},
"r65": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.4-08(h)(1)(Note 1))",
"Topic": "235",
"URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
},
"r66": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.4-08(h)(2))",
"Topic": "235",
"URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
},
"r67": {
"Name": "Accounting Standards Codification",
"Publisher": "FASB",
"Topic": "235",
"URI": "https://asc.fasb.org/topic&trid=2122369"
},
"r68": {
"Name": "Accounting Standards Codification",
"Paragraph": "23",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Subparagraph": "(b)",
"Topic": "250",
"URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793"
},
"r69": {
"Name": "Accounting Standards Codification",
"Paragraph": "24",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Topic": "250",
"URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793"
},
"r7": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02(28))",
"Topic": "210",
"URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r70": {
"Name": "Accounting Standards Codification",
"Paragraph": "5",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Subparagraph": "(b)",
"Topic": "250",
"URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793"
},
"r71": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(b)(3)",
"Topic": "250",
"URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
},
"r72": {
"Name": "Accounting Standards Codification",
"Paragraph": "11",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(a)",
"Topic": "250",
"URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
},
"r73": {
"Name": "Accounting Standards Codification",
"Paragraph": "11",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(b)",
"Topic": "250",
"URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
},
"r74": {
"Name": "Accounting Standards Codification",
"Paragraph": "3",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "250",
"URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794"
},
"r75": {
"Name": "Accounting Standards Codification",
"Paragraph": "4",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "250",
"URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794"
},
"r76": {
"Name": "Accounting Standards Codification",
"Paragraph": "7",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(a)",
"Topic": "250",
"URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
},
"r77": {
"Name": "Accounting Standards Codification",
"Paragraph": "7",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(b)",
"Topic": "250",
"URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
},
"r78": {
"Name": "Accounting Standards Codification",
"Paragraph": "9",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "250",
"URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794"
},
"r79": {
"Name": "Accounting Standards Codification",
"Paragraph": "10",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Topic": "260",
"URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256"
},
"r8": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02(29))",
"Topic": "210",
"URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r80": {
"Name": "Accounting Standards Codification",
"Paragraph": "11",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Topic": "260",
"URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1377-109256"
},
"r81": {
"Name": "Accounting Standards Codification",
"Paragraph": "16",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Topic": "260",
"URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1505-109256"
},
"r82": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Topic": "260",
"URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256"
},
"r83": {
"Name": "Accounting Standards Codification",
"Paragraph": "60B",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Subparagraph": "(c)",
"Topic": "260",
"URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256"
},
"r84": {
"Name": "Accounting Standards Codification",
"Paragraph": "60B",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Subparagraph": "(d)",
"Topic": "260",
"URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256"
},
"r85": {
"Name": "Accounting Standards Codification",
"Paragraph": "7",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Topic": "260",
"URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256"
},
"r86": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(a)",
"Topic": "260",
"URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
},
"r87": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(c)",
"Topic": "260",
"URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
},
"r88": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "260",
"URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257"
},
"r89": {
"Name": "Accounting Standards Codification",
"Paragraph": "3",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "260",
"URI": "https://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537"
},
"r9": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02(3)(a)(4))",
"Topic": "210",
"URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r90": {
"Name": "Accounting Standards Codification",
"Paragraph": "15",
"Publisher": "FASB",
"Section": "55",
"SubTopic": "10",
"Topic": "260",
"URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e3842-109258"
},
"r91": {
"Name": "Accounting Standards Codification",
"Paragraph": "52",
"Publisher": "FASB",
"Section": "55",
"SubTopic": "10",
"Topic": "260",
"URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258"
},
"r92": {
"Name": "Accounting Standards Codification",
"Publisher": "FASB",
"Topic": "260",
"URI": "https://asc.fasb.org/topic&trid=2144383"
},
"r93": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Topic": "272",
"URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054"
},
"r94": {
"Name": "Accounting Standards Codification",
"Paragraph": "22",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(a)",
"Topic": "280",
"URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
},
"r95": {
"Name": "Accounting Standards Codification",
"Paragraph": "22",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(b)",
"Topic": "280",
"URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
},
"r96": {
"Name": "Accounting Standards Codification",
"Paragraph": "22",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(e)",
"Topic": "280",
"URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
},
"r97": {
"Name": "Accounting Standards Codification",
"Paragraph": "22",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "280",
"URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
},
"r98": {
"Name": "Accounting Standards Codification",
"Paragraph": "30",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(a)",
"Topic": "280",
"URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599"
},
"r99": {
"Name": "Accounting Standards Codification",
"Paragraph": "30",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(b)",
"Topic": "280",
"URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599"
}
},
"version": "2.1"
} |
